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8PATIENTS IN THIS THESIS
At the moment that the first paper on Sjögren-Larsson syndrome was written (chapter 2.1 of
this thesis), the number of patients known in Nijmegen was limited to 11. In the studies that
followed more patients could be included. At this moment (October 2001) we know 20 Dutch
patients with SLS. The type and the subject of the studies often determined the character or
number that was allocated to individual patients. This table has been added to this thesis for
the convenience of the reader who wants to know 'who is who'.
Patient Family Sex, year of birth  Chapters in this thesis
2.1 2.2 2.3 2.4 2.5 3.1 3.2 3.3 3.4 4.1 4.2
1 I M, 1992 A 12 3 4 . 2 . x x . .
2 II F, 1990 B 15 6 9 A 4 . x x 1 .
3 III M, 1983 C2 2 11 12 . 13 . . x . 2
4 III M, 1990 C1 3 4 7 B 12 . . x . .
5 IV F, 1985 D2 5 9 11 C 15 . . x . 1
6 IV F, 1986 D1 8 8 10 . 14 . . x . .
7 V F, 1981 E 13 12 13 . 6 . x x . 4
8 VI F, 1982 F 10 10 14 . 5 . . x . 3
9 VII F, 1978 G 1 13 15 . 7 . x x . 5
10 VIII M, 1957 H1 . 14 16 . 18 . . . . .
11 VIII F, 1953 H2 . 15 17 . 19 . . . . .
12 IX F, 1991 . 11 5 8 . 9 1 x x . .
13 IX M, 1997 . 4 1 2 . 8 2 x x . .
14 X F, 1988 . 6 . . . 11 . . . . .
15 X M, 1992 . 14 . 6 . 10 . . . . .
16 XI F, 1953 . . . . . 17 . . . . .
17 XI M, 1954 . . . . . 16 . . . . .
18 XII M, 1990 . 9 7 5 . 3 . . x . .
19 XIII M, 1995 . 7 2 3 . 1 . . x . .
20 XIV F, 2000 . . . 1 . . . . . . .
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General introduction and aims of the study
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In 1957, Torsten Sjögren and Tage Larsson reported on a group of 28 patients with an
identical clinical picture (Sjögren T, Larsson T. Acta Psych Neurol Scand 1957;32:1-113). At
the end of their extensive report they summarize and conclude:
The clinical picture is characterized by congenital stationary low-grade oligophrenia,
congenital stationary pronounced ichthyosis, which may be diagnosed as
ichthyosiform erythrodermia, and congenital symmetric spastic pyramidal symptoms
in the extremities, especially the legs. With one exception the spastic disorders are
those found in typical cases of Little’s disease; for some patients there was
information that the gait had been gradually deteriorating. In a majority of the cases
the oligophrenia was diagnosed as idiocy (IQ up to about 30), and in the rest as
marked imbecility (higher IQ up to 50). Degeneration of the pigmented epithelium of
the macula and its surroundings was diagnosed in three cases. The clinical analysis
and the case descriptions reveal a not insignificant variability in the cardinal
symptoms. In spite of this variability it is manifest that the morbid picture is so
distinctive that the diagnosis can be made confidently on the sole basis of a clinical
examination.
No reduced syndrome or solitary occurrence of low-grade oligophrenia, ichthyosis or
spastic pyramidal symptoms was found among the parents and sibs of the affected.
The disease has a genetic causation. The mode of inheritance is monohybrid
autosomal recessive.
The Sjögren-Larsson syndrome (SLS) is a rare, intriguing neurocutaneous disorder. The
patients are severely handicapped by spasticity and mental retardation. Clearly visible, the
skin is affected as well. The first report on the metabolic basis of SLS appeared in 1988
(Rizzo WB, et al. J Clin Invest 1988;81:738-744). From that moment the biochemical and
molecular genetic defects that underlie SLS have further been unraveled. It has been proven
that SLS is caused by deficiency of the microsomal enzyme fatty aldehyde dehydrogenase
(FALDH) in 1991 (Rizzo WB, Craft DA. J Clin Invest 1991;88:1643-1648). Five years later,
the FALDH cDNA was cloned and the first mutations in this gene were demonstrated in
patients with SLS (De Laurenzi V, et al. Nature Genet 1996;12:52-57). Thus, the clinical
diagnosis SLS can nowadays been proven in all patients by demonstrating enzyme deficiency
and by molecular genetic studies of the FALDH gene. However, 10 years after the first
demonstration of FALDH deficiency in SLS, scientists have only been able to lift the tip of
the corner of the veil with regard to the pathophysiology of SLS. As a result, the search for a
causal treatment of patients with SLS remains a matter of great concern.
In September 1997 two groups, under the leadership of Dr Jan Rotteveel (Nijmegen) and Prof.
Dr Ronald Wanders (Amsterdam), decided to focus on SLS research in a joint project. During
the subsequent years, we were happy to get in contact with the scientific group of Dr Ertan
Mayatepek (Heidelberg), who contributed importantly to the SLS teamwork. The studies - as
described here - aim to investigate the clinical, biochemical, and molecular genetic aspects of
SLS in a relatively large series of patients. They add new insights to the pathophysiological
mechanisms that might cause SLS, and as such contribute to the development of a new
treatment strategy.
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CHAPTER 2
Clinical features of Sjögren-Larsson syndrome
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CHAPTER 2.1
Sjögren-Larsson syndrome
Clinical and MRI/MRS findings in FALDH deficient patients
P.H.M.F. van Domburg, M.A.A.P. Willemsen, J.J. Rotteveel, J.G.N. de Jong, H.O.M.
Thijssen, A. Heerschap, J.R.M. Cruysberg, R.J.A. Wanders, F.J.M. Gabreëls, P.M. Steijlen
Neurology 1999;52:1345-1352
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ARTICLE ABSTRACT
Objective: To determine the spectrum of clinical and MRI/1H-MRS features of patients with
fatty aldehyde dehydrogenase (FALDH) deficiency. Background: The Sjögren- Larsson
syndrome (SLS) was originally defined as a clinical triad consisting of ichthyosis, spastic di-
or tetraplegia, and mental retardation, with autosomal recessive inheritance. By now, both the
deficiency of the enzyme FALDH, and the genetic mutations on chromosome 17 responsible
for this deficiency, have been identified. SLS, defined by fibroblast FALDH deficiency, seems
to be a much broader syndrome. Methods: The clinical findings of 11 FALDH deficient
patients of different ages and one patient with the characteristic SLS-like ichthyosis, but
without FALDH deficiency, were evaluated in relation to their cerebral MRI, and to 1H-MRS
in six patients. Results: The severity of neurological symptoms showed considerable variation.
Fundoscopic perifoveal glistening dots and the characteristic SLS-like ichthyosis were present
in all patients. Serial MRI findings showed evidence of retarded myelination, and a variable
degree of dysmyelination. 1H-MRS showed an accumulation of free lipids in the
periventricular white matter, even before the stage of visible dysmyelination.  Conclusions:
The neurological consequences of FALDH deficiency show considerable variation. The
characteristic pattern of ichthyosis and retinal degeneration are consistently seen, yet they are
not pathognomonic. MRI/1H-MRS findings suggest an accumulation of  long-chain fatty
alcohol intermediates, resulting in retarded myelination and dysmyelination.
INTRODUCTION
The clinical triad of congenital ichthyosis, with gradually developing spastic di- or tetraplegia
and  mental retardation, was defined as a distinctive syndrome in 28 Swedish patients 40 years
ago (Sjögren-Larsson syndrome (SLS), McKusick no. 270200).1,2 The eventual Swedish
cohort of 58 patients in 41 families comprises the largest and most completely studied group,3
in which the genetic mutation has recently been elucidated.4 Current knowledge of this rare
neurocutaneous disease is based on observations from these patients and from genetically
unrelated cases, reported worldwide.5,6 Additional features, like the presence of the
characteristic perifoveal glistening white dots in the ocular fundus,7,8 have also been reported
since.
In 1988 Rizzo and colleagues reported that oxidation of long-chain fatty alcohols was
deficient in SLS patients, due to a dysfunctional enzyme complex fatty alcohol:NAD+
oxidoreductase (FAO).9 This enzyme complex consists of separate proteins: fatty alcohol
dehydrogenase (FADH) catalyzes the oxidation of fatty alcohol to fatty aldehyde; fatty
aldehyde dehydrogenase (FALDH) catalyzes the oxidation of fatty aldehyde to fatty acid
(Figure 1).10 Subsequent detailed biochemical studies have shown that the primary enzymatic
defect lies in the microsomal FALDH component.11 These enzymes, and the FALDH gene,
have been studied extensively. The FALDH gene on chromosome 17p11.2 has recently been
sequenced and its tissue expression determined in detail.12,13 Distinct mutations have been
identified in this gene in three unrelated patients.14
In contrast to the currently available detailed knowledge on the genetic and
biochemical features of the Sjögren-Larsson syndrome, relatively little attention has been paid
to the phenotype and the possible clinical, and in particular the neurological, signs of a faulty
fatty alcohol metabolism.15 We now report on clinical, cerebral magnetic resonance imaging
(MRI) and proton MR spectroscopy (1H-MRS), findings in a group of 11 patients with
15
FALDH deficiency. The aim of this study is to instigate further search on the pathophysiology,
and ultimately to find a therapy for, this so far untreatable disorder.
Figure 1. Fatty alcohol cycle in man, with presumed end-products in the central nervous
system and skin, after Rizzo et al., 1988, 1991. For abbreviations see text.
PATIENTS AND METHODS
Eleven patients (seven women, four men; Table 1) were referred by the geno-dermatologist
[PMS], because of the characteristic pattern of  congenital ichthyosis and deficient fibroblast
FALDH activity. None of the parents were consanguineous, nor were there ancestors of
Swedish origin. Patients C1 and C2, patients D1 and D2, and patients H1 and H2 were siblings
belonging to single families. One additional patient with the same SLS-like and not otherwise
classifiable ichthyosis, but normal fibroblast FALDH activity also underwent further clinical
and cerebral MRI investigation. The results of neurological and ophthalmological examination
are presented in terms of the WHO-classification of impairments, disabilities and handicaps,
assessing impairments on a standardized three-point scale (none-minor-major), depending on
the interference with normal function-for-age for neuromotor and mental development, visual
function, speech and  language progress, and musculoskeletal system development.16
Laboratory investigations
The activity of FAO (of which the FALDH fraction is rate limiting) was measured in cultured
skin fibroblast homogenates using the methods described by Rizzo et al.9,10 Of the various
substrates used, such as hexadecanol or octadecanol (C-16 and C-18 carbon chain length
respectively), octadecanol has been proven to be most sensitive to FALDH deficiency.10
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MRI and 1H-MRS
MRI and 1H-MRS of the brain were performed with a 1.5 Tesla Siemens Vision MR system,
using the standard head coil. Imaging was carried out with 5 mm transverse and sagittal slices,
with the following sequences: spin echo (SE) T1-weighted (T1W), echo time (TE) 15 msec,
repetition time (TR) 450 msec, SE proton density-weighted (PDW) and T2-weighted (T2W),
TE 20 and 80 msec, TR 2200-3500 msec. For 4 cases (A, B, D1, D2) scans were repeated after
some years and evaluated with particular emphasis on the progression of myelination.17
Retarded myelination is defined as a delay of myelin deposition, demonstrable by follow-up
MRI investigations. In such cases, normal myelin is demonstrable at a later point in
development, at sites where no mature myelin signal was demonstrable on earlier MRI.
Without follow-up data the term hypomyelination might be applied in such cases.
Dysmyelination, according to Poser's definition,18 is the breakdown of already formed
(possibly also delayed) myelin. The  associated, usually symmetrical, MR signal disturbances
are seen at locations were myelin must have been constituted earlier. In such a case myelin is
demonstrable at other locations where it developed later than the myelin deposited at the
dysmyelinated site. The areas involved show high signal-intensity on T2W images.
Localized  1H-MR spectra were acquired using STEAM (stimulated-echo acquisition
mode) or PRESS (point-resolved spatially localized spectroscopy sequence) at TE  30 or 135
ms and TR = 2500-4000 ms (volume 3.5-10 cc). Spectroscopic imaging datasets were also
acquired (TE = 135/Tr = 2000, matrix 16 x 16, FOV 200 mm) for 1.5 cm thick transverse
slices. Spectral signals of N-acetyl aspartate (NAA), Choline (Cho), and Creatine (Cr) were
extracted in time domain, but were not further evaluated for this study.
RESULTS
Clinical findings
Table 1 summarizes the clinical findings for all patients, presented in terms of the
impairments at their current age, with their FALDH deficiency (see 'methods'). It is notable
that most of them were born preterm. They had erythema at birth. Their skin gradually became
thickened and scaly during the first year of life, and in some cases desquamation of the palms
and soles also occured. Later on a wrinkled brown-yellowish hyperkeratosis gradually
developed, with prediliction sites at the main flexor folds of extremities, including the neck,
axilla and around the umbilicus (Figure 2). These areas are (sometimes rather sharply)
outlined by an otherwise rough grey-brown skin, with non-lamellar fine scaliness of varying
intensity, largely sparing the palms, soles, face and inguinal area. There were no bone
dysplasias or abnormalities of the acra or nails (musculoskeletal system development). The
hair was slightly thinned or normal. Sweating was normal, but the patients invariably suffered
from pruritis (which is usually not a finding in other ichthyoses).
Nervous system involvement was indicated by the development of an abnormal gait,
with pyramidal signs, in the first two years of life. In the typical cases neuromotor and mental
developmental delay were gradually progressive, but seemed to reach a plateau phase during
youth. None of the severely affected children could use more than short sentences, often
producing incomprehensible syllables. Comprehension of language was relatively spared,
however, in most cases. No other neurological signs were found, apart from spastic di- or
tetraplegia (the legs being far more severely affected than the arms), pseudobulbar dysarthria,
loss of visual acuity, and mental retardation. None of our patients suffered from epilepsy,
apart from absences in D1. There was no indication of peripheral and spinal sensory
conduction disorder, either clinically or by somatosensory evoked potentials (SSEP) of the
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median and sural, or posterior tibial nerve (recorded on Neuropack Four mini, Nihon Kohden
apparatus) in seven cases. Early and late evoked responses were excitable in all but one
patient (patient F: normal median nerve EP, no sural or posterior tibial nerve EP), but with
delayed late components in three cases (D1, D2, G).
Glistening dots on the macular region of the retina (Figure 3) were ultimately seen
with ophthalmoscopy in all investigated patients, but were not present in patients A and B at
their first examination, at the age of 2 and 3 years respectively. All children had subnormal
visual acuity, with photophobia and with a tendency to extra-foveal fixation. The two older
patients (H1 and H2), a brother and sister, both had a mild but characteristic pattern of
ichthyosis and perifoveal glistening dots. The residual FALDH enzyme levels in these patients
(Table 1) were within the range found in other SLS patients. Neither had visual impairment.
Patient H2 was neurologically normal. Her brother (patient H1) had hyperreflexia of the legs
with extensor plantar response and high arched feet, but no impairment of gait. He refused
neuropsychological examination, but based on his communication skills his IQ is estimated
80-90. An additional patient (woman, 6 years old) had the characteristic pattern of SLS-like
ichthyosis, but without reduced fibroblast FALDH activity. She showed no neurological or
ophthalmological signs on clinical examination. Cerebral MRI in this patient was normal.
  
Figure 2. Details of the characteristic appearance of the skin of patient B, showing a close-up
of the neck (left) and axillary region (right).
  
Figure 3. Characteristic perifoveal glistening
dots of the retina (patient H1).
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Table 1. Summary of clinical findings and FAO/FALDH activity at a given age.
Patient,
sex, age (y)
Gestational
age (wk)
FAO/
FALDH*
Ichthyosis Neuromotor**
development
Visual§
impairment
Speech†
language
Mental‡
development
Glistening
dots
Additional
A, M, 4   37  3.2 severe major  major  major  minor   + -
B, F, 6   38  6.3 severe major***  minor  minor  major   +   -
C1, M, 6   34  3.8 severe major***  major  major  major   + Pseudobulbar
dysarthria
D1, F, 10   36  3.7 severe major***  minor  major  major   + Absences
D2, F, 11.5   35  4.5 severe major  minor  major  major   +   -
C2, M, 13   33  5.1 severe major***  major  major  major   + Pseudobulbar
dysarthria
E, F, 15   37.5  5.2 severe major  minor  major  major   + Febrile
convulsions
F, F, 15   36.5  5.1 severe major  major  major  major   + Slight
dysarthria
G, F, 16.5   28  5.6 severe major  minor  major  major   + Pseudobulbar
dysarthria
H 1, M, 39    ?  7.9 moderate minor  none  minor  minor   + 2 healthy
children
H2, F, 42    ?  6.4 mild none  none  none  none   + 1 healthy
child
*
 FAO/FALDH activity, in pmol/min.mg, using C-18 fatty alcohol as substrate; normal values (n=13): 19.7 - 54.3 pmol/min.mg. ** Spastic
di/tetraplegia (see 'Patients and methods'). *** Confined to wheelchair. § Minor = 0.3 < acuity < 0.8; major =acuity < 0.3. † Major = > 5 months
behind chronological age. ‡ Minor = 1-2 yrs behind chronological age; major = > 2 yrs behind.
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Results of cerebral MRI and 1H-MRS
As shown in Table 2, repeated MRI established a variable, but significant, degree of retarded
myelination in the youngest patients (A, B and D1), particularly for subcortical association
areas of the frontal, parietal, and temporal convexity (Figure 4), which could not be attributed
to the normal biological variation. At this early stage there were no MRI signs of
de/dysmyelination. Some of the patients (D1, C2, F and G) variably showed patchy
dysmyelination in later years, most particularly of lobar tracts and radiations of corpus
callosum. In two cases (C1 and D2) T2W images showed laminar hypointense signals, parallel
with cortical gyri, comparable with those seen in cases with laminar necrosis. There were no
other signs of atrophy, morphogenetic abnormalities or  circumscribed lesions.
Figure 4. MRI, transverse
images, SE T2W, of patient B, at
the age of 3 (left side of the
picture) and 7 years (right side),
respectively, showing retarded
myelination particularly of
subcortical U-fibres and
occipital trigone (arrows). Note
the high signal intensity of
immature myelin, with reduced
signal intensity at the later age.
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Table 2. Summary of MRI and 1H-MRS findings, including follow-up studies.
Patient Age (y)*) Retarded myelination Dysmyelination 1H-MRS +)
 A 1.5 U-fibres, LT (F,T) - -
 A 2 LT (T) - -
 B 3 U-fibres (F,T,P), LT (O,F) - -
 B 4 U-fibres(T,P), LT - -
 B 5 U-fibres (T,P), LT - -
 B 7 U-fibres (P), LT(O) - Lipid peak
 C1 5.5 - - Lipid peak
 D1 2 LT (P,O,F) - -
 D1 10 - LT (P,O,F), U-fibres (P,F), CI Lipid peak
 D2 3 - - -
 D2 11.5 - - Lipid peak
 C2 13 - Pons, CI, LT (P,F) Lipid peak
 E 13 - - -
 F 15.5 - CC, LT (P) Lipid peak
 G 17.5 - LT (P) -
 H1 38 - - -
 H2 41 - - -
*)
 Age at which  MRI investigations were performed. +) 1H-MRS results are given for white
matter; spectroscopy was only performed in patients  B, C1, C2, D1, D2, and F. LT = Lobar
tracts, occipital and frontal trigone/radiations of corpus callosum included; F = frontal; O =
occipital; P = parietal; T = temporal; CC = corpus callosum; CI = capsula interna.
Six patients (B, C1, D1, D2, C2, and F) underwent 1H-MRS investigation. In all these patients
MR spectra of voxels in white matter showed abnormal signals at the "lipid" region, between
0.8 - 1.6 parts per million (ppm), both at TE = 30 and 135 ms (Figure 5), with suitable care to
suppress spectral contamination of lipid signals from outside the voxel (particularly
subcutaneous fat). At TE = 30 ms the integral of these signals ranged from 0.5 to 2.5 times the
intensity of the NAA peak. Several areas with gray matter (e.g. parietal and occipital) did not
show these peaks. In other (non-SLS) patients from the same range of age no such signals
were observed in the same experimental conditions. Spectroscopic imaging revealed that the
most intense "lipid" peaks were located periventricular (posterior and frontal trigones). In
vitro 1H-MR spectra of fatty alcohols showed similar peaks between 0.8 and 1.6 ppm
(personal observation). The other common spectral peaks were assigned to Cho (3.2 ppm), Cr
(3.0 ppm) and NAA (2.0 ppm) respectively.
Figure 5. MRI, transversal and
sagittal images, SE T2W, of patient
C1 at the age of 6 years, with 1H-MR
spectrum. The box indicates the
location and size of the voxel from
which an 1H-MR spectrum at TE =
30 ms is obtained from white matter
at the posterior trigone, showing the
prominent pathologic lipid peak
(lip.), apart from the common
spectral peaks of Cho, Cr and NAA.
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DISCUSSION
Clinical features
We examined 11 patients with variable features of the neurocutaneous syndrome defined by
Sjögren and Larsson (1957) and proven FALDH deficiency in cultured fibroblasts. Nine
patients fulfilled the classical triad of severe ichthyosis, with mental deficiency and severe
spastic di- or tetraplegia. Pseudobulbar dysarthria and loss of visual acuity were variably
present at a later age. There was no other neurological system involvement, although some
impairment of central parts of somatosensory tracts is possible. In the typical cases the
neurological features manifested themselves within the first 1-2 years of life, after which
developmental milestones were progressively delayed. An initial ability to walk some steps
alone was lost, resulting in progressive spasticity, often leading to contractures. We can
support the previously suggested correlation between the degree of mental retardation and that
of spasticity.2,15 Language comprehension was not proportionately impaired, and the children
generally were cheerfully attentive to educational efforts. The complete neurological picture,
with spasticity, mental deterioration, particularly affecting speech production, dysarthria, and
visual impairment fits the rather uniform pattern of the leukodystrophies.19
The congenital erythrodermic, gradually lichenificating and itchy ichthyosis of SLS is
a highly characteristic generalized hyperkeratosis (Figure 3), that can be distinguished both on
clinical5,6,20 and ultrastructural15,21 grounds. This is generally the first symptom that brings the
children to the attention of a physician. The most consistent additional finding in all our
patients was macular degeneration, consisting of  perifoveal glistening spots of unkown
nature, at ophthalmoscopic examination (Figure 4). These precipitants seem to develop only
after the age of 2-4 years, because our patients A and B had no retinal abnormalities on
examination at an earlier age. Ophthalmoscopy is often hampered with these patients because
of poor cooperation and photophobia, which indeed might have been the reason for the lower
incidence of these subtle fundoscopic findings in earlier studies.7 Although highly
characteristic, they do not seem to be pathognomonic for SLS.22 Visual acuity was impaired in
9 of our 11 patients (Table 1). It remains to be determined whether loss of visual acuity is a
consequence of these retinal deposits,7 or dysmyelination in optic tracts.23  The finding of
perifoveal glistening dots in our patients H1 and H2, who had normal visual acuity and no
signs of dysmyelination on MRI, is an argument in favour of the latter.
Our patients H1 and H2 had a somewhat milder but characteristic pattern of ichthyosis.
They had no neurological impairment, although one of them (H1) exhibited hyperreflexia of
the legs with bilateral Babinski's sign on clinical examination, and he seemed feeble-minded.
The FALDH activity in  these patients (23% and 18% of normal mean, respectively) was
somewhat higher than the level in most other patients (see Table 1), but in the range of  SLS
homozygotes. It may be noted that the determination of FAO/FALDH activity using
hexadecanol (C-16 fatty alcohol chain length) as a substrate, which appears somewhat less
sensitive to FAO/FALDH-activity than octadecanol,10 resulted in residual activity of 12 and
37 % respectively, the latter being nearly in the range of heterozygotes.9
Contrary to our expectations, the same SLS-like ichthyosis was seen in a patient who
was neither FALDH deficient nor had clinical neurological or ophthalmological features of
SLS, and who had no cerebral MRI abnormalities. Apparently, the characteristic SLS-like
ichthyosis alone is not pathognomonic for FALDH deficiency or SLS.6,24 Furthermore,
FALDH deficiency by itself will not always cause the full neurological syndrome in all
patients.25 Genetically different, but clinically similar syndromes also have been described
with dwarfism, hypogonadism and epilepsia (“Rud’s syndrome”), alopecia, or bone
dysplasias.20,26 Systemic lipidosis, with hepatosplenomegaly and myopathy, must also be
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excluded, as a possible cause.27 Cerebellar signs or peripheral nerve involvement may be
indicative of other diseases,28 particularly also Refsum's disease, steroid sulfatase deficiency
and adrenoleukodystrophy, although polyneuropathy has been reported incidentally in atypical
SLS.29 None of our patients had convulsive epileptic seizures. Epilepsy has been reported to
occur in 1/3 to 1/2 of the patients, which matches the incidence in any severely mentally
retarded population.2
Additional cerebral MRI and autopsy data
Whereas gross anatomical structures of brainstem, cerebellum, basal ganglia, corpus callosum,
and cerebral cortex were found to be normal in these patients, our MRI data suggest retarded
myelination, particularly of subcortical association fibres, in the first years of life. This
observation in serial MRI during early development (Figure 2), has not been reported in other
MRI studies, which also emphasise the preservation of subcortical U-fibres.30,31 Involvement
of these subcortical fibre tracts has been confirmed on autopsy.23 In later years myelination
seems to advance, but signal disturbances in the white matter, which tend to be confluent in
the more severe cases, suggest dysmyelination in the internal capsule, corpus callosum, oval
centre, lobar tracts and incidently also the brainstem (Table 2). The  oldest patients, H1 and H2,
who had the least marked neurological signs of SLS, had a normal MRI. In cases C1 and D2
MRI signal disturbances with the appearance of cortical laminar necrosis were shown, for
which we have no explanation. Although their gestational ages were about the youngest (34
and 35 weeks, respectively), they did not go through a period of (perinatal) hypoxia. Cortical
involvement in laminar-fashion has also been attested in other inborn errors of metabolism,
such as lysosomal disorders.32 The lower level of myelin disturbances (according to MRI
findings) in our typical cases compared with those reported in earlier studies might be
accounted for by the early stage of the disease, given our patients’ younger ages, indicating
progressive dysmyelination with age.The imaging data are as yet inadequate to allow a
definite correlation of MRI findings with FALDH values or with the severity of clinical
manifestations.
Only a few reports on post mortem findings in SLS are available.5,23,33 In none of these
case studies was the diagnosis confirmed by the determination of FAO/FALDH activity. The
principal finding in all cases was that of patchy or diffuse disseminated loss of myelin in the
central nervous system, the myelinated tracts of the spinal cord being involved to a lesser
degree. Diffuse spinal cord atrophy on MRI has been reported in incidental cases, without
proven FALDH deficiency.34 An inconsistent loss of gray matter, including basal ganglia, is
reported, along with a tendency toward accumulation of astrocytes, lipoid substances,5,33 and
lipofuscin-like pigments.8,33 Although fragmentary as yet, the data on imaging and autopsy
suggest a basic disorder of central myelination and (more widespread) accumulation of lipoid
substances as a direction for further research on the pathophysiology of this disease.
Interpretation of 1H-MRS findings
The MRS findings in 6 of our patients, aged 6.5-15 years, showed a significantly high,
abnormal "lipid" peak, with small line width, in the spectral range of 0.8-1.6 ppm, in the
periventricular white matter, most particularly around the posterior and frontal horns (Figure
5). A similar observation has been made before, for a 25 year old man with SLS.35 This
finding suggests the local accumulation of unusual free lipids or lipophilic substances,
confined to the periventricular white matter. This lipid peak also appeared before the stage of
MRI-detectable dysmyelination in patients B and C1. Similar but less pronounced lipid-type
signals, with a broader peak, have been reported in MRS spectra of childhood
adrenoleukodystrophy,36 multiple sclerosis,37 and peroxisomal disorders.38 This might point to
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a contribution of non-specific lipid breakdown products of myelin,37 lipid-laden astrocytes or
phagocytes.5,23,33 In SLS an accumulation of intermediates in the fatty alcohol cycle (Figure
1), or their reaction products, is more likely. Theoretically the substrates most likely to form
this circumscribed lipid peak in our patients are long chain fatty alcohols, which might
accumulate in plasma and fibroblasts of SLS patients.9,15 In vitro 1H-MR spectra of fatty
alcohols showed similar peaks between 0.8 and 1.6 ppm (personal observation).
Accumulation of reaction products of fatty aldehydes is also possible, in view of their high
reactivity, which should lead to their forming adducts with other (membrane) components in
the CNS, the skin and the retina.11,15,39
Long-chain (C-15 to C-24) fatty alcohols function as the substrate for biosynthesis of
wax esters, particularly abundant in the skin, and glycerol ether lipids, especially
plasmalogens, which are prominent in CNS myelin.10 In spite of a growing understanding of
the structure and function of human aldehyde dehydrogenases, which includes microsomal
FALDH,11 little is yet known about the way a disturbance of the fatty alcohol cycle might
interfere with CNS myelination and keratinization of skin.15 Dietary restrictions for SLS
patients, aimed at reducing the long chain fatty acid intake, have not as yet proved helpful.40
As we learn more about the pathophysiology of FALDH deficiency we may eventually find
ourselves in a position to devise an effective rational therapy.
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ARTICLE ABSTRACT
Sjögren-Larsson syndrome (SLS) was originally described as a triad of spasticity, mental
retardation and congenital ichthyosis. The syndrome reflects an underlying deficiency of
microsomal fatty aldehyde dehydrogenase (FALDH). We report clinical data on pregnancy,
labor and neonatal period in 15 patients. Pregnancies were uncomplicated, except for preterm
rupture of membranes in three pregnancies, and the occurrence of preterm birth. Mean
gestational age was 35.3 weeks (S.D. 2.4 weeks), and preterm birth was found in 73% of the
children, while all children were born before or in the 38th week of gestation. Birth weight
was normal for gestational age in all patients. The neonatal period was free from serious
complications, apart from hemolytic disease in two patients. Preterm birth was found in 7% of
the healthy siblings, reflecting the normal population. Prematurity and spasticity are intrinsic
and concurrent parts of SLS, without causal relation. SLS should be considered in every
neonate with congenital ichthyosis, especially when the child is born preterm. A possible
explanation for preterm birth in SLS could be the defective inactivation of leukotriene B4
(LTB4), which has recently been demonstrated in patients with SLS.
INTRODUCTION
Sjögren-Larsson syndrome (SLS) is an autosomal-recessively inherited disorder which was
originally described by Sjögren and Larsson in 1957 as a clinical triad of spastic di- or
tetraplegia, mental retardation and ichthyosis.14,15 The congenital ichthyosis usually brings the
patient to medical attention before spasticity and mental retardation are apparent. These
neurological symptoms gradually manifest themselves in the first year of life. Glistening white
dots on the retina are the most specific additional clinical finding that can be seen in many
cases.4 SLS patients show defective oxidation of medium- and long-chain (aliphatic) fatty
aldehydes, caused by a deficiency of microsomal fatty aldehyde dehydrogenase (FALDH).13
The FALDH gene has been mapped to chromosome 17p11.2, and mutations in this gene have
been identified in SLS patients.1 The accumulation of fatty alcohols and the modification of
macromolecules by fatty aldehydes have been postulated as the underlying pathophysiological
mechanisms, that give rise to the symptoms.13,5 Curative treatment strategies are not
available.11
We report on preterm birth as a clinical sign in SLS, and discuss its relevance for
diagnosing this neurocutaneous disorder. We propose a plausible, if speculative causal link
between the inborn error of metabolism in SLS patients and their preterm birth.
PATIENTS AND METHODS
Clinical data were obtained by reviewing the medical records of 15 children with SLS.
Diagnosis has been proven in 14 patients by demonstrating FALDH deficiency in cultured
skin fibroblasts. The one patient (patient 14) for whom enzyme analysis has not been
performed, shows the classical clinical picture and comes from a family with SLS (family V).
Patients 2 and 3, 4 and 11, 5 and 8, as well as 6 and 14 are siblings. Patients 4 and 11, and 6
and 14 have consanguineous parents. Three families (I, III, and V) originate from Turkey. The
gestational ages of all the healthy siblings (n=15)  were obtained by medical correspondence
or by asking the parents. All gestational ages were rounded to half weeks.
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The incidence of preterm birth in the Dutch population has been calculated on the base
of data obtained from the national birth registry in 1995, and was found to be comparable with
the incidence in other western societies such as Canada.6
Table 1. Obstetric and neonatal features in Sjögren-Larsson syndrome.
Patient Family Sex,
year of birth
Pregnancy Delivery Gestational
age (wks)
Gestational age
(wks) of healthy
siblings
Neonatal
period
1 I F, 1978 28 phototherapy
2 II M, 1983 33 40.5, 39.5, 39.5
3 II M, 1990 34 see patient 2
4 III M, 1997 34.5 33
5 IV F, 1985 breech 35 phototherapy
6 V F, 1988 PROM 35 phototherapy *
7 VI M, 1995 35 39.5, 40, 40.5 phototherapy
8 IV F, 1986 36
9 VII M, 1990 PROM 36 38, 42.5
10 VIII F, 1982 breech 36.5 43
11 III F, 1991 breech 36.5 see patient 4 phototherapy
12 IX M, 1992 breech 37 39, 40.5 phototherapy
13 X F, 1981 37.5 41.5
14 V M, 1992 PROM induced 37.5 phototherapy *
15 XI F, 1990 38 41.5, 43
Pregnancy was normal, delivery was spontaneous with cephalic presentation, and neonatal
period was uncomplicated, unless otherwise designated. PROM: preterm rupture of
membranes. * Hemolytic disease due to AB0 incompatibility.
RESULTS
The children, 8 girls and 7 boys, all suffered from the classical symptoms of SLS. They
showed a congenital ichthyosis that was recognized in the first months of life as the first sign
of ‘something being wrong’. Gradually, spasticity and mental retardation became evident in
the first year after birth. All children were born in The Netherlands.
Findings regarding pregnancy, birth and neonatal period are summarized in Table 1.
All mothers were healthy. All pregnancies were singleton. Fetal conditions seemed normal in
all pregnancies, i.e. there were no signs of infection, erythoblastosis, distress or other
problems. Three pregnancies were complicated by preterm rupture of membranes (PROM),
which led to the labor being induced in one case.
Gestational age ranged from 28 to 38 weeks (mean 35.3 weeks, S.D. 2.4 weeks).
Eleven children (73%) were born preterm, i.e. before the 37th week of gestation, and all
children were born in or before the 38th week of gestation. It follows that preterm birth is
more frequent in SLS (p<0.001, chi-square test) than in the normal population, in which 7.0%
of all live births is preterm [see Patients and Methods section]. Birth weight was normal for
gestational age in all patients. Perinatal asphyxia, defined as a 5-minute Apgar score less than
6,  was not observed. The neonatal period was complicated by hemolytic disease of the
newborn due to AB0 incompatibility in two siblings. In both cases the disease was
successfully treated by phototherapy. Five other patients required short-term phototherapy for
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mild hyperbilirubinemia, a common concomitant of premature birth. No other complications
occurred in the neonatal periods of any of the patients.
Fourteen of the 15 (93%) healthy siblings were born at term (mean 40.1 weeks, S.D.
2.4 weeks), conforming with the normal population. The gestational ages of the siblings are
included in Table 1.
DISCUSSION
We describe the occurence of preterm birth as an important clinical finding in proven SLS
patients, providing detailed data on pregnancy, delivery, and neonatal period.
Early reports on SLS, including the extensive clinical and genetic study of Sjögren and
Larsson themselves, did not reveal any data concerning gestational age. In 1982 Jagell and
Heijbel were the first who briefly paid attention to preterm birth in SLS.3 Their survey covers
35 patients diagnosed on clinical grounds. Information with regard to gestational ages is
absent for 10 patients. Thirteen of the remaining 25 patients (52%) are recorded as born
preterm. Exact gestational ages are not presented. The authors considered prematurity as a
non-specific finding in children with severe mental retardation. A survey of the literature now
available, in text books and from a Medline search, reveals no data that would confirm this
general statement. Seventeen years after Jagell and Heijbel, we were the next who have
noticed the occurence of preterm birth in several SLS patients.15
The gestational age of a newborn child with SLS might easily be overestimated,
because of the widespread ichthyosis that is present at birth.8 The aspect of the skin can be
misinterpreted as a sign of postterm birth, and might be one of the possible explanations for
the fact that prematurity has not fully been recognized as a clinical sign in patients with SLS
thus far.
Recently, we have found evidence of  defective leukotriene B4 degradation in SLS
patients.16 FALDH deficiency blocks the conversion of ω-aldehyde-LTB4 to ω-carboxy-LTB4,
leading to high (urinary) concentrations of the very active metabolites LTB4 and ω-hydroxy-
LTB4 (Figure 1). This finding may be significant  in the pathophysiology of preterm birth in
SLS, and fits in nicely with the modern concept of preterm labor as an intrauterine
inflammatory response syndrome.2
The complex (patho-) physiological mechanisms that underlie the initiation and
maintenance of term and preterm labor have been studied extensively.2,7 Much attention has
been given to prostaglandines and leukotrienes, which are potent lipid mediators derived from
arachidonic acid through the cyclooxygenase and the lipoxygenase pathway respectively
(Figure 1).7,9,12 Available experimental evidence suggests that leukotrienes, especially
leukotriene B4 (LTB4), might play a role during labor.17 Placental LTB4 production is high in
early pregnancy, remains low during the third trimester, and increases in spontaneous labor at
term.10 The concurrence of a disturbed inactivation of LTB4 and preterm labor in SLS might
point to a causative relation between the inborn error of metabolism in the fetus and its
preterm birth. These findings in SLS patients might contribute to the further elucidation of the
(patho-) physiological processes that underlie term and preterm labor in general.
In patients with congenital ichthyosis, SLS is generally considered in case of affected
relatives, or at the moment that emerging neurological signs complete the clinical picture. The
definite diagnosis in our patients often seemed to be delayed because the initial neurological
symptoms were interpreted as a sign of infantile encephalopathy in connection with preterm
birth. The inclusion of prematurity as an intrinsic part of the syndrome should give rise to the
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suspicion of SLS in every neonate with preterm birth and ichthyosis, and make the diagnostic
delay in early childhood less likely.
Figure 1. Metabolic pathways of biosynthesis of leukotrienes (LT), prostaglandins, and
thromboxanes, and microsomal degradation of LTB4 to ω-carboxy-LTB4. ω-Carboxy-LTB4 is
further degraded via peroxisomal β-oxidation.
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ARTICLE ABSTRACT
Purpose: To report the ocular manifestations associated with the Sjögren-Larsson syndrome in
a series of patients with proven fatty aldehyde dehydrogenase deficiency. To emphasize the
clinical importance of the ophthalmological features of the Sjögren-Larsson syndrome. To
discuss the metabolic disturbances that might give rise to the ophthalmological picture.
Methods: Fifteen patients with Sjögren-Larsson syndrome underwent a standardized
ophthalmological examination. In patients of appropriate age, and who were able to co-
operate, additional investigations were performed. Results: All patients exhibited bilateral,
glistening yellow-white crystalline deposits that were located in the innermost retinal layers
and appeared during the first two years of life. Repeated fundus photography in individual
patients showed that the dots became more numerous as the patients got older. Photophobia,
subnormal visual acuity, myopia, and astigmatism were found in most of the patients.
Fluorescein angiography was performed in three patients and showed a mottled
hyperfluorescence of the retinal pigment epithelium, without leakage. Color vision,
electroretinography, and electro-oculography could only be performed in a small number of
patients and showed no abnormalities. Visual evoked potentials were found to be abnormal in
six out of eight patients. Conclusions: In Sjögren-Larsson syndrome, patients exhibit highly
characteristic bilateral, glistening yellow-white retinal dots from the age of 1 to 2 years
onwards. The number of dots increases with age. The extent of the macular abnormality does
not correlate with the severity of the ichthyosis or with the severity of the neurological
abnormalities. A high percentage of patients shows additional ocular signs and symptoms,
notably marked photophobia.
INTRODUCTION
The Sjögren-Larsson syndrome (McKusick no. 270200) is a neurocutaneous disorder
characterized by congenital ichthyosis, spasticity, and mental retardation.1-3 The syndrome is
rare, but occurs world-wide, and has an autosomal recessive mode of inheritance. The
ichthyosis is usually present at birth, and is the sign that first attracts medical attention. The
neurological features emerge in the first two years of life. Ocular manifestations include
glistening dots in the macular area of the retina, whose nature is unknown.4 The presence of
these distinctive foveal and parafoveal crystals is thought to be a cardinal and perhaps a
pathognomonic sign of the syndrome.
Sjögren-Larsson syndrome is caused by deficient activity of fatty aldehyde
dehydrogenase (FALDH), a transmembrane protein that is part of the microsomal enzyme
complex fatty alcohol: nicotinamide-adenine (NAD+) oxidoreductase (FAO).5 FALDH
catalyzes the oxidation of many different medium- and long-chain fatty aldehydes to the
corresponding fatty acids.6,7 The cDNA encoding FALDH has recently been cloned and many
different mutations have been found in patients with Sjögren-Larsson syndrome.8,9 Curative
treatment strategies are not available.10
This study aims 1) to assess the ocular manifestations of Sjögren-Larsson syndrome in
a series of patients with proven FALDH deficiency, 2) to emphasize that ophthalmologic
examination of undiagnosed patients can be helpful in diagnosing the syndrome, and 3) to
speculate on the nature of the macular glistening dots in view of the underlying inborn error of
metabolism.
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PATIENTS AND METHODS
Standardized ophthalmological examinations were performed on 13 children and 2 adults with
Sjögren-Larsson syndrome at the University Hospital Nijmegen between 1991 and 1999. All
patients were examined by the same ophthalmologist (JRMC). Clinical neurocutaneous
features had already suggested the syndrome. The diagnosis was confirmed by demonstrating
deficient FAO/FALDH activity in cultured skin fibroblasts using the methods described by
Rizzo et al.5,11
All patients underwent a standardized ophthalmological examination, including
assessment of best-corrected visual acuity, measurement of refraction after cyclopentolate
cycloplegia, external examination, anterior segment slit-lamp microscopy, and direct and
indirect ophthalmoscopy. Photography of the ocular fundus was performed after mydriasis,
with accurate focusing, because out-of-focus photographs do not show the crystals. Several
pictures were taken each time, to eliminate the effects of reflexes and artefacts. Color slides
(64 ISO) were printed at a magnification of 35°. Additional examinations, including
measurement of intraocular pressure, elaborate color vision testing, Goldmann kinetic visual
field examinations, electroretinography, electro-oculography, visual evoked cortical potentials
(with pattern reversal checksize 17, 10 and 7 minutes of arc), and fluorescein angiography
were carried out on patients who could co-operate.
The neurological and neuroradiological features of Patients 3, 4, 6, 8-15 have been
described by van Domburg et al. as Patients A, C1, B, D1, D2, F, C2, E, G, H1, and H2
respectively.12 The genetic defect in Patients 1 and 5 has previously been elucidated and
reported.13
RESULTS
All children, 6 boys and 7 girls, showed the classical clinical signs of ichthyosis, spasticity,
and mental retardation, except the youngest (Patient 1). As would be expected at six months
of age, he only showed the dermatological abnormality. Both adult patients (Patients 14 and
15), who are brother and sister, exhibited an atypical phenotype with congenital ichthyosis,
but without (Patient 14) or with only mild (Patient 15) neurological involvement. All patients
were born in the Netherlands. Patients 1 and 5, 4 and 11, 8 and 9, as well as 14 and 15, are
siblings. Patient 1, 5, and 13 have parents who come from Turkey, all other patients originate
from The Netherlands. FAO/FALDH deficiency was proven in cultured skin fibroblasts taken
from each patient. The major clinical signs, including the detailed ophthalmological findings,
and FAO/FALDH activity are summarized in the Table.
The age at initial ocular examination ranged from 6 months to 37 years. Thirteen
(87%) patients suffered from moderate to severe photophobia. Visual acuity could not be
measured in the youngest patients (Patients 1 and 2). All other patients, except the female
adult patient with atypical Sjögren-Larsson syndrome (Patient 15), had bilateral subnormal
corrected visual acuity ranging from 0.16 to 0.6. Measurement of refraction after cycloplegia
showed a shift to mild and moderate myopia (spherical equivalent: mean, -1.3 diopters;
ranges, +1.5 to -6.5 diopters). Ten children (67%) showed astigmatism of more than 1 diopter.
Horizontal corneal diameters were all within normal limits. Nystagmus was present in one
patient, and strabismus, i.e. alternating exotropia, was found in two patients. With slit-lamp
examination, conjunctivae were normal, and corneas and lenses were clear in all children. The
lenses in both adult patients showed mild cortical opacities. Pupillary appearance and
reactivity to light were normal. Intraocular pressures were within normal limits.
36
Figure 1. Right eye of Patient 10. (Top) Macular glistening dots at the age of 11 years.
(Middle) Increased density of macular glistening dots at the age of 16 years. (Bottom)
Fluorescein angiography at the age of 16 years: mottled hyperfluorescence of the retinal
pigment epithelium in the posterior pole.
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Figure 2. Right eye and left eye of Patient 12. (Top) Macular glistening dots at the age of 13
years. (Middle) Increased density of macular glistening dots at the age of 17 years. (Bottom)
Fluorescein angiography at the age of 17 years: mottled hyperfluorescence of the retinal
pigment epithelium in the posterior pole, including the macular area.
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Table. Neurocutaneous and ocular features*, and FAO/FALDH activity in patients with Sjögren-Larsson syndrome.
Patient No.,
Sex, Age (y)†
FAO/FALDH
pmol/min.mg‡
Ichthyosis Neurologic
Involvement
Visual Acuity with
Refraction (right and left
eye)
External and
Slit-Lamp
Examination
Macular
Glistening
Dots
Additional Ocular Examination
1, M, 0.5 0.0 Severe Mild Not recordable
Not recordable
Normal Absent None
2, M, 3 4.7 Severe Moderate VA? with S-1.0
VA? with S-1.0
Photophobia Yes None
3, M, 5 3.2 Severe Severe 0.16 with S-1.00
0.16 with S-1.00
Photophobia, dry
corneas
Yes VEP: absent response
4, M, 5 3.8 Severe Severe 0.4 with S-1.5=C-1.25x15°
0.5 with S-0.5=C-0.25x155°
Photophobia,
blepharitis
Yes VEP: weak response
5, F, 6 3.3 Severe Severe 0.4 with S+0.25=C-0.5x64°
0.4 with S+1.25=C-3.0x90°
Photophobia Yes ERG: normal
6, F, 8 6.3 Severe Severe 0.3 with S+2.0=C-1.0x 25°
0.6 with S+1.0=C-0.25x25°
Photophobia Yes VEP: delayed response
7, M, 8 3.7 Severe Severe 0.4 with S-7.0
0.4 with S-5.75=C-1.25x23°
Photophobia Yes None
8, F, 9 3.7 Severe Severe 0.6 with C-2.0x90°
0.4 with C-2.0x97°
Photophobia Yes VEP: absent response
9, F, 10 4.5 Severe Severe 0.6 with C-0.75x85°
0.5 with C-1.25x100°
Photophobia Yes VEP: normal
10, F, 11 5.1 Severe Severe 0.3 with S-0.25=C-2.25x71°
0.3 with S-2.25=C-2.0x116°
Photophobia,
blepharitis
Yes FAG: hyperfluorescent. EOG, VEP, CV:
normal
11, M, 12 5.1 Severe Severe 0.25 with C-2.25x10°
0.25 with C-2.25 170°
Photophobia,
blepharitis
Yes VEP: weak response
12, F, 12 5.2 Severe Severe 0.25 with S+0.75=C-1.5x0°
0.25 with S+1.25=C-1.5x0°
Photophobia,
exotropia
Yes FAG: hyperfluorescent. VEP: OD weak
response, OS delayed response. CV,
ERG: normal
13, F, 16 5.6 Severe Severe 0.3 with S-4.0=C-3.0x170°
0.3 with S-2.0=C-3.0x25°
Exotropia,
nystagmus
Yes None
14, M, 34 7.9 Moderate Mild 0.8 with S-0.25
0.5 with S 0.00
Photophobia,
lens opacity
Yes FAG: hyperfluorescent. Mildly decreased
scotopic ERG. CV: diminished red
sensitivity. EOG: normal
15, F, 37 6.4 Mild None 1.0 with S 0.00
1.0 with S 0.00
Photophobia,
lens opacity
Yes CV: diminished red sensitivity. ERG,
EOG: normal.
*All findings represent bilateral ocular findings. †Age at first ocular examination. ‡FAO/FALDH activity, measured using C-18 fatty alcohol as a
substrate; normal value (n=13), 19.7 to 54.3 pmol/min.mg. CV = color vision; EOG = Electro-oculography; ERG = Electroretinography; FAG
= Fluorescein angiography; VEP = Visual evoked potentials.
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The initial ophthalmoscopic examination of the patients (JRMC) disclosed bilateral
glistening yellow-white crystalline deposits in the macular area in all patients except in the 6-
month-old boy (Patient 1), in whom the typical lesions were clearly visible when he was re-
examined at the age of 17 months. The macular glistening dots, as they are generally referred
to, were visible with three modes of examination: direct ophthalmoscopy, slit-lamp
biomicroscopy with a 90 diopter lens, and with fundus photography. The dots were found in
the fovea and parafoveal area, but not in the foveola or the retinal periphery. The crystals were
yellow-white, of irregular shape and varied considerably in size. They were generally
scattered, but seemed to be confluent at some places. Based on our clinical impression at
ophthalmoscopic examination as well as on the photographic characteristics of the dots, we
believe that the dots are located in the innermost layers of the retina. The number of dots
ranged from only a few in the youngest children to tens of dots in the teenagers. As a group,
the youngest children (Patients 1 to 5) showed less glistening dots than do the older ones
(Patients 6 to 13). Patients 14 and 15 unmistakably had the same macular glistening dots, but
fewer than most of the children. Repeated fundus photography was performed in several
patients, and invariably showed  the number of glistening dots to increase with age. Optic
disks and retinal vessels were normal in all patients. Figures 1 and 2 show the
ophthalmoloscopic picture of the macular glistening dots (top) and their progression (middle),
as well as the results of fluorescein angiography (bottom), in Patients 10 and 12.
Fluorescein angiography was performed in 3 patients and showed a mottled
hyperfluorescence of the retinal pigment epithelium in the macular area, without leakage. The
area of hyperfluorescence was larger than the area in which the crystals were visible. The
crystals did not block the fluorescence. Color vision tests could be performed in 4 patients
who showed normal results of 8° tests and nearly normal results of 2° tests. Anomaloscope
readings were only possible in the two adult patients and showed a mild shift of the mid-
matching point towards red. Electroretinography was performed in 4 patients and was found
to be within normal limits in 3 patients, while the response in the adult Patient 14 was mildly
decreased. Electro-oculography was performed in 3 patients and showed normal light
peak/dark trough ratio of both eyes (Arden ratio > 2.0). Visual evoked cortical potentials with
pattern reversal stimulation were examined in 8 patients. The responses were absent or weak
in 4 patients, delayed in 2 patients, and normal in two patients.
DISCUSSION
Our series consists of 15 patients with Sjögren-Larsson syndrome, in whom the diagnosis has
been  biochemically confirmed by demonstrating deficient activity of FALDH. The most
striking ocular feature is the presence of  bilateral retinal glistening yellow-white dots in all
patients. These glistening dots are similar to those described in previous reports.4,14,15
The prevalence of macular glistening dots in Sjögren-Larsson syndrome as reported in
the literature ranges considerably. In their original paper (1957), Sjögren and Larsson reported
on the ocular findings of 13 patients, aged 6 to 61 years.1 The authors found ‘degeneration of
the pigmented epithelium of the macula and its surrounding’, and ‘circular pigment
aggregations of about one tenth the size of the papilla’ in 3 (25%) out of 12 patients in whom
funduscopy had been performed. The other patients were reported to show normal ocular
fundi. Theile (1974) performed ocular examination in 76 patients, and reported the presence
of glistening dots in 15 (20%) of them.16 Jagell (1980) found the characteristic dots in all
(100%), i.e. 30, patients that had been examined.4 That series included 5 patients who had
originally been described by Sjögren and Larsson as being normal at ophthalmological
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examination. Rizzo (1999) stated that ‘one-third of patients exhibit a distinctive and perhaps
pathognomonic presence of glistening white dots surrounding the macular region of the retina,
which first appear after several years of age’.17 We assume that the discrepancies in the
literature have their origin in two important clinical difficulties. The first is the fact that most
of the patients who have been reported were diagnosed on clinical grounds without the
opportunity to confirm FALDH deficiency, raising the possibility that a number of them
suffered from diseases other than the Sjögren-Larsson syndrome. The second pitfall is the fact
that the glistening dots may be difficult to recognize, especially in the photophobic child, or if
the investigator does not expect the ophthalmoscopic feature.
The retinal glistening dots were not present at the initial examinations of the youngest
patient (Patient 1) at the age of 6 months. When the boy was re-examined at the age of 17
months, the typical dots were clearly visible. Both examinations have been performed by the
same ophthalmologist (JRMC). Patients 3 and 6 have previously been investigated, and have
been reported to show retinal glistening dots at the ages of 4 and 6 years respectively.12 In the
literature, retinal glistening dots are described as early as in a 4-months-old girl,18 a 1-year-old
boy,4 and a 2½-year-old boy,14 and are reported to appear after birth.17
So far, the macular glistening dots have been thought to be stationary.4 For several
reasons, however, we assume that the retinal glistening crystals are progressively deposited.
First, as stated above, the lesions make their appearance during infancy. Second, we have
found an increasing number of dots when comparing fundus photographs that were taken over
the years from individual patients. Third, the youngest children show, as a group, less
glistening dots than the oldest ones. Although our study lacks adult Sjögren-Larsson syndrome
patients, we assume that the progressive number of dots will reach an equilibrium in the adult,
based on the descriptions of the retinal abnormalities in adult patients. We found no
correlation between the number of dots and the severity of the dermatological and
neurological symptoms, which corresponds with previous reports.4,15
The results of ophthalmoscopy and fundus photography in our series of 15 patients
strongly suggest that the macular crystals are located in the innermost layers of the retina. The
same observation has been made by Jagell.4 The functional consequences of the presence of
the crystalline deposits is difficult to appreciate. Their accumulation might cause subnormal
corrected visual acuity, but does not seem to directly compromise other retinal functions, as
reflected by normal results of color vision tests, electro-oculography, and electroretinography,
in our patients and in patients reported in the literature.4,14,16,19 The crystals might lead to
subnormal anatomy (pathological fluorescein angiography) and subnormal function of
photoreceptors (diminished red sensitivity), as appears from additional ophthalmological
examinations in our patients and as reported in the literature.4,14,16,19 The pathological changes
of the visual evoked cortical potentials reflect the known disturbances in the myelination of
the central nervous system.12 We have no explanation for the high prevalence of myopia and
astigmatism in our children with Sjögren-Larsson syndrome and those previously reported.
Histopathological features of the eyes have been reported only twice.20,21 McLennan et
al. described the history of a female patient with severe ichthyosis, mental retardation and
spasticity, who died at the age of 24 years.21 The clinical course, as described extensively, was
progressive from childhood onwards. Ophthalmological examination did not reveal macular
glistening dots. These findings might argue against the diagnosis of Sjögren-Larsson
syndrome. Histopathological findings included a marked reduction in the number of retinal
ganglion cells and a reduction in the number of axons in the retina and optic nerve, with
absence of myelin in the optic nerve. No evidence of any pigmentary lesion in the macular
area was found, and the retinal pigment epithelium appeared intact. Nilsson and Jagell
reported on a 23-year-old male patient who was said ‘to have suffered from the Sjögren-
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Larsson syndrome’, but whose neurological and dermatological features were not described.20
Nor was it stated whether the patient had ocular abnormalities. The authors found a very high
retinal content of lipofuscin and melanolipofuscin granules, with a low number of melanin
granules. The pigment epithelial cells were voluminous. Histopathological features that might
suggest the presence of macular glistening dots were not found. When considering these
reports, one has to keep in mind the uncertainty of the diagnosis of Sjögren-Larsson syndrome
and the absence of (reported) ophthalmoscopic abnormalities in both patients.
Sjögren-Larsson syndrome is an inborn error of lipid metabolism caused by deficient
activity of FALDH. This enzyme catalyzes the conversion of medium- and long-chain fatty
aldehydes, whether synthesized from fatty alcohols or not, to the corresponding fatty acids.
FALDH has high activity towards saturated and unsaturated aliphatic aldehydes ranging from
6 to 24 carbons in length.6,7 The accumulation of fatty alcohols or the reaction of fatty
aldehydes with large molecules (with subsequent accumulation as lipofuscin like structures)
are thought to play a role in the pathophysiology of Sjögren-Larsson syndrome.3,22
Which pathophysiological mechanisms underlie the macular dystrophy in Sjögren-
Larsson syndrome? The retina has a very active lipid metabolism, in which large amounts of
long-chain fatty acids are involved.23,24 The biochemical compositions of the macula and the
peripheral retina are strikingly different with respect to fatty acids as well as carotenoids.25-27
Is it simply that the metabolism of lipids is the highest in the macula, or does the unique
biochemical composition of the macula explain its involvement in FALDH deficiency? Lipid
peroxidation might also be of pathophysiological importance in Sjögren-Larsson syndrome,
since lipid peroxidation is an important source of the fatty aldehydes.6,28 The macular part of
the retina is generally more susceptible to oxidative stress than the peripheral retina, and
might for that reason be involved in Sjögren-Larsson syndrome. Finally, we have recently
discovered the crucial role of FALDH in the degradation, i.e. inactivation, of leukotriene B4
(LTB4).29 LTB4 is a highly active proinflammatory mediator, and is predominantly produced
by blood cells, but can also be synthesized in the retina itself.30,31 It has been demonstrated
that light and trauma elicit the synthesis of LTB4 in the isolated rat retina in vitro, and that
leukocytes infiltrate the subretinal choroid and optic nerve in response to local administration
of LTB4.32,33 Altogether, it might be postulated that defective LTB4 degradation gives rise to
elevated retinal LTB4 concentrations and leads to the retinal abnormalities in Sjögren-Larsson
syndrome.
Crystalline retinopathy has been noted in a variety of conditions, including primary
hereditary ocular diseases such as Bietti’s crystalline dystrophy, inborn errors of metabolism
and renal pathology (e.g. Alport’s syndrome, membrano-proliferative glomerulonephritis,
cystinosis, and abetalipoproteinemia), tamoxifen chemotherapy, and the use of
canthaxanthine.34-40 However, the concurrence of yellow-white colored crystals with a
scattered distribution in the foveal and parafoveal areas, and the absence of additional visible
retinal abnormalities, are highly characteristic for Sjögren-Larsson syndrome. The
ophthalmological picture cannot be confused with any of the above-mentioned disorders,
when the additional ocular findings and the patient’s medical history are taken into account.
In conclusion, recognition of the highly characteristic macular glistening dots could
point to Sjögren-Larsson syndrome in undiagnosed patients. Thus, accurate ophthalmological
examination can prevent unnecessary diagnostic procedures as well as the diagnostic delay
that is often encountered in patients with Sjögren-Larsson syndrome.17,41 Because the
consequences of deficient FALDH activity are directly visible in the retina, repeated
ophthalmological examinations of Sjögren-Larsson syndrome patients could be of value in
elucidating the pathophysiological mechanisms that underlie the syndrome and in evaluating
(future) treatment strategies.
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CHAPTER 2.4
MRI and 1H MRS studies in Sjögren-Larsson syndrome:
characterization of the leukoencephalopathy
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ARTICLE ABSTRACT
Background: Sjögren-Larsson syndrome (SLS) is an inborn error of lipid metabolism. Its main
features are ichthyosis, spasticity, and mental retardation. Limited cerebral magnetic
resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) studies performed
so far have shown white matter abnormalities and the presence of an abnormal 'lipid' signal.
To further characterize the nature of the cerebral involvement in SLS we studied the findings
on serial MRI and MRS examinations in a large series of patients. Methods: MRI was
performed in 17 SLS patients, aged 5 months to 45 years. Single voxel MR spectra were
acquired from cerebral white and gray matter in 15 patients. LCModel fits were used to obtain
metabolite tissue contents. Follow-up examinations were performed in 13 (MRI) and 11
(MRS) patients. Results: MRI showed retardation of myelination and a persistent myelin
deficit. A zone of increased signal intensity was seen in the periventricular white matter on
T2-weighted images. MRS of white matter revealed a prominent peak at 1.3 ppm, normal
levels of N-acetylaspartate, and elevated levels of creatine, choline, and myo-inositol. MRS of
gray matter was normal. In the patient studied at the youngest age, MRI abnormalities
emerged during the first years of life. The other patients had stable MRI and MRS
abnormalities from the first examination onwards. Conclusion: The patterns of MRI and MRS
abnormalities are similar in all patients but the severity varies. They are confined to the
cerebral white matter and consist of the accumulation of lipids, periventricular gliosis, delayed
myelination, and a permanent myelin deficit.
INTRODUCTION
The Sjögren-Larsson syndrome (SLS) is an inborn error of fatty alcohol oxidation with an
autosomal recessive mode of inheritance. The well-known clinical triad includes ichthyosis,
spastic di- or tetraplegia and mental retardation.1 The congenital ichthyosis usually brings the
patient to medical attention, whereas spasticity and mental retardation become apparent later
in the first or second year of life. In addition, preterm birth, pruritus, and ocular abnormalities
including a juvenile macular dystrophy occur in the majority of cases.2-6
The defect in fatty alcohol oxidation in SLS is caused by the deficiency of microsomal
fatty aldehyde dehydrogenase (FALDH), a component of the fatty alcohol:NAD+
oxidoreductase enzyme complex.6,7 The FALDH gene has been mapped to chromosome
17p11.2, and mutations in this gene have been identified in SLS patients.6 The accumulation
of fatty alcohols, the modification of macromolecules by fatty aldehydes, and the presence of
high concentrations of biologically active lipids have been postulated as the underlying
pathophysiological mechanisms that give rise to the clinical features.6-13
A limited number of case reports have been published concerning neuroradiological14-
20
 and neuropathological21-28 findings in SLS. These reports, as well as our previous paper in
this journal,3 have stressed the presence of cerebral white matter abnormalities. Proton
magnetic resonance spectroscopy (MRS) studies of cerebral white matter have shown an
unusual 'lipid' signal that may represent accumulated fatty alcohols or their metabolites.3,15,19
In order to clarify the nature of the cerebral involvement in SLS, we performed
repeated magnetic resonance imaging (MRI) and MRS examinations in a series of 17 patients
with SLS with ages between 5 months and 45 years. In this paper we report the findings of
this study.
47
PATIENTS AND METHODS
Subjects
Seventeen SLS patients (eight male and nine female) from 13 different families were
investigated. Patients 2 and 8, 7 and 12, 10 and 11, as well as Patients 16 and 17, were
siblings belonging to single families. The ages at the time of investigation ranged from 5
months to 45 years. The diagnosis of SLS was confirmed by demonstrating FALDH
deficiency and by mutation analyses of the FALDH gene in each patient.
Patients 1-15 showed the classical clinical triad of congenital ichthyosis, spasticity,
and mental retardation, with onset of the neurological features in the first two years of life.
Spasticity mainly involved the legs, and gradually worsened. Although ambulation had been
preserved in some patients, they all used wheelchairs in everyday life. Speech production was
markedly affected in all patients. The interindividual, intrafamilial and interfamilial
differences were relatively minor. Patients 16 and 17 had a mild phenotype of SLS, as
previously described.3 None of the patients suffered from any other serious disease.
Fourteen out of 17 patients underwent more than one MRI (table 1). In 15 patients
MRS was performed; in 11 the investigation was repeated at least once (table 2). Nine healthy
control subjects, mean age 18.7 (range 10-25) years, underwent MRI and MRS using the same
protocols as in the SLS patients.
Magnetic Resonance Imaging
All MR investigations were performed on a Siemens Magnetom spectrometer (1.5 T) using a
standard circular polarized head coil. The MRI protocol generally consisted of localizers in
three orthogonal directions, followed by a T1-weighted spin echo (SE) sequence in coronal
direction (repetition time (TR)/echo time (TE): 650/15 msec), a proton density (PD)- and T2-
weighted turbo spin echo (TSE) sequence in transversal direction (TR/TE: 3100/16 and 98
msec), and a T1-weighted SE sequence in sagittal direction (TR/TE: 476/15 msec).
The images were evaluated for stage of myelination and presence of gray and white
matter signal abnormalities according to a previously published protocol.29 The white matter
signal abnormalities were graded with regard to the degree of signal change on T2-weighted
MR images (grade 0 = normal signal intensity; grade 1 = mildly increased signal intensity;
grade 2 = severely increased signal intensity). Moreover, the distribution pattern of the
abnormal signals was recorded by indicating the predominantly affected brain regions. The
severity of the cerebral atrophy was divided into three grades (grade 0 = no atrophy; grade 1 =
mild enlargement of the ventricular system and/or the subarachnoid spaces; grade 2 = severe
enlargement of the ventricular system and/or the subarachnoid spaces).
1H Magnetic Resonance Spectroscopy
Prior to the MRS measurements the magnetic field homogeneity was optimized by an
automatic shim procedure. Single voxel MR spectra were acquired using stimulated-echo
acquisition mode (STEAM)30 localization (TR/mixing time/TE = 3000/30/20 or 30 msec;
number of acquisitions (Nacq) = 64). Cubic voxels of 8 ml were positioned at two locations,
mainly containing either white matter (parieto-occipital trigone) or gray matter (midline
parieto-occipital). Spectroscopic imaging (MRSI) data sets were acquired from a 15-mm thick
transversal or oblique slice through the ventricles using point-resolved spectroscopy
(PRESS)30 volume pre-selection (TR/TE = 2000/135 msec; Nacq = 2; matrix size 16x16; field
of view 240 mm). Chemical-shift selective water suppression was applied. In addition, spectra
without water suppression were recorded (Nacq = 4 for single voxel spectra and Nacq = 1 for
MRSI data) which were used for eddy current correction and zero-order phasing.
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The spectral region between 4.0 and 1.1 ppm of each single voxel spectrum (TE = 20
msec) was analyzed by LCModel31 to obtain metabolite tissue contents. To enable fitting of
the 'lipid' peak present in the MR spectra of white matter of the patients, the basis set of
spectra of model compounds was extended with a signal representing lipid methylene proton
spins. This virtual spectrum was obtained by shifting the acetate spectrum of the basis set in
such a way that the single resonance of acetate appeared at 1.3 ppm, the approximate
resonance position of the 'lipid' peak. The spectra of lactate, ethanol, and β-hydroxybutyrate,
which all have some intensity around 1.3 ppm, were not included in the LCModel fit. In this
way relative values of the intensity of the 'lipid' peak were obtained in arbitrary units. The
region with a broad resonance present between 0.8 and 0.9 ppm in spectra of white matter of
patients was omitted in the analysis as inclusion of this region generally resulted in baseline
distortions. In some spectra the signal intensity present at 3.6 ppm was partly fitted to myo-
inositol and partly to glycine. However, virtually no signal intensity was found at this position
in spectra obtained at TE = 135 ms (as expected for glycine). Therefore, the part of this
resonance fitted to glycine was recalculated and also assigned to myo-inositol (Ins). Tissue
levels of the following metabolites were added together and presented as the sum: N-
acetylaspartate and N-acetylaspartylglutamate as 't-NAA' (total NAA); free choline and the
choline-containing compounds phosphocholine and glycerophosphorylcholine as ‘Cho’;
glutamine and glutamate as 'Glx'; and creatine and creatine phosphate, as 'Cr'. The spectra of
Patient 10 were not taken into account in the quantitative analysis, as only frontal white matter
was investigated in this patient. Of Patient 5 the gray matter spectrum could not be analyzed
because of movement artifacts.
For the single voxel STEAM and the MRSI data as shown in figures 4 and 5 post-
processing software of the manufacturer was applied. The time domain data were multiplied
by a Gaussian filter and zero-filled from 1K to 2K data points. The spectra were corrected for
eddy current artifacts, and the residual water signal was removed using a high-pass filtering
technique. After Fourier transformation only a minor first order phase correction was
necessary. Chemical shifts are given in parts per million (ppm) with the methyl signal of NAA
at 2.03 ppm.
RESULTS
Magnetic Resonance Imaging
Progress of myelination was abnormally slow during the first years of life (Patients 1, 2, 4,
and 9). However, there also was a permanent myelin deficit. Small areas of subcortical white
matter remained insufficiently myelinated in all regions throughout the follow-up period, even
in the oldest patients. The myelin deficit is illustrated in figures 1-3.
All patients had a zone of abnormally high signal intensity in the periventricular white
matter on T2-weighted images. The zone had slightly low or normal signal intensity on T1-
weighted images. It extended from frontal to occipital, and had either a frontal (figure 1) or,
more often, a parieto-occipital predominance (figure 2). A zone of subcortical white matter
was spared in all patients. This spared subcortical zone was wider and included more tissue
than the insufficiently myelinated U-fibers described above only. The signal change on T2-
weighted images was either severe (figure 1) or mild (figure 2); an 'intermediate' signal change
was not observed. The areas of abnormal signal intensity were confluent in all patients (figure
1-3) except for Patient 14 who had more patchy white matter abnormalities. The corpus
callosum was only affected in Patients 10 and 14. The limited image quality in some patients
did not allow a systematic assessment pyramidal tracts in the brain stem. However, whenever
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good quality images were available at brain stem level, subtle signal abnormalities were seen
in these tracts. The cerebellar white matter was normal in all cases. We did not observe
abnormalities in gray matter structures. Further details of the MRI abnormalities are given in
table 1.
Our data cover the ages between 5 months and 45 years (see table 1). Patient 2 was the
youngest patient studied. At the age of 5 months, the periventricular white matter had a
normal signal intensity considering its largely unmyelinated state (figure 3A). At 16 months, a
periventricular zone of abnormal signal was visible (figure 3B), and was found unchanged at
25 months and 35 months (figure 3C). In all patients the white matter abnormalities remained
unchanged during follow-up: there was neither an increase nor a decrease in degree of signal
change or the extent of the signal abnormalities.
Mild enlargement of the ventricular system was found in six patients. This ventricular
enlargement was found to be non-progressive during the follow-up period.
Table 1. Results of Cerebral MRI in 17 SLS Patients
Patient Sex Number
of MRIs
Age range
(yr)
Myelin
deficit
Periventricular zone of
abnormal signal
Atrophy
Degree Predominance
1 F 2 0.8 - 1 1 1 PO 0
2 M 4 0.4 - 2 1 1 PO 0
3 M 2 3 - 5 1 1 PO 0
4 M 3 1 - 8 1 1 PO 0
5 M 1 8 1 1 PO 0
6 M 1 8 1 2 FP 0
7 M 2 5 - 9 1 1 PO 0
8 F 2 6 - 9 1 1 PO 0
9 F 7 3 - 10 1 1 PO 0
10 F 1 10 1 1 FP a 1
11 F 3 11 - 14 1 1 PO 0
12 M 4 12 - 16 1 2 FP 1
13 F 3 12 - 17 1 1 PO 1
14 F 3 15 - 17 1 2 FP a,b 0
15 F 3 16 - 21 1 1 PO 1
16 M 1 38 0 1 PO 1
17 F 2 41 - 45 1 1 PO 1
The results given in this table reflect the findings of each patient's last MRI study. The degree
of myelin deficit, periventricular signal abnormalities, and atrophy are scored as follows: 0 =
none; 1 = mild; 2 = severe. PO = parieto-occipital; FP = fronto-parietal; a = corpus
callosum involved; b = patchy white matter lesions.
1H Magnetic Resonance Spectroscopy
The MR spectra of the cerebral occipital white matter of SLS patients showed a prominent
and narrow peak at 1.3 ppm which is not seen in healthy controls (figure 4). This resonance
was clearly visible at all echo times (20, 30 and 135 msec). In addition, the spectra usually
contained an increased signal intensity at about 0.8-0.9 ppm. These findings are compatible
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Figure 1. T2-weighted MR images of Patient 12 at 16 years. Note the severe signal changes of the periventicular white matter with predominant
involvement of the frontal trigones. Note also the small areas of unmyelinated subcortical association fibers.
Figure 2. T2-weighted MR images of Patient 7 at 9 years. Note that small areas of subcortical association fibers are unmyelinated. These images
reflect the pattern of mild signal changes of the periventicular white matter, predominantly involving the occipital trigones.
Figure 3. T2-weighted MR images of Patient 2 at the age of 5 months (Fig 3A), 16 months (Fig 3B), and 35 months (Fig 3C). There is a delay in
the maturation of the white matter on all three images. The unmyelinated periventricular white matter shows no abnormal signal intensities (Fig
3A). Fig 3B and Fig 3C show the non-progressive, slight signal abnormalities of the periventricular white matter that mainly involve the occipital
trigones.
Figure 3 →
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Table 2. Results of 1H-MRS of Parieto-occipital White and Gray Matter in 15 SLS Patients and Nine Healthy Controls
White matterPatient Number
of MRSs
Age range
(yr) Metabolites (mmol/l)Lipid peak
(a.u.) t-NAA Cr Cho Ins Glx
1 2 0.8 - 1 2.8 9.2 5.4 2.2 3.8 13.5
2 4 0.4 - 2 2.0 8.4 5.3 1.8 4.5 12.2
3 2 3 - 5 27.8 11.1 5.4 2.4 8.1 10.5
4 1 8 23.4 11.1 6.0 2.1 5.3 13.6
5 1 8 11.2 8.5 4.8 2.0 4.0 8.6
7 2 5 - 9 15.5 10.1 6.1 1.8 5.1 13.4
8 2 6 - 9 1.9 11.3 6.1 2.1 5.8 11.3
9 4 7 - 10 11.5 11.4 5.2 1.9 4.0 14.3
10 1 10 present . . . . .
11 3 11 - 14 13.6 9.9 6.3 2.1 6.0 13.0
12 4 12 - 16 19.8 11.9 6.0 2.0 6.3 10.2
13 2 17 - 17 20.3 10.5 6.6 1.8 6.7 16.0
14 3 15 - 17 8.6 12.7 6.8 1.9 5.4 15.3
15 2 21 - 21 6.9 11.0 7.6 2.4 5.5 14.5
17 1 45 1.6 8.9 6.0 1.8 3.6 9.8
White matter SLS (n = 14) 11.9 (8.3) *** 10.4 (1.3) 6.0 (0.7) ** 2.0 (0.2) ** 5.3 (1.2) ** 12.6 (2.1)
Controls (n = 9) 0.6 (0.6) 9.6 (0.9) 5.1 (0.3) 1.7 (0.3) 3.5 (1.0) 12.4 (0.9)
Gray matter SLS (n = 13) 0.8 (0.7) 11.5 (1.4) 7.3 (0.8) 1.6 (0.3) 4.4 (1.2) 18.1 (3.3)
Controls (n = 9) 1.1 (0.8) 11.1 (0.5) 6.5 (0.5) 1.4 (0.1) 4.3 (0.8) 15.6 (2.0)
The data in this table give the results concerning each patient's last investigation. The intensity of the lipid peak is expressed in arbitrary units
(a.u.). In the lower part of the table, mean (SD) values are given for the lipid peak and the metabolites. ** p < 0.01, *** p < 0.001, SLS patients
compared with healthy controls (unpaired two-tailed t-test).
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with the presence of abnormal amounts of lipids, with the methylene proton spins resonating
at 1.3 ppm and the methyl proton spins at 0.8-0.9 ppm. The 1.3 ppm peak was not found in
cerebral gray matter (n = 13) or cerebellum (n = 1).
MRSI revealed that the most intense 'lipid' peaks were located in the periventricular
region in the posterior and frontal trigones (figure 5). The 'lipid' peak appeared to be higher in
the posterior than in the anterior trigone, but this was not systematically investigated in all
patients.
In table 2, the results are given for the relative intensity of the abnormal 'lipid' peak at
1.3 ppm as well as the tissue levels of the other metabolites in white and gray matter as
compared to control data. Apart from an increased 'lipid' peak significant increases were
observed for Cr, Cho, and Ins levels in white matter of SLS patients but not in gray matter.
DISCUSSION
Magnetic Resonance Imaging
The MR images exhibited three abnormal phenomena in the patients: disturbance of
myelination, a zone of abnormal signal intensity within the periventricular white matter, and
mild cerebral atrophy.
All patients, except Patient 16, showed an MRI picture compatible with initially
delayed and eventually permanently deficient myelination. The process of myelination appears
to be arrested just before the latest structures myelinate, which are - from a MRI point of view
- the subcortical association fibers.32,33 Disturbances in myelination have not been described in
SLS before. A possible explanation for this is that mild defects in myelination may be difficult
to appreciate, especially when other MRI abnormalities are prominent. The pathophysiological
mechanisms that cause delayed and deficient myelination in SLS, and the functional
consequences are presently unclear.
In all patients, we found a zone of abnormally high signal in the periventricular white
matter on T2-weighted images. Our findings suggest that this hyperintense zone arises or
becomes apparent during the process of myelination (figure 3) and is non-progressive
thereafter. Only one other patient has been reported in the literature, who underwent repeated
neuroimaging from an early age onwards.19 That patient had a normal CT of the brain at the
age of one year, whereas repeated CT and MRI at higher ages revealed marked white matter
involvement, in conformity with our findings. It is striking that also the clinical neurological
signs become apparent within the first one or two years of life and remain relatively stable
after that.
With the exception of one image,20 all MR images presented in the literature exhibit
severe white matter involvement,14-20 whereas we have found mild involvement to be much
more frequent in our patients. This discrepancy may reflect the general tendency to report on
severe findings. We did not find a correlation between severity of white matter involvement
and the age of the patient or the severity of the neurological abnormalities. In all our cases the
white matter abnormalities showed either predominant involvement of the frontal trigone (n =
4) or the occipital trigone (n = 13). In the patients with severe signal abnormalities we found
always predominant involvement of the fronto-parietal brain areas, as is the case in most
patients in the literature.
The periventricular white matter abnormalities on T2-weighted images were confluent
in all cases, except in Patient 14 who had patchy abnormalities. Patchy involvement of white
matter on MRI has previously been reported in only one other patient with SLS18 and can be
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considered as an atypical variant. The corpus callosum was involved in only two patients of
our series, and in three of the 12 patients investigated by MRI reported in the literature.14,17,20
Mild cerebral atrophy was found in most patients over 10 years of age. The changes
were non-progressive during the follow-up period. This period, however, may have been to
short to document progression. Also the literature data are insufficient to answer the question
whether there is typically progressive cerebral atrophy in SLS or not.
Our series includes 4 pairs of siblings. Only one pair of siblings (Patient 2 and 8) had identical
MRI abnormalities (table 1). Figures 1 and 2 show the images of two brothers and illustrate
the differences that can be found between siblings. We did not find an explanation for these
intrafamilial differences in individual dietary habits, use of drugs, or co-existing disease
among others. Comparable differences in MRI findings within SLS families have been
reported previously.18,20
1H Magnetic Resonance Spectroscopy
The MR spectra of cerebral white matter of SLS patients are characterized by the presence of
a prominent and narrow resonance at 1.3 ppm, at which position protons of methylene (-CH2-)
groups resonate. It is highly probable that the peak reflects the accumulation of one or more
lipids that can not be metabolized due to FALDH deficiency. FALDH catalyzes the oxidation
of medium- and long-chain fatty aldehydes derived from fatty alcohols. Therefore, the
accumulated lipids would be fatty alcohols or fatty aldehydes. The peak at 1.3 ppm is narrow
and is still visible at a long TE of 135 msec, indicating a long T2. This implicates that the
accumulated lipids are present as mobile molecules moving freely or within inter- or
intracellular droplets. The lipid signal does not arise from lipids that are located inside lipid
bilayers such as membranes, because the low mobility of lipids organized in this way would
lead to broad resonances which are not visible at long TEs.
 In conformity with the findings of Mano and colleagues19, we observed another
abnormal but much smaller peak at 0.8-0.9 ppm within the cerebral white matter. This peak is
thought to reflect the protons from methyl (-CH3) groups, which are constituents of many lipid
molecules.
In contrast to the long list of substrates for FALDH in vitro,8 elevated concentrations
of only a very limited number of metabolites have been demonstrated in body fluids and
cultured skin fibroblasts of SLS patients. These include the saturated fatty alcohols with a
chain length of 16 and 18 carbons (hexadecanol and octadecanol respectively),11 their
corresponding fatty aldehydes (hexadecanal and octadecanal),9,10 leukotriene B4 (LTB4) and
its omega-oxidation product 20-hydroxy-LTB4.13 Although in vitro MRS of long-chain fatty
alcohols results in a narrow peak at 1.3 ppm,3,19 it would be necessary to analyze brain lipids
of an SLS patient to identify with certainty which compounds are represented by the peak at
1.3 ppm.
A striking finding was that the peak at 1.3 ppm was only present in the white matter and
not in the cortex, and that it had its maximum height in the posterior and anterior trigones,
where the signal abnormalities on T2-weighted images were seen (figure 5). However, we did
not find a systematic relationship between height of the 'lipid' peak and degree of signal
change on T2-weighted images.
In four patients (Patients 1, 2, 8, and 17) we observed a relatively low intensity of the
resonance at 1.3 ppm. The low intensities of the 'lipid' peaks in Patients 1 and 2 may suggest
that like the periventricular zone of signal abnormalities on MRI, the 'lipid' peak emerges in
the course of the first one or two years of life. Serial investigations in other individual patients
showed some variability of the intensity of the peak, but there was no systematic increase (or
decrease) with increasing age of these patients. Small, unavoidable differences in the position
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Figure 4. 1H-MR spectra obtained from cerebral white matter (A) and gray matter (B) of
Patient 3, echo time 20 msec. The voxel locations in the occipital trigone (A) and in the
central occipital gray matter (B) are indicated in the image. Note the presence of the high,
sharp 'lipid' peak at 1.3 ppm, and a small peak at 0.8-0.9 ppm in the spectrum obtained from
the white matter.
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of the voxel may explain this intraindividual variability. Patient 17, in whom virtually no
'lipid' peak was observed, has a mild phenotype SLS with ichthyosis and a crystalline
retinopathy, but no neurological abnormalities. However, her cerebral MRI studies are slightly
abnormal.
A comparable but smaller 'lipid' peak at 1.2-1.3 ppm has been described in one patient
with Niemann-Pick disease type C,34 a lipid storage disorder based on defective intracellular
lipid trafficking. It was postulated that the peak arises from the accumulation of protons of the
long carbon chain of glucosyl- and lactosylceramides. The presence of abnormal lipid signals
has been reported in patients suffering from degenerative disorders and multiple sclerosis.35-37
However, in the latter patients the 'lipid' peaks are less intense, have a broader line width and
can only be visualized with short TE.
In addition, we found increased levels of Cr (+18%), Cho (+18%), and especially Ins
(+51%) in the white matter of our patients, whereas t-NAA and Glx were normal. These
findings are compatible with white matter gliosis without significant axonal damage or
loss.36,37 Active demyelination would lead to a higher Cho level. Miyanomae and colleagues15
reported a decrease of NAA in cerebral white matter of a 25-year-old patient, which might
contrast with our findings. However, it has to be taken into account that the authors only
reported relative values (NAA/Cr and NAA/Cho). We did not find a correlation between
severity of MRI abnormalities and spectroscopic changes.
Neuropathology
Reviewing the neuropathological literature on SLS is hampered by the fact that this diagnosis
has not been proven in any of the patients reported. We would agree with Jagell2,38 that the
clinical descriptions of the patients reported by Bredmose,21 Baar and colleagues,22
Sylvester,23 Silva and colleagues24 and Wester and colleagues25 are highly suggestive of SLS,
whereas the cases described by Yamamoto and colleagues,26 McLennan and colleagues,27 and
Yamaguchi and Handa28 are atypical. The most extensive description was given by
Sylvester.23 The author studied described the existence of a 'pearly-grey strip, 1.0 cm in width,
from the frontal to occipital regions with sparing of the arcuate fibres'. In addition small
Figure 5. Metabolite map derived
from MRSI data of Patient 12
showing the spatial distribution of
the 'lipid' peak over the cerebral
white matter. The peak has its
maximum height around the
anterior and posterior trigones.
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droplets of free fat as well as lipid droplets within microglia were found. Pathology was
further characterized by a considerable deficit of myelin, axonal damage and astrogliosis in
the centrum semiovale and the corticospinal tracts. A reduced number of Betz cells was found
in the precentral gyrus. Mild to marked myelin deficit, slight loss of neurons, and an excess of
astrocytes have also been reported by others, but the presence of lipid droplets was not
explicitly mentioned. The neuropathological observations are largely in agreement with our
MRI and MRS findings. The most important difference is that we found a normal t-NAA level
in the white matter areas with abnormal signal, which is an argument against extensive axonal
damage.
CONCLUSIONS
The patterns of MRI and MRS abnormalities of the brain are strikingly similar among SLS
patients, but the severity varies. The morphological and biochemical abnormalities are already
present during the first years of life and subsequently show little or no progression. They are
confined to the cerebral white matter and the corticospinal tracts, and consist of the
accumulation of lipid substrates, delayed myelination, periventricular gliosis, and a permanent
myelin deficit. The 'lipid' peak at 1.3 ppm in the MR spectrum of cerebral white matter is
characteristic for SLS and may offer a quantitative parameter to measure the effects of (future)
therapeutic interventions.39
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CHAPTER 2.5
Skeletal muscle involvement in Sjögren-Larsson syndrome
M.A.A.P. Willemsen, M. Lammens, A. Verrips, H. ter Laak, J.J. Rotteveel
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ARTICLE ABSTRACT
The Sjögren-Larsson syndrome (SLS) is considered a neurocutaneous syndrome with
congenital ichthyosis, spasticity, and mental retardation as the main clinical features.
Stationary mental functions and neuroradiological abnormalities contrast with slowly
progressive decline of motor performance in many SLS patients. For this reason we studied
the histopathology of skeletal muscles in three randomly selected SLS patients. Type 1 fiber
predominance was present in all specimens. The muscle fibers generally had a small diameter,
and there was some increase in interstitial connective tissue and fat. The most striking
abnormalities consisted of marked type 1 fiber atrophy (Patient A), and abundance of
lobulated fibers (Patient B) and ring fibers (Patient C). These results point to skeletal muscle
involvement in SLS, but leave its origin unclear. Our findings shed a new light on SLS, and
may explain why motor performance gradually worsens with increasing age. Future
pathophysiological studies on SLS may be facilitated by the potential availability of relatively
large amounts of affected tissue.
INTRODUCTION
The Sjögren-Larsson syndrome (SLS; McKusick no. 270200) is an autosomal recessively
inherited disorder that was originally recognized due to the co-existence of congenital
ichthyosis, spasticity, and mental retardation.1 A juvenile macular dystrophy, pruritus, and
preterm birth, have been reported as additional clinical features.2-5 SLS is an inborn error of
lipid metabolism caused by deficiency of the microsomal enzyme fatty aldehyde
dehydrogenase (FALDH).4 The FALDH gene has been mapped to chromosome 17p11.2 and
mutation analysis has identified many different mutations in this gene in SLS patients.4
FALDH is considered a housekeeping enzyme and its gene expression has been demonstrated
throughout many different tissues. In humans, high levels of expression of the FALDH gene
are also noted in skeletal muscles.6 The widespread expression of the FALDH gene contrasts
with the consequence of FALDH deficiency, i.e. SLS, that always has been considered a
neurocutaneous syndrome. FALDH catalyses the oxidation of many different medium- and
long-chain fatty aldehydes, mostly derived from fatty alcohols, to the corresponding
carboxylic acids.4,7,8 The physiological role of fatty alcohol metabolism in humans is largely
unknown. The biochemical consequences of FALDH deficiency are an accumulation of fatty
alcohols and aldehyde-modified macromolecules, and defective inactivation of the
biologically highly active lipid leukotriene B4. How these processes subsequently lead to the
clinical features in SLS is not well understood.
The mental handicap and spasticity as well as the findings on cerebral magnetic
resonance imaging in SLS are generally considered to be non-progressive.1-5 Nevertheless,
most patients gradually become wheelchair dependent during the first two decades of life.1-5
Clinical or electromyographic abnormalities that could point to involvement of the peripheral
nervous system have never been reported in SLS,1-5 except for three cases with atypical
SLS.9,10 Skeletal muscle abnormalities have never been documented. Clinical features of
myopathy could, however, easily be overlooked in SLS because pyramidal signs dominate the
neurological picture, and clinical evaluation is hampered by the presence of mental
retardation. In a search for an explanation for the decline of motor performance, we
hypothesized that skeletal muscle abnormalities may occur in SLS.
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PATIENTS AND METHODS
Patients
Patient A, a 10-year-old girl, Patient B, a 10-year-old boy, and Patient C, a 16-year-old girl,
suffer from the classical SLS phenotype. Their clinical, biochemical, and genetic
characteristics have recently been described in detail (Patient A, B, and C correspond to
Patient 4, 12, and 15, respectively).5 Additionally, normal nerve conduction velocities and
amplitudes were measured in Patient A and C. Serum creatine kinase levels were normal.
Needle electromyographic studies of the muscles were not performed since informed parental
consent was not obtained. Almost all SLS patients require corrective orthopedic surgery in the
first decades of life, thus we consider these three patients as a random selection from our
series of 20 SLS patients.
Muscle Biopsy
Skeletal muscle specimens were obtained from the gastrocnemic muscle (Patient A) and the
quadriceps muscle (Patients B and C) during corrective orthopedic operations, after having
obtained informed parental consent. The muscle specimens were routinely processed for light
and electron microscopic investigations.11
RESULTS
We found pathological changes on light microscopic investigation of the muscle specimens in
all three patients (Table 1). In all patients there was a type 1 fiber predominance, which was
most prominent in patient B.  The muscle fibers generally had a small diameter, and
interstitial connective tissue and fat were slightly increased in all patients. The most striking
abnormalities however, consisted of severe type 1 fiber atrophy (Patient A), remarkable
abundance of lobulated fibers (Patient B) and the presence of ring fibers (Patient C). These
prominent abnormalities are illustrated in Figure 1-3. Fiber type grouping was never observed.
Additionally, electron microscopy revealed infrequent but still remarkable large intrafibrillar
fat droplets with a diameter up to 1800 nm (Patient A), and some pseudomyelin structures and
large mitochondria with a length up to 2000 nm (Patient B).
DISCUSSION
The pathological changes of the muscles in these SLS patients, especially the small diameters
of the muscle fibers and the slight increase in interstitial connective tissue and fat, are non-
specific. Severe atrophy of type 1 fibers was demonstrated in the gastrocnemic muscle of
Patient A. The question arises whether such a marked atrophy of type 1 fibers could be the
consequence of the upper motor neuron disorder of the patient. In children with cerebral palsy,
gastrocnemic muscle may be normal but may also show mild atrophy of type 1 (and/or type 2)
fibers.12,13 In contrast to the findings in children with cerebral palsy, type 2 fiber atrophy
(instead of type 1) is more consistently found in adult patients with spastic paresis due to
stroke.14-16 Myopathic conditions with marked type 1 fiber atrophy are myotonic dystrophy,
congenital fiber type disproportion, and various other types of congenital myopathy.11,15,16
Lobulated fibers as observed in Patient B and ring fibers as seen in Patient C are
myopathic changes that are mainly found in myotonic dystrophy, various forms of muscular
dystrophy, and congenital myopathy.16,17 Especially lobulated fibers are very rare in children,
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Table 1. Skeletal Muscle Histopathology in 3 Patients with Sjögren-Larsson Syndrome
Patient Muscle Type 1 Fibers Type 2 fibers Comments
% Diameter (µm) % Diameter (µm )
A
Controls
Gastrocnemius 54
35-50
22.8 (8-33)
45 (25-65)
46
50-65
42.7 (25-54)
45 (25-65)
Type 1 fiber atrophy
B
Controls
Quadriceps 84
35-50
25.4 (4-42)
45 (25-65)
16
50-65
21.1 (4-33)
45 (25-65)
Lobulated fibers
C
Controls
Quadriceps 66
35-50
47.8 (25-71)
60 (40-80)
34
50-65
47.5 (33-58)
60 (40-80)
Ring fibers
Control values are given in italics. Age adjusted normal values for quadriceps muscle were
from our own laboratory, and comparable with the values reported in the literature (see also
reference 16). Gastrocnemic muscle: normal values for fiber type distribution were from the
literature, and normal values for fiber diameter were taken over from the values for
quadriceps muscle (gastrocnemic fibers are only slightly larger than quadriceps fibers).16
and they have not been reported in association with upper motor neuron abnormalities,
spasticity, and joint contractures.
The final interpretation of the abnormalities should be facilitated by the fact that these
patients suffer from the same genetic disorder. The overall picture of these three pathologic
muscle specimens can not simply be attributed to chronic spasticity with onset early in life,
neither to peripheral neuropathy. It can be hypothesized that FALDH deficiency affects
skeletal muscles directly or that systemic abnormalities due to FALDH deficiency, e.g.
circulating toxic fatty alcohols, give rise to secondary myopathic changes. The lipid substrates
and the metabolic routes involved in SLS do not play a role in intracellular energy
metabolism, as is the case in myopathies due to defective mitochondrial ß-oxidation and
transmembrane transport of fatty acids. Furthermore, lipid storage is not a prominent feature
in the muscles studied here. Thus, it is likely that muscular involvement in SLS is caused by
mechanisms different from those in other well-known metabolic myopathies.
The skeletal muscle is the first reported non-ectodermal organ that is
histopathologically affected in SLS. Myopathic changes may explain why patients with stable
central nervous system signs and symptoms still show slow deterioration of motor
performance. In the follow-up of SLS patients more attention should be paid to muscle power
and endurance. To unravel the separate contributions of spasticity and myopathy to the
patients' motor handicaps is a future challenge.
Our findings need further confirmation in more SLS patients. They may in fact
broaden the clinical concept of SLS from neurocutaneous disorder to multi-system disease.
Finally, the potential availability of relatively large amounts of clinically affected tissue may
facilitate further pathophysiologic studies in SLS, because so far research was mainly
performed using blood leukocytes and cultured fibroblasts.
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Figure 1. Gastronemic muscle
biopsy of Patient A with small
type 1 fibers (ATP-ase stain,
pH 4.2; bar = 50 µm).
Figure 2. Multiple lobulated
fibers in quadriceps muscle
biopsy of Patient B (succinate
dehydrogenase stain; bar = 50
µm).
Figure 3. Ring fiber (arrow) in
quadriceps muscle biopsy of
Patient C (haematoxylin-eosin
stain; bar = 50 µm).
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CHAPTER 3.1
Clinical, biochemical and molecular genetic characteristics of 19
patients with the Sjögren-Larsson syndrome
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ARTICLE ABSTRACT
The Sjögren-Larsson syndrome (SLS) is an autosomal recessively inherited neurocutaneous
disorder caused by  deficient activity of the microsomal enzyme fatty aldehyde dehydrogenase
(FALDH). We report the clinical characteristics and the results of molecular studies in 19 SLS
patients. Patients 1-17 show the classical triad of severe clinical abnormalities including
ichthyosis, mental retardation and spasticity. Most patients were born preterm, and all patients
exhibit ocular abnormalities and pruritus. Electro-encephalography shows a slow background
activity, without other abnormalities. Magnetic resonance (MR) imaging of the brain shows an
arrest of myelination, periventricular signal abnormalities of white matter, and mild
ventricular enlargement. Cerebral 1H MR spectroscopy reveals a characteristic, abnormal lipid
peak. The degree of white matter abnormality in the MR images and the height of the lipid
peak in 1H MR spectra do not correlate with the severity of the neurological signs. The
clinical presentation and the clinical course is strikingly similar in these patients. Patient 18
shows a mild phenotype that essentially contains the same - but less severe - clinical features.
Patient 19 exhibits the typical - but very mild - dermatological and ocular abnormalities,
without any clinical neurological involvement.
The diagnosis of SLS was confirmed by demonstration of the enzyme defect in
cultured skin fibroblasts. Furthermore, as might be predicted from the essential role of
FALDH in leukotriene B4 (LTB4) metabolism, elevated urinary concentrations of LTB4 and
20-OH-LTB4 were found in all patients studied. Molecular studies of the FALDH gene
revealed eight different mutations, including three new ones: a large 26-bp deletion (21-
46del), a missense mutation (80C>T), and an insertion mutation (487-488insA). The vast
majority of SLS patients seem to be severely affected independent of their genotype.
INTRODUCTION
The Sjögren-Larsson syndrome (SLS; McKusick no. 270200) is an autosomal recessive
neurocutaneous disorder that was originally recognized in the co-existence of congenital
ichthyosis, spastic di- or quadriplegia and mental retardation.1-3 Additional clinical findings
that have been reported include a juvenile macular dystrophy, pruritus, and preterm birth.4-8
SLS was originally described in the county of Vasterbotten in northern Sweden. Probably due
to founder effects and inbreeding, a high prevalence (8.3 per 100,000) is found in this
population while its prevalence over the whole of Sweden is only 0.4 per 100,000. SLS is now
known to occur world-wide and - in the absence of clusters of patients reported elsewhere - its
prevalence has been estimated as 0.4 per 100,000 or lower. Recently, we have described
beneficial effects of the leukotriene B4 (LTB4) synthesis inhibitor zileuton in the treatment of
SLS.9 No other causative therapeutic options are available at present.
SLS is an inborn error of lipid metabolism caused by a deficiency of the microsomal
enzyme fatty aldehyde dehydrogenase (FALDH).10,11 This enzyme catalyses the oxidation of
medium- and long-chain fatty aldehydes, whether or not derived from fatty alcohols, to the
corresponding carboxylic acids (Fig. 1).12-14 It has been postulated that FALDH deficiency
may lead to an accumulation of fatty alcohols or aldehyde-modified macromolecules with
structural consequences for cell-membrane integrity, and that it may lead to elevated
concentrations of biologically highly active lipids.11,15,16
In 1994 the FALDH gene was mapped to chromosome 17p11.2.17 Its genomic
organisation and tissue-dependent expression have subsequently been elucidated.18,19 The
gene consists of 10 exons and 9 introns, and spans about 31 kb. The cDNA for FALDH
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encodes a protein of 485 amino acids. This protein has a hydrophobic carboxyl-terminal
amino acid sequence that is assumed to be necessary for microsomal membrane anchoring.20
Alternative splicing of the FALDH gene results in a transcript with an additional sequence
(exon 9’). The protein produced from this mRNA is far less abundant, and its function is
unknown. Mutation analysis has identified many different mutations in the FALDH gene in
SLS patients.21-28 The extensive report by Rizzo and colleagues shows that SLS is associated
with a striking number of different mutations.26 The available studies that deal with the
molecular biology of SLS provide only very limited clinical data.
This study aims to outline the clinical signs and symptoms together with the
biochemical characteristics and the mutational spectrum of SLS, based on a series of 19
patients from 13 families.
PATIENTS AND METHODS
Patients
Our series consists of 19 patients from 13 families (Table 1). Patients 1-17 suffer from the
classical phenotype with severe involvement of the skin, the CNS, and the eyes. Patients 18
and 19 have mild clinical features. Families VII, VIII and IX originate from Turkey, while the
other families have their roots in The Netherlands. The parents in families IV, VIII, and IX are
known to be consanguineous. The fathers of patients 1 and 5 are relatives in the second
degree.
CH3-(CH2)16-COOH
octadecanoic acid
CH3-(CH2)16-CO-S-CoA
octadecanoyl-CoA
CH3-(CH2)16-CH2OH
octadecanol
CH3-(CH2)16-CHO
octadecanal
FALDH
CH3-(CH2)16-COOH
octadecanoic acid
Figure 1. Fatty aldehyde dehydrogenase
(FALDH) catalyzes the oxidation of fatty
aldehydes, e.g. octadecanal as illustrated
here, to fatty acids. CoA=coenzym A.
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The degree of spasticity was scored based on the ability to ambulate: the patient is
confined to a wheelchair (3); the patient uses a wheelchair in everyday life, but is able to walk
a short distance with or without the help of aids (2); the patient has a mild spastic gait or
shows involvement of the pyramidal tracts on physical examination (1); there are no signs or
symptoms of involvement of the pyramidal tracts (0). Mental performance was measured in
10 patients using standard intelligence tests, and estimated - based on school performance and
communication skills - in the other patients. Mental retardation has been defined as an IQ <
70, and classified according to the WHO criteria.29 Electro-encephalography was routinely
performed in 13 patients using a 32-channel Oxford Instruments Profile digital EEG-system.
Clinical findings on Patients 2, 4-7, 12-15, 18 and 19 and detailed results of
ophthalmologic investigations of Patients 1-9, 12-15, 18 and 19 have previously been
described.7,30
Magnetic resonance (MR) imaging and 1H MR spectroscopy
Cerebral MRI and 1H MR spectroscopy of the brain have been performed in 16 and 13
patients respectively, using the methods described previously.7 All MR images were
systematically evaluated and scored. The abnormalities of the cerebral white matter were
graded with regard to the intensity of the pathological signal on T2-weighted images (grade 0
= normal white matter; grade 1 = mildly increased signal intensity; grade 2 = severely
increased signal intensity). The MR spectra were evaluated with regard to the presence of the
characteristic lipid peak.31,32,7 For that purpose, MR spectra from the occipital white matter
(echo time (TE) 30 ms; repetition time (TR) 3000 ms; volume of interest 20x20x20 mm) were
selected in each patient. In those spectra, we compared the height of the lipid peak with the
height of the N-acetylaspartate (NAA) peak, and graded it as follows: 0 (no lipid peak visible),
1 (lipid peak < NAA peak), or 2 (lipid peak > NAA peak). The spectral signs of the lipid peak,
NAA, choline, and creatine were not quantified for this study.
Biochemical investigations
The FALDH activity was measured in cultured skin fibroblasts, using octadecanol as the
substrate. We used the methods as described by Rizzo and colleagues,10,11 with only minor
modifications.27
The concentrations of LTB4, 20-OH-LTB4, and 20-COOH-LTB4 were measured in
urine (n = 16) and CSF (n = 8). The LTB4 degradation capacity of fresh polymorphonuclear
leukocytes was determined in six patients. The methods used have been described in detail,
together with most of the results for SLS patients as a group.16
Mutation analysis
The genomic DNA from peripheral blood cells was isolated for genetic analysis using a
diatom matrix as described by Boom and colleagues.33
PCR-RFLP analysis
For rapid screening of the 943C>T mutation, genomic DNA was amplified in a 25 µl PCR
reaction containing 10 mM Tris-HCl (pH 8.4 at 25°C), 1.0 mM MgCl2, 50 mM KCl, 0.1
mg/ml bovine serum albumin, 0.2 mM each dNTP, 2.5 U Taq polymerase (Promega) and the
sense primer 5’-CAG TTC ATC CAC GTG CTC AG-3’, and the anti-sense primer 5’-AGA
GCC AGA GGC TTT TCA CG-3’. DNA amplification was performed in a PTC–100
thermocycler from M.J. Research Inc. programmed as follows: 120 s at 96°C before starting
cycling, 5 cycles of 30 s at 96°C, 30 s at 55°C and 60 s at 72°C followed by 30 cycles of 30 s
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at 94°C and 60 s at 72°C, with a final extension at 72°C for 10 min. Subsequently PCR
products were digested with MnlI and were analysed by agarose gel (2% w/v) electrophoresis.
Sequence analysis
The FALDH gene was amplified in 7 fragments under PCR conditions as described above,
using the M13-tagged primers as listed in Table 3. DNA amplification was performed in a
PTC–100 thermocycler from M.J. Research Inc. programmed as follows: 60 s at 96°C  before
starting cycling, 5 cycles of 30 s at 96°C, 30 s at 55°C and 180 s at 72°C followed by 30
cycles of 30 s at 96°C and 180 s at 72°C, with a final extension at 72°C for 10 min. Sequence
analysis of the PCR fragments using BigDye fluorescent labelled M13 primers was performed
on an Applied Biosystems 377A automated DNA sequencer following the manufacturer's (PE
Applied Biosystems, Foster City, CA) protocols.
RESULTS
The clinical features of the patients, the results of MRI, 1H MR spectroscopy, and EEG, the
concentrations of LTB4, 20-OH-LTB4, and 20-COOH-LTB4, the enzyme activities of
FALDH, and the mutations in the FALDH gene are summarized in Table 1 and 2.
Clinical features
Patients 1-17
The dermatological manifestations of these patients were strikingly similar. In the first months
after birth the cutaneous features were often mild. During the first year of life, however, the
skin took on a highly characteristic appearance with brownish yellow discoloration and a
markedly wrinkled hyperkeratosis (Fig. 2). The ichthyosis was generalized, with sparing of the
face only. Pruritus was an accompanying disabling feature in all patients, and was present
every day. Since the skin disorder was the most prominent sign in early infancy, most patients
were first seen by the dermatologist. In some patients the characteristic appearance of the
ichthyosis was recognized, which led to an early diagnosis of SLS. In others, the diagnosis
was made in infancy after emerging neurological signs became apparent.
          
Figure 2. Photographs of the highly characteristic abnormalities of the skin of the neck of a
14-year-old girl with Sjögren-Larsson syndrome (Patient 12). The skin shows a severe
yellowish brown wrinkled hyperkeratosis with scratches as a sign of the accompanying
pruritus.
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Spasticity was found in all seventeen patients, predominantly involved the legs, and presented
during the first two years of life with gradual worsening. All patients used a wheelchair in
everyday life. Patients 1, 5, 6, 12, and 15, however, had maintained the capability to walk a
short distance (< 25 meters) with the use of aids, and Patients 8 and 9 were able to walk up to
100 meters unsupported. Joint contractures of the legs had developed in all patients and often
necessitated orthopaedic corrections. Speech production was affected in all, based on
pseudobulbar dysarthria in combination with cognitive defects. The patients' mood was
strikingly good. All children attended special schools for the mentally handicapped. The
mental retardation should be qualified as 'mild' to 'moderate'. In addition, mental performance
was characterized by a marked slowness. Clinical follow-up, parental reports, and results at
school, as documented by the teaching staff, showed no loss of acquired skills. One or more
epileptic seizures occurred in three children, none of them requiring chronic treatment with
antiepileptic drugs. The neurological picture varied slightly between the patients, with
comparable differences within and between families.
The macular dystrophy was characterized by the presence of retinal crystals, generally
referred to as “glistening white dots” (Fig. 3). The number of retinal crystals seemed to
increase slightly with age.30 Inter-individual differences in the number of dots in patients of
the same age group were negligible. Bilateral corrected visual acuity ranged between 0.6 and
0.16. Photophobia was a remarkable additional finding.
All EEG recordings (Patients 2, 4-9, 12-15) showed symmetric slow background
activity with an alpha rhythm frequency of 7 to 8 Hz. None of the EEGs revealed epileptiform
patterns or abnormal changes of amplitude.
Patients 18 and 19
Patient 18, a male, was born after a normal pregnancy and delivery. In the first nine months of
life, the skin was unremarkable. Thereafter a generalized fine scaling of the skin with
hyperkeratotic, well-demarcated and yellow-brown coloured plaques developed gradually.
Pruritus and photophobia were additional symptoms. Psychomotor development was normal
during childhood. Difficulties with walking developed during adolescence, and gradually
worsened during the following decades. At the age of 36 years, he was investigated by the
neurologist and ophthalmologist. The patient seemed feeble-minded, had a mild spastic gait,
Figure 3. Photograph of the fundus of the
left eye of a 14-year-old girl with Sjögren-
Larsson syndrome (Patient 12). The juvenile
macular dystrophy is characterised by the
presence of crystalline deposits, the so-
called ‘retinal glistening dots’.
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and hyperreflexia of the legs and extensor plantar responses. Speech was unremarkable. The
ocular abnormalities consisted of subnormal visual acuity, the presence of macular glistening
dots, and photophobia. The EEG showed a symmetric background activity with an alpha
rhythm frequency of 7 to 8.5 Hz, without other abnormalities. The patient has two healthy
children.
Patient 19, the sister of Patient 18, was born preterm. However, the precise gestational
age could only be estimated as "three months too early". Her skin was reported normal until
the age of nine months, at which time she developed skin symptoms similar to those of her
brother but less extensive. The characteristic skin lesions were only found in the main flexor
folds of the extremities including the axillae. Occasionally she experiences pruritus. Her
intellectual development was normal. There were no motor complaints. Neurological
examination revealed no abnormalities. Ophthalmologic examination showed the typical
retinopathy and photophobia. Her EEG was normal (alpha rhythm: 10 - 11 Hz). She has given
birth to one healthy child.
The parents and the siblings (4 brothers and 1 sister) of Patients 18 and 19 are healthy,
and show no neurological or dermatological abnormalities.
MRI and 1H MR spectroscopy
The MRI studies showed no gross structural defects. Three abnormal phenomena were
observed on T2-weighted images. First, small areas of the subcortical association fibres of the
frontal, parietal, and occipital convexities, as well as the temporal pole were found to be
unmyelinated in all but one patient (Patient 18). Secondly, all patients showed a
periventricular zone, extending from frontal to occipital, of hyperintense signal disturbances.
Thirdly, mild ventricular enlargement was found in the oldest patients. There were no signs of
severe atrophy. 1H MR spectroscopy revealed the presence of the characteristic lipid peak in
all patients, except Patient 19.
Biochemical characteristics
Urine was determined to be free of protein, erythrocytes and leukocytes. The concentrations of
LTB4 and 20-OH-LTB4 were found to be highly elevated in all patients (n = 16), while 20-
COOH-LTB4 was absent. This pattern fits with a metabolic block between 20-OH-LTB4 and
20-COOH-LTB4, due to FALDH deficiency. None of the three metabolites were found in
healthy controls (detection limit < 5 nmol/mol creatinine). The mean (SD) concentrations of
LTB4 and 20-OH-LTB4 in 14 severely affected patients were 29.9 (14.3) and 291.6 (148.2)
respectively. The results of patients 18 and 19 fell within this range.
CSF showed normal values for erythrocytes, leukocytes, total protein, albumin (and Q-
albumin), glucose, and lactate in all patients (n = 8). Mean (SD) concentration of LTB4 in CSF
was 134.5 (22.1) pmol/l, which equals the mean (SD) concentration (114.7 (57.1) pmol/l) in
control samples. The concentrations of 20-OH-LTB4 and 20-COOH-LTB4 in CSF were below
the detection limit (< 15 pmol/l) in SLS patients and controls.
Molecular biology
We found nine different mutations in 13 families (Table 1 and 2). Three of these mutations (a
large 26-bp deletion (21-46del), 487-488insA and 80C>T) have not been reported before.
Homozygosity was found in 10 patients, while eight patients were compound heterozygous.
Five mutations were only found in single families. Heterozygosity has been proven in all
parents, except in family XII from which material was not available.
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  Table 1. Clinical, biochemical and molecular genetic characteristics of 19 SLS patients from 13 families
Family I II III IV V VI VII VIII IX X XI XII XIII
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Sex, age (yrs) M, 4 M, 7 M, 9 F, 9 F, 17 F, 18 F, 21 M, 2 F, 8 M, 7 F, 11 M, 9 M, 16 F, 13 F, 14 M, 45 F, 46 M, 42 F, 46
Clinical features
  Skin
     Ichthyosis 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 1
     Pruritus 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 1
  Brain
     Spasticity 2 3 3 3 2 2 3 2 2 3 3 2 3 3 2 3 3 1 0
     Mental Performance MR MR MR 55 56 54 50 MR 61 MR MR 49 48 MR 48 MR MR 83 84
     Seizures - - - - - - - - - + + - + - - - - - -
  Eye
     Visual acuity . 0.16 0.4 0.6 0.3 0.25 0.3 . 0.4 . . 0.5 0.25 0.6 0.6 . . 0.8 1.0
     Retinal crystals + + + + + + + + + . . + + + + . . + +
     Photophobia + + + + + + - + + + + + + + + . . + +
  Birth
     Gestational age 35 37 36 38 36.5 37.5 28 34.5 36.5 37.5 35 34 33 36 35 . . term <37
Metabolites (urine)
  LTB4 42 12 27 38 16 69 40 26 24 15 . 29 38 23 19 . . 17 23
  20-OH-LTB4 337 114 161 347 124 622 512 361 392 97 . 283 319 210 203 . . 192 176
  20-COOH-LTB4 <5 <5 <5 <5 <5 <5 <5 <5 <5 <5 . <5 <5 <5 <5 <5 <5
MR imaging, T2-weighted
  Retarded myelination + + + + + + + + + + . + + + + . . - +
  Periv. hyperintens signals 1 1 1 1 2 1 1 1 1 2 . 1 2 1 1 . . 1 1
  Mild ventr. enlargement - - - - - + + - - - . - + + - . . + +
1H MR spectroscopy
  Lipid peak 2 2 2 1 1 2 1 1 1 . . 2 2 . 1 . . . 0
Electro-encephalography
  Slow background activity . + . + + + + + + . . + + + + . . + -
FALDH activity
  Octadecanol 4.7 3.2 3.7 6.3 5.1 5.2 5.6 0.0 3.3 . 8.8 3.8 5.1 3.7 4.5 . 9.4 7.9 6.4
  LTB4 . . . . . . . <1 <1 . . <1 <1 . . . . 3.2 2.7
Mutation analysis
  Allele 1 [1] [3] [3] [5] [1] [1] [6] [7] [7] . [8] [1] [1] [1] [1] [1] [1] [3] [3]
  Allele 2 [2] [4] [3] [5] [2] [5] [6] [7] [7] . [8] [1] [1] [3] [3] [1] [1] [9] [9]
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Legend of Table 1. Symbols used: M (male), F (female). The severity of the ichthyosis,
pruritus, and motor disabilities due to spasticity, were scored as follows: 0 (absent), 1 (mild),
2 (moderate), or 3 (severe). Mental performance is given as the total IQ score, or described
as mental retardation (MR). Epileptic seizures, retinal crystals, photophobia, retarded
myelination (MRI), mild ventricular enlargement (MRI), and slow background activity (EEG)
were denoted as - (absent) or + (present). The intensity of the white matter lesions (MRI) were
graded 0 (absent), 1 (mild), or 2 (severe). Periv. = periventricular; ventr. = ventricular. MR
spectroscopy: the height of the lipid peak compared to the NAA peak was scored as follows: 0
(no lipid peak visible), 1 (lipid peak < NAA peak), or 2 (lipid peak > NAA peak). Gestational
age is given in weeks (normal range: 37 to 42 weeks). Concentrations of LTB4, 20-OH-LTB4,
and 20-COOH-LTB4 in urine are expressed in nmol/mol creatinine; the concentrations of all
three metabolites are < 5 nmol/mol creatinine in healthy controls. With octadecanol as
substrate, FALDH activity is expressed in pmol/min/mg protein; reference 19.7 - 54.3 (n =
13). With LTB4, FALDH activity is expressed as % of the initial amount of substrate (i.e.
LTB4); reference 42.8 - 60.1 (n = 10). The numbers of the different mutations are explained in
Table 2. Missing data are indicated by a full stop.
Table 2. Identification of the mutations found in 13 SLS families
Mutation
number in
Table 1
Number of families with
at least one allele
affected by the mutation
Nucleotide change Protein change
[1] 6 1297-1298delGA Truncation
[2] 2 798G>C K266N
[3] 4 943C>T P315S
[4] 1 21-46del Truncation
[5] 2 80C>T L27P
[6] 1 487-488insA Truncation
[7] 1 1381-1384delGAAA Truncation
[8] 1 733G>A D245N
[9] 1 551C>T T184M
DISCUSSION
Clinical aspects
In 1957 Sjögren and Larsson described a series of patients who suffered from a severe
disorder with three cardinal features: ichthyosis, mental retardation and spastic di- or
quadriplegia. Since then, the syndrome has borne their names. The underlying enzyme
deficiency was discovered 31 years later and it took another 6 years before the genetic defect
was unravelled. The full clinical spectrum of SLS can now be examined in patients in whom
the diagnosis has been proven and the biochemical and genetic basis have been resolved.
The skin disorder in SLS has a characteristic appearance with its prominent
generalized hyperkeratosis and remarkable brownish yellow colour. All patients also suffer
from severe pruritus. The presence of pruritus in SLS contrasts with other ichthyotic skin
disorders that are generally non-itching. For this reason, pruritus has to be recognized as an
important additional symptom that strongly suggests SLS in patients under investigation.
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The ocular abnormalities that can be found in SLS seem to be undervalued in the
literature. We have recently performed a detailed study on the ophthalmologic features in 13
patients and found multiple abnormalities in all patients.30 Photophobia, macular dystrophy,
and decreased visual acuity, are the most prominent of the ophthalmologic abnormalities. It is
important to note that the glistening white dots of the retina can easily be overlooked in young
and less co-operative patients who suffer from photophobia. This seems the best explanation
for the report of a lower prevalence of macular dystrophy in the literature. The nature of the
crystalline deposits in the retina is unclear. It is speculated that they might represent
accumulations of long-chain fatty alcohols or fatty aldehydes.
Preterm birth was reported for 12 out of 17 (71%) SLS patients in this series, and
seems to be one of the features of the syndrome.8 The reason for the preterm birth is unclear.
It is hypothesized that it relates to the defective LTB4 degradation in SLS. Despite their
preterm birth, none of the patients suffered from perinatal or neonatal complications. For this
reason, spasticity in SLS and preterm birth should be interpreted as co-existing features. The
spasticity should not be attributed to the prematurity.
The patients' spasticity gradually worsens during the first decades of life, leading to
contractures and - in most patients - to wheelchair dependency. The number of retinal crystals
seems to increase slightly with age, and cerebral MRI shows a mildly enlarged ventricular
system in the oldest patients. These findings might reflect a very slow progressive course of
the disease. On the other hand, the mental handicap and the other clinical features of SLS,
seem to be non-progressive in all patients.
Patients 18 and 19 exhibit most of the classical features of SLS but they are far less
severely affected. Their ichthyosis has the same age of onset and the same appearance as in
Patients 1-17, but affects a far less extensive area of the skin. Pruritus is less severe. The
characteristic retinopathy was found in both patients. Both patients have a normal intelligence,
and only Patient 18 developed a (relatively mild) spastic diplegia from the second decade of
life. Barnard and colleagues described two brothers with a marked speech defect, ichthyosis,
spasticity, and the typical crystalline retinopathy. In contrast to the severe spasticity and
involvement of the eye and skin, both men were reported to be 'responsive and intelligent'.34 It
is not reported whether the diagnosis in this family has been biochemically proven. Nigro and
colleagues described three siblings with decreased FALDH activities (in the range of SLS
patients), and a mild phenotype.35 All three patients showed mild spasticity, but only two of
them had skin abnormalities (demarcated plaques of hyperkeratotic yellow-brown skin). Their
speech was normal, and there was no evidence of mental retardation in these patients.
Ophthalmologic investigations did not indicate any abnormalities. The authors don't report on
preterm birth or pruritus. To our knowledge, these three families (Barnard et al.,34 Nigro et
al.,35 and family XIII reported in this paper) are the only ones with 'non-classical' SLS. There
are two possible explanations for the rarity of reports on mildly affected SLS patients. First,
mild SLS might indeed be extremely rare. The uniformity of the severe clinical features of our
Patients 1-17 might favour the assumption that phenotypic variation is uncommon in SLS.
The other possibility is, however, that SLS is insufficiently recognized in mildly affected
patients. In those cases where the classical features occur together but are mild, it should still
be possible to recognize SLS. However, when an isolated 'SLS feature' is encountered in the
absence of the other two features of the classical triad, it will be very difficult to realize that
the patient might be suffering from SLS. As routinely performed laboratory investigations
don't offer any biochemical marker for SLS the identification of mildly affected patients is
further hampered.
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Table 3. PCR primers used to amplify the FALDH gene from genomic DNA
Fragment Name Sequence
A -29exonFALDHf 5’-[-21M13] GAC CGT GCA GTT CTC TGC AG-3’
Intron1FALDHr 5’-[M13rev] AAG ACT CCA GTC CAC AAG TG-3’
B Intron1FALDHf 5’-[-21M13] GTT GTC ACT ACA GGT GTA CC-3’
Intron3FALDHr 5’-[M13rev] AAG AGA CTG CAA TTG GGT CC-3’
C Intron3FALDHf 5’-[-21M13] TAT TTG GCA GTG CAA GAG TTT GT-3’
Intron5FALDHr 5’-[M13rev] GGA GAA ACA AAT GGG GAT GC-3’
D Intron5FALDHf 5’-[-21M13] AGA TTG ATT TTG GGG CAT GG-3’
Intron6FALDHr 5’-[M13rev] AGC TAC AGG TAC AGT ATA CC-3’
E Intron6FALDHf 5’-[-21M13] GAA AGG CAT GGA TAA GTG AC-3’
Intron8FALDHr 5’-[M13rev] ACA GCT GGC TAT TTC AGC AG-3’
F Intron8FALDHf 5’-[-21M13] GGA GTG CAT GTG AGC TTT CC-3’
Intron9FALDHr 5’-[M13rev] ATA TGC ATC TGG CAG CCA TC-3’
G Intron9FALDHf 5’-[-21M13] AGA CAG GAG GTG TCT GAG TC-3’
1714exon10FALDHr 5’-[M13rev] CCC TAG CTC AAA GTT CCA AG-3’
The primers were selected using the genomic sequences with GenBank numbers U75286 to
U75297 as published by Rogers and colleagues (Rogers et al., 1997). [M13rev]: cag gaa aca
gct atg acc; [-21M13]: tgt aaa acg acg gcc agt.
MRI and 1H MR spectroscopy
The results of cerebral MRI are abnormal in all patients studied by us, but lack specificity. A
clear relation between the degree of the MR abnormality and the neurological features could
not be demonstrated. 1H MR spectra reveal a typical lipid peak that is present in all severely
affected patients. This sharp lipid peak clearly differs from the lipid signals that are found in
other disorders with white matter involvement, and is thought to arise from the accumulation
of long-chain fatty alcohols or fatty aldehydes.7,31,32 The height of the lipid peak (as compared
to the height of the NAA peak) does not seem to predict the severity of the neurological
features. Although the findings in only one mildly affected patient don’t provide much basis
for speculation, the absence of the peak in Patient 19 might still suggest that its presence
marks the severe phenotype of SLS.
FALDH: the enzyme and its substrates
Aldehyde dehydrogenases (ALDHs) are a group of enzymes that catalyse the oxidation of
aldehydes to their corresponding carboxylic acids.36,37 They are widely distributed throughout
all species. These enzymes all have their individual subcellular localisations and tissue
distributions. Some ALDHs can oxidize only a limited range of substrates, while others have
broad substrate specificity. In humans, at least twelve ALDHs have been identified. They are
generally referred to as ALDH1 to ALDH9, FALDH or ALDH10, succinic semialdehyde
dehydrogenase (SSDH), and methylmalonate semialdehyde dehydrogenase (MMSDH).
Phylogenetic studies have demonstrated that the human ALDH3, 7, and 8, and FALDH are
closely related. Some regions of the protein are highly conserved in these and other human
ALDHs, and in many ALDH families from other species.
The measurement of FALDH activity in leukocytes or cultured skin fibroblasts can
easily discriminate between patients and healthy controls when  the C18 aliphatic fatty alcohol
(octadecanol) or aldehyde (octadecanal) is used as a substrate.5,7,11 In our experience (> 40
patients), FALDH residual activities in patients range between 0 and 25% of the mean value
in controls, without overlap with the normal range. However, it is assumed that the level of
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residual activity as measured is higher than the true FALDH activity. One explanation for this
phenomenon could be that other aldehyde dehydrogenase isozymes, present in the cytoplasm
or in other cell compartments, will - at least under in vitro conditions - also react with
octadecanol or octadecanal. This fact has so far hampered the elucidation of the relationship
between the genetic defect, the degree of FALDH deficiency, and the phenotypic expression.
The measurement of the LTB4 degradation capacity of fresh leukocytes might offer a solution
to these problems. Briefly, radiolabeled LTB4 is added to isolated leukocytes, and the amount
of radiolabeled 20-COOH-LTB4 is measured after an incubation period of 15 minutes. The
amount of radiolabeled 20-COOH-LTB4 is expressed as the percentage of the initial amount
of LTB4. We found that leukocytes of four severely affected patients did not oxidize any (<
1%) LTB4 to 20-COOH-LTB4. The leukocytes of the mildly affected patients showed minimal
- but unmistakable - residual activity: they were able to convert 3.2% (Patient 18) and 2.7%
(Patient 19) of LTB4 to 20-COOH-LTB4. The leukocytes of 10 healthy controls showed
activities of 51.4% (SD 5.4%). Although the results of these investigations have to be
interpreted with caution because of the limited number of patients that were tested, they seem
promising. The measurement of the LTB4 degradation capacity might offer the first
opportunity to determine the true residual activity of FALDH in SLS patients. If so, it
provides a tool to study the correlation between residual enzyme activity and clinical
phenotype.
When free fatty alcohols are measured in plasma, octadecanol and hexadecanol are
found to be elevated in SLS patients.38 Technical difficulties in fatty alcohol analyses,
however, still hinder their quantification. Moreover, fatty alcohols have also been shown to
accumulate in patients suffering from other inborn errors of metabolism.39 The pathological
urinary excretion of LTB4 and 20-OH-LTB4 is a biochemical marker for SLS.16 All patients
have abnormally elevated concentrations of both metabolites, with a normal concentration of
20-COOH-LTB4. This pattern has never been found in other patients. The concentrations of
these metabolites in the mildly affected Patients 18 and 19 do not differ from the
concentrations in the severely affected patients. Based on these results, we conclude that the
analyses of LTB4 and its metabolites in urine can be used as a diagnostic tool for SLS. The
excretion pattern is highly characteristic, but the concentrations of the metabolites do not
predict the severity of the phenotype.
Biochemical investigations of CSF have so far not revealed any abnormality in SLS
patients. Surprisingly, even (20-OH-)LTB4 concentrations are normal in CSF. The latter
contrasts with the systemic (urinary) values and points to an as yet unknown 'escape
mechanism' of the CNS.
FALDH: the gene
We found nine different mutations in 13 families, including three unreported mutations.
Overall, missense and deletion mutations seem to occur most often in the FALDH gene of
SLS patients.25,26
The 943C>T mutation leads to the substitution of serine for the highly conserved
proline at position 315 in the FALDH protein and is, together with the 1297-1298delGA
mutation, held responsible for a large part of all mutations in patients of European
origin.22,40,41 In the patients presented here, they affect 20 out of 36 alleles (56%). The 1297-
1298delGA mutation22 as well as the 1381-1384delGAAA mutation27 are predicted to result
in a truncated FALDH that no longer anchors to the microsomal membrane, with consequent
loss of enzymatic function. The 798G>C mutation has recently been found in a compound
heterozygous patient, who also carried the common 943C>T mutation.26 Clinical data for the
patient were not given. Expression studies of the 798G>C mutation in Chinese hamster ovary
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cells revealed an enzyme with relatively high (55%) residual activity.26 Importantly, the
authors found that the mutation resulted in an unstable mRNA. Thus, this mutation seems to
have a greater effect on the amount of enzyme produced than on the activity of the actual
enzyme. Our patients 1 and 5 are compound heterozygous for the 798G>C and the 1297-
1298delGA mutation. The presence of the 798G>C mutation in these two patients with the
classical features of SLS supports its pathogenic significance. Another missense mutation,
namely 733G>A, was originally regarded as a polymorphism,25 but has subsequently been
reported to result in severe reduction of FALDH activity.26 We found this mutation in an
inbred family with two homozygous patients, which confirms its destructive consequences.
Two missense mutations of the FALDH gene, namely 551C>T and 943C>T, were
shown to occur in the siblings with a mild phenotype (Family XIII). Both patients were found
to be compound heterozygous for these mutations. Heterozygosity for the 551C>T mutation
could be proven in the mother and three siblings of the patients, while the father carried the
943C>T mutation. The 551C>T mutation has previously been described in four probands with
SLS.26
 
 The clinical features in these patients have not been reported. The mutation has been
predicted to cause the substitution of threonine at 184 by methionine (T184M). Threonine 184
is demonstrated in human ALDH 1-10 and SSDH, and is part of a well-conserved region of
human ALDHs. This threonine is just upstream of two glycine residues (G185 and G190)
which were found to participate in NAD binding.42 The T184M mutation might change the
binding of NAD and thereby increase the Km for this substrate. We were unable to confirm
this hypothesis experimentally, because a 10-fold increase in the concentration of NAD did
not lead to higher residual activity of the protein (data not shown). Expression of the 551C>T
mutation into FALDH-deficient Chinese hamster ovary cells resulted in severe loss of
FALDH catalytic activity (< 1% of wild type).26 Based on the actual knowledge about both the
551C>T and the 943C>T mutations, as summarized above, it seems impossible to explain the
mild phenotype of these patients on the basis of their genotype.
The 80C>T mutation in exon 1 has never been reported before. We have found it in
one compound heterozygote and one homozygous patient. This mutation leads to substitution
of leucine to proline at position 27. This is the most amino-terminal mutation of any of the
previously reported missense mutations. The leucine at position 27 is well conserved among
aldehyde dehydrogenases in humans and other species including fungi and bacteria, and is
found in the cytosolic, mitochondrial as well as microsomal isozymes.36,37 Figure 4 illustrates
the homology of different aldehyde dehydrogenases and the high conservation of the amino
acid leucine at position 27 in FALDH. Insertion mutations are rarely found in SLS, and
Figure 4. Alignment of six amino acid sequences of different human and vertebrate ALDH’s.
Protein Subcellular
distribution
Amino acid sequence
Human ALDH10 microsomal SR P L R F R L Q Q L E A L R R M V Q E R
Rat ALDH3 microsomal SR P L R F R L Q Q L E A L R R M V Q E R
Mouse ALDH3 microsomal SR L R F R L Q Q L E A L R R M V Q E R
Human ALDH3 cytosolic R P L F R Q Q L E A L R Q E
Human ALDH7 microsomal R P R Q L L R Q E
Human ALDH8 microsomal R P R Q L L Q E
The alignment is based on the reports by Yoshida and colleagues (Yoshida et al., 1998) and
Perozich and colleagues (Perozich et al., 1999). The bold ‘L’ reflects the amino-acid leucine
at position 27 in FALDH. FALDH is denoted as ALDH10.
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isolated 1 bp insertions have only been reported in two families.25,26 The finding of the (new)
487-488insA mutation in exon 4, that causes a frameshift, is remarkable from this point of
view. The other new, and large, 26 bp deletion mutation of exon 1 (21-46del) in Patient 4
gives rise to a frameshift from codon 7. Although deletion mutations are quite common in
SLS, such gross mutations are rare.
All reports on the molecular biology of SLS published up to now have stated that the
patients who were analysed suffered from SLS without giving details of the phenotypes. The
phenotype of Patients 1-17 is essentially uniform with regard to the occurring features as well
as their course, although slight differences between patients can be found. This clinical
homogeneity is in favour of the assumption that there is only slight phenotypic variation
within most SLS patients. A wide spectrum of mutations contrasts with a phenotype with
consistent severe involvement of the skin, the CNS and the eyes.
CONCLUSION
On clinical grounds the diagnosis of SLS should be considered in any neonate or infant with a
congenital ichthyosis, especially when the child is born preterm. In an infant not yet
diagnosed, emerging neurological features should point to SLS. If the diagnosis of SLS comes
into consideration, one should look for such additional clinical features as pruritus, retinal
glistening dots and photophobia. These additional features are decisive for the clinical
diagnosis. Cerebral MRI reveals arrested myelination maturation and periventricular white
matter involvement, but these findings lack specificity. The demonstration of the
characteristic lipid peak on cerebral 1H MR spectroscopy, however, can offer another clue to
the diagnosis. In atypical cases, the differential diagnosis might encompass peroxisomal
disorders (e.g. Refsum disease), and many other rare syndromes which involve multiple
organs.5,7,43
The demonstration of elevated concentrations of free fatty alcohols in cultured
fibroblasts or in plasma, or the abnormal presence of metabolites of LTB4 degradation in
urine, can provide biochemical confirmation of the clinical suspicion of SLS. Definite proof
that a patient actually suffers from SLS has to come from measurement of FALDH activity
and molecular studies of the FALDH gene. Although some mutations (943C>T and 1297-
1298delGA) have a high prevalence, in many patients thorough molecular studies will be
necessary to reveal the individual genetic defect. Genetic and biochemical studies can also be
used for prenatal diagnosis. FALDH activity can be measured in cultured amniocytes or
cultured chorionic villus cells. Mutation analysis of a chorionic villus sample is another
possibility, especially in those families with a known genetic defect.
From Patients 18 and 19 it can be seen that SLS is not always a severely disabling
disorder. We have no clear explanation for the occurrence of a mild phenotype in these
patients. One could speculate that unusual dietary habits within the family might have
protected the patients from the developing severe signs of SLS, but we did not find arguments
for this when discussing this matter with the patients. Moreover, it is known that a high
proportion of the fatty alcohols in the human body is not ingested, but rather produced by
endogenous lipogenesis. Compensating mechanisms have to be looked for in a beneficial
genetic background. These patients may help us to reveal the mechanisms that beneficially
influence the signs and symptoms of SLS. Moreover, they should motivate us to look for SLS
in less severely affected patients with unexplained ichthyosis, spasticity, or ocular
abnormalities.
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A novel 4-bp deletion mutation in the FALDH gene segregating in
a Turkish family with Sjögren-Larsson syndrome
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ARTICLE ABSTRACT
Two Turkish siblings with the Sjögren-Larsson syndrome, a rare neurocutaneous disorder
based on an inborn error of microsomal fatty alcohol metabolism, are described. Fatty
aldehyde dehydrogenase (FALDH) activity is deficient in both patients. We found a novel 4-
bp deletion mutation (1384-1387delGAAA) of the FALDH gene in this family. Both patients
are homozygous for the mutation, and heterozygosity has been proven in both parents. The
mutation is expected to impede anchoring of FALDH to the membrane of the endoplasmic
reticulum, in this way leading to deficient enzyme activity.
INTRODUCTION
The Sjögren-Larsson syndrome  (SLS; McKusick no. 270200) is an autosomal-recessively
inherited neurocutaneous disorder characterized by the clinical triad of ichthyosis, spastic
diplegia and mental retardation. The ichthyosis is usually present at birth and brings the
patient to medical attention. The neurological features emerge in the first two years of life.
Glistening white dots of the retina are an additional clinical finding that can be found in a
majority of patients.1,2
Biochemically, the syndrome is caused by the deficiency of microsomal fatty aldehyde
dehydrogenase (FALDH). This enzyme, being a component of the fatty alcohol:NAD+
oxidoreductase (FAO) enzyme complex, catalyzes the oxidation of many different medium-
and long-chain fatty aldehydes to fatty acids.3 It has not been established how the FALDH
deficiency leads to the symptoms in SLS. The modification of macromolecules by an excess
of fatty aldehydes, and the accumulation of fatty alcohols are possible pathophysiologic
mechanisms.
The FALDH gene has been mapped to chromosome 17p11.2.4 It consists of 10 exons
and 9 introns, spanning about 31 kb. The cDNA for FALDH encodes a protein of 485 amino
acids with a highly hydrophobic amino acid sequence at the carboxy-terminal region, which is
assumed to be necessary for microsomal membrane anchoring.5-7 So far, mutation analysis of
the FALDH gene has almost exclusively been performed in patients from Swedish and
northern European descent. Seven different mutations have been identified, including two 1-
bp deletions, one 2-bp deletion, two point mutations, an insertion and a deletion/insertion.8-11
Two of these mutations, namely 943C>T and 1297-1298delGA, are present in almost one-half
of the SLS alleles.9,12 We report a novel deletion mutation of the FALDH gene in two Turkish
siblings who suffer from SLS.
MATERIALS AND METHODS
Patients
A girl (patient 1) aged 7 years, and her 6-month-old brother (patient 2) both presented with
congenital ichthyosis. The girl showed spastic diplegia of the legs and mental retardation. She
had glistening white dots of the retina. The boy only showed subtle signs of neurological
involvement, and no retinal abnormalities, which can be explained by his young age. Their
healthy consanguineous parents originate from Turkey. Two relatives, who are siblings from
another consanguineous couple in this same family, live in Turkey and suffer from identical
clinical symptoms.
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Enzyme measurements
The activity of FAO/FALDH was measured in cultured skin fibroblast homogenates using a
medium of the following composition: 50 mM glycine-NaOH (pH 9.5), 2.5 mM NAD+, 0.5
mg/ml bovine serum albumine and 12 µM [14C]-octadecanol. Final protein concentration: 125
µg/ml. Reactions were allowed to proceed for 40 min. at 37°C and terminated by adding 2 ml
methanol containing 2% (v/v) acetic acid followed by 1 ml chloroform. After vigorous
mixing, phases were separated by low speed centrifugation and the chloroform phase
collected. After evaporation under nitrogen, the residue was taken up in chloroform/methanol
(1/1 (v/v)) and applied to a Siliga Gel 60-plate, using hexane/diethylether/acetic acid (60/40/1
(v/v/v)) as eluent. Radioactive octadecanol and octadecanoic acid were quantified using an
Imaginer and the results obtained were used to calculate the actual rates.
Mutation analysis
The genomic DNA from peripheral blood cells was isolated for genetic analysis using diatoms
matrix as described by Boom et al.13
A fragment of the FALDH gene  including exon 8 and 9 was amplified in a 25 µl PCR
reaction containing 10 mM Tris-HCl (pH 8.4 at 25°C), 1.0 mM MgCl2, 50 mM KCl, 0.1
mg/ml bovine serum albumine, 0.2 mM each dNTP, 2.5 U Taq polymerase (Promega) and the
following M13-tagged primers (12.5 pmol each): in8FALDHf
-21M13 5’-tgt aaa acg acg gcc agt
GGA GTG CAT GTG AGC TTT CC-3’ and in9FALDHrM13rev 5’-cag gaa aca gct atg acc
ATA TGC ATC TGG CAG CCA TC-3’. DNA amplification was performed in a PTC–100
thermocycler from M.J. Research Inc. programmed as follows: 120 s at 96°C initial to cycling,
5 cycles of 30 s at 96°C, 30 s at 55°C and 30 s at 72°C followed by 25 cycles of 30 s at 96°C
and 30 s at 72°C, with a final extension at 72°C for 10 min.
Sequence analysis of the PCR fragment using BigDye fluorescent labelled M13
primers was performed on an Applied Biosystems 377A automated DNA sequencer following
the manufacturer's (PE Applied Biosystems, Foster City, CA) protocols.
RESULTS AND DISCUSSION
The clinical symptoms and the family history of our patients strongly pointed to the diagnosis
of SLS. FALDH activity was severely deficient in both patients, with a value of 3.3 and 0.0
pmol/min.mg protein in patient 1 and 2 respectively (median FALDH activity in 13 healthy
controls: 40.9, range 19.7-54.3 pmol/min.mg protein). To determine the genetic defect in this
family we sequenced the gene encoding FALDH.
In both children we detected a 4-bp deletion (1384-1387delGAAA) in exon 9 of the
FALDH gene (Figure 1). This frameshift mutation is predicted to result in premature
termination of translation at codon 474 and replacement of the carboxy-terminal 24
aminoacids [462-EKLGLLLLTFLGIVAAVLVKAEYY-485] by [462-NSVSCCSLSWVL-473].
Both patients are homozygous for this deletion, and heterozygosity has been demonstrated in
the parents.
An alternatively spliced product of the FALDH gene is known, that contains an
additional 125 nucleotides (designated 9’) between exon 9 and exon 10.7 The 1384-
1387delGAAA mutation occurs upstream of exon 9’, for which reason it will similarly
compromise the translation of both FALDH gene transcripts.
The FALDH is a transmembrane protein located in the endoplasmic reticulum (ER).
The deleted 24 carboxy-terminal aminoacids contain a predicted transmembrane domain
(aminoacids 464-480) and ER membrane retention signal [481-KAEY-484]. Therefore it is
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likely that the deletion of nucleotides GAAA 1384-1387 results in a truncated FALDH that no
longer can be anchored to the microsomal membrane. This mutation is approximating the
carboxy-terminal end of the FALDH gene more than the other mutations that have been found
so far. On the ground that our patients have FALDH deficiency and suffer from the classical
symptoms of SLS, it can be concluded that membrane anchoring is essential for the
preservation of FALDH activity.
In Sweden and the northern European countries, two mutations of the FALDH gene
(943C>T and 1297-1298delGA) are found in almost one-half of the SLS alleles. Based on the
relatively high prevalence of SLS in the northern part of Sweden and the spectrum of
mutations in European patients, there seems to be a founder effect for SLS in the northern part
of Sweden. More reports concerning mutation analysis of the FALDH gene in patients with
SLS from other origins than northern Europe are necessary to elucidate the genetic
backgrounds of this rare but world-wide occurring syndrome.
Figure 1.
Electropherogram of a
control subject, patient 1
(the identical pattern of
patient 2 is not shown)
and both parents, showing
the sequence surrounding
the 4-bp deletion (1384-
1387delGAAA, indicated
by an arrow) in the
FALDH gene.
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ARTICLE ABSTRACT
In six patients with the Sjögren-Larsson syndrome, which is caused by a defect of microsomal
fatty aldehyde dehydrogenase, the  urinary excretion of LTB4 and ω-hydroxy-LTB4 was found
to be highly elevated, whereas ω-carboxy-LTB4 was absent. This abnormal pattern of urinary
excretion of LTB4 and its metabolites appears to be unique to patients with SLS, and offers a
new modality for the diagnosis of this disorder. Moreover, defective inactivation of LTB4
might be of pathophysiological significance in the course of the disease.
INTRODUCTION
The Sjögren-Larsson syndrome (SLS) is an autosomal-recessively inherited disorder
characterized by congenital ichthyosis, spastic diplegia and mental retardation.1,2
Biochemically, the syndrome is caused by the deficiency of microsomal fatty aldehyde
dehydrogenase (FALDH) which catalyzes the oxidation of medium- and long-chain (aliphatic)
fatty aldehydes derived from fatty alcohols.2-4 Accumulation of fatty alcohols and
modification of macromolecules by an excess of fatty aldehydes are thought to be the
pathophysiologic mechanisms underlying SLS. However, plasma fatty alcohol concentrations
are not elevated in all patients, and until now, all other laboratory investigations of plasma,
urine, and cerebrospinal fluid have never revealed any significant abnormality.2-4 Diagnosis of
SLS therefore required measuring FALDH activity in cultured fibroblasts and/or mutation
analysis of the FALDH gene.
Leukotriene B4 (LTB4), synthesized from arachidonic acid via the 5-lipoxygenase
pathway, is a potent pro-inflammatory mediator that plays a role in a variety of disease
processes.5-7 It is predominantly produced by polymorphonuclear leukocytes, which also
metabolize both endogenously generated as well as exogenous LTB4. The biological half-life
of LTB4 is regulated by microsomal ω-oxidation to the less active but still chemotactic
metabolite ω-hydroxy-LTB4 (Figure).8 Subsequent microsomal degradation of ω-hydroxy-
LTB4 yields ω-aldehyde-LTB4 and ω-carboxy-LTB4 respectively.9 ω-Carboxy-LTB4 is further
degraded by peroxisomal β-oxidation. Cytochrome P-450LTB4 can catalyze the microsomal
oxidation of ω-aldehyde-LTB4 to ω-carboxy-LTB4 in polymorphonuclear leukocytes, but
another aldehyde dehydrogenase is preferentially involved.5,10 The latter enzyme appears to be
distinct from FALDH, based on the  difference in pH optimum.3
Given the known deficiency of microsomal FALDH in SLS, we postulated that the
metabolism of LTB4 might be affected in this disorder. We therefore analyzed urinary
excretion of LTB4 and its oxidation products in patients with SLS and healthy controls.
PATIENTS AND METHODS
Random urine samples from 6 patients with SLS (4 girls, 2 boys; median age, 7.2 years; range,
0.5 to 19.0 years) and 30 healthy controls (median age, 11.0 years; range, 0.5 to 21.0 years)
were screened and determined to be free of protein and cellular elements (leukocytes,
erythrocytes, casts), before being stored in plastic containers at -80°C until analysis.
All SLS patients exhibited the characteristic clinical symptoms described in this
condition.1,2 Median gestational age was 36.5 (range, 28.0 to 38.5) weeks. Severe pruritis was
present in all except the youngest patient. One child suffered from mild asthma. None of the
patients used any  medications except topical lubrications (two patients). In all patients the
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clinical diagnosis was confirmed by demonstrating FALDH deficiency in cultured skin
fibroblasts.
Urinary LTB4, ω-hydroxy-LTB4 and ω-carboxy-LTB4 were separated by reversed-
phase HPLC and subsequently quantified by immunoassays and/or gas chromatography-mass
spectrometry using (18O)-labeled leukotrienes as internal standards, as previously described by
our laboratories.11 Values are expressed as nmol/mol creatinine.
                        
Figure. Metabolism of LTB4. P-450LTB = LTB4 20-hydroxylase (a cytochrome P450 enzyme).
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RESULTS AND DISCUSSION
The urinary concentrations of LTB4 and its ω-oxidation products for the patients with SLS and
healthy controls are summarized in the Table. LTB4 and ω-hydroxy-LTB4 were readily
detected in the urine of all patients with SLS, whereas these compounds were undetectable in
the urine from healthy controls. ω-Carboxy-LTB4, the oxidation product of ω-hydroxy-LTB4,
was not detected in the urine of patients with SLS or in the urine from control subjects.
Table. Concentrations of LTB4, ω-hydroxy-LTB4 and ω-carboxy-LTB4 in urine of patients
with Sjögren-Larsson syndrome and healthy controls.
Leukotriene
(nmol/mol creatinine)a
Sjögren-Larsson
syndrome (n=6)
Healthy
controls (n=30)
LTB4 35b   (12-69) <5
ω-hydroxy-LTB4 391b   (114-622) <5
ω-carboxy-LTB4 <5 <5
aValues given are median; range is given in parentheses.
bp<0.01 compared to healthy controls (Wilcoxon-Mann-Whitney test).
In monkeys and rabbits, following intravenous administration of LTB4, neither LTB4 nor its
metabolites are detectable in the urine due to rapid and extensive degradation.12 As previously
demonstrated,11 endogenous LTB4 and its metabolites are not detectable in human urine under
physiological conditions (Table). The present results indicate that the degradation of  LTB4 is
impaired in patients with SLS, and point to a crucial involvement of FALDH in the
conversion of ω-aldehyde-LTB4 to ω-carboxy-LTB4. Apparently, neither the enzyme
identified by Sutyak et al.10 nor cytochrome P-450LTB4 can compensate for the defect in LTB4
inactivation which occurs as a consequence of FALDH deficiency.
Defective metabolism of LTB4 is the first biochemical pathway demonstrated to be
abnormal in vivo in patients with SLS. This disorder represents the first and only condition yet
described with pronounced urinary excretion of LTB4 and ω-hydroxy-LTB4. Thus, analyses of
these metabolites in urine offers a new and noninvasive diagnostic approach for patients with
SLS. Moreover, defective LTB4 inactivation might be one of the mediators responsible for the
severe pruritus in patients with SLS.13
Currently, there is no effective treatment for SLS. Although it is uncertain whether
defective inactivation of LTB4 has a pathophysiologic role in SLS, our observations provide a
rationale for therapeutic trials of presently available leukotriene synthesis inhibitors and, when
available, specific LTB4 receptor antagonists or inhibitors, in patients with SLS.
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ARTICLE ABSTRACT
The Sjögren-Larsson syndrome (SLS) is a neurocutaneous disorder, caused by deficient
activity of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH). FALDH catalyzes
the oxidation of medium- and long-chain fatty aldehydes to their corresponding carboxylic
acids. SLS is diagnosed by demonstrating the enzyme deficiency or by mutation analysis of
the FALDH gene, while laboratory investigations of plasma, urine, and cerebrospinal fluid do
not reveal any diagnostic abnormality. Leukotriene (LT) B4 is a pro-inflammatory mediator
synthesized from arachidonic acid. LTB4 is inactivated by microsomal ω-oxidation,
successively yielding 20-OH-LTB4, 20-CHO-LTB4 and 20-COOH-LTB4. Since FALDH is
involved in LTB4 degradation, we have analyzed LTB4 and its metabolites in urine and
cerebrospinal fluid as well as the degradation capacity for LTB4 in fresh polymorphonuclear
leukocytes (PMN) of SLS patients. The urinary concentrations of LTB4, 20-OH-LTB4 and 20-
COOH-LTB4 are below the detection limit in healthy controls. The urine of all SLS patients
(n=13) exhibited highly elevated concentrations of LTB4 and 20-OH-LTB4, while 20-COOH-
LTB4 was absent. Cerebrospinal fluid levels of LTB4, 20-OH-LTB4 and 20-COOH-LTB4 were
found to be normal (n=7). PMN isolated from four patients were shown to be unable to
convert 20-OH-LTB4 to 20-COOH-LTB4. Our findings provide unambiguous evidence for
defective LTB4 degradation in SLS patients, and offer new and non-invasive diagnostic tools.
Moreover, they open new pathophysiological considerations, with the prospect of rational
treatment strategies.
INTRODUCTION
Leukotrienes (LTs) are potent pro-inflammatory mediators that have a biological role in the
function of leukocytes, smooth muscle contraction, and vascular tone and permeability.1-3
They are produced by different cells including mast cells, eosinophils, basophils, and
polymorphonuclear leukocytes (PMN). Their biosynthesis starts with phospholipase A2 that
catalyzes the release of arachidonic acid from cell-membrane phospholipids (Figure 1).
Arachidonic acid is subsequently converted to 5-HPETE (5S-hydroxyperoxy-6,8,11,14-
eicosatetraenoate) and LTA4 by the enzyme 5-lipoxygenase. LTA4 is the common
intermediate, and can be converted to both major groups of leukotrienes, namely LTB4 and the
cysteinyl LTs. LTB4 is formed by enzymatic action of LTA4 hydrolase, while LTC4 synthase
catalyzes the formation of LTC4. LTD4 and LTE4 are biologically active products of LTC4.
The pathophysiological significance of LTs has come to light in a variety of human disease
processes, especially in disorders that are characterized by chronic inflammation.2-5 The recent
pharmacological availability of specific LT synthesis inhibitors and LT receptor antagonists
has further increased the scientific and clinical interest in the LTs.4-6 Despite the voluminous
data available on LT biosynthesis and metabolism, and their roles in different immune-
mediated diseases, comparatively little is known about their significance in
(patho)physiological processes in the human central nervous system.
SLS is an autosomal recessively inherited disorder of lipid metabolism, characterized
by congenital ichthyosis, spastic di- or quadriplegia and mental retardation.7-9 Magnetic
resonance (MR) imaging of the brain reveals retarded myelination or dysmyelination, and MR
spectroscopy shows an abnormal lipid peak in the cerebral white matter.9 Biochemically, the
syndrome is caused by the deficient activity of microsomal enzyme FALDH (EC number
1.2.1.48) which catalyzes the oxidation of medium- and long-chain fatty aldehydes derived
from fatty alcohols.10-12 The accumulation of fatty alcohols and the modification of
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macromolecules by an excess of fatty aldehydes are thought to be the pathophysiologic
mechanisms underlying SLS.12,13 Diagnosis of SLS requires measuring FALDH activity in
leukocytes or cultured fibroblasts and/or mutation analysis of the FALDH gene.8,14
When we were studying the biochemical defect in SLS, the pathway of LTB4
degradation attracted our attention. The biological half-life of LTB4 is regulated by
microsomal ω-oxidation to the less active but still chemotactic metabolite 20-OH-LTB4
(Figure 1).2,3,15 Subsequent microsomal degradation of 20-OH-LTB4 yields 20-CHO-LTB4
and 20-COOH-LTB4, respectively. 20-COOH-LTB4 is further degraded by peroxisomal β-
oxidation. FALDH is involved in the conversion of 20-CHO-LTB4 to 20-COOH-LTB4.
Recently, we have found elevated urinary concentrations of LTB4 and 20-OH-LTB4 whereas
20-COOH-LTB4 was absent in patients with SLS.16
This study aims to further investigate the metabolism of LTB4 in SLS, and to discuss
the significance of the results with regard to the pathophysiology of SLS.
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Figure 1. Metabolic pathways of biosynthesis of leukotrienes (LTs), prostaglandins, and
thromboxanes, and microsomal degradation of LTB4 to 20-COOH-LTB4. 5-HPETE: 5S-
hydroxyperoxy-6,8,11,14-eicosatetraenoate. Enzymes denoted: 5-lipoxygenase (1),
cyclooxygenase (2), and fatty aldehyde dehydrogenase (3).
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PATIENTS AND METHODS
Patients
All 13 SLS patients, mean age 10.1 (SD 5.6) years, exhibited the characteristic clinical
symptoms described in this condition, i.e. ichthyosis, mental retardation and spastic di- or
quadriplegia. A juvenile macular dystrophy and photophobia were found in all patients as
additional ophthalmologic features. Mean gestational age was 35.2 (SD 2.5) weeks. Severe
pruritus was present in all except the youngest patient. One child suffered from mild asthma.
None of the patients used any medications except topical lubrications (two patients). In all
patients the clinical diagnosis was confirmed by demonstrating FALDH deficiency in cultured
skin fibroblasts.
Collection of samples and leukotriene extraction
Random urine samples from 13 patients with SLS and 30 healthy controls of the same age
group were screened and determined to be free of protein and cellular elements (e.g.
leukocytes, erythrocytes), before being stored at -80°C until they could be analyzed. Samples
of cerebrospinal fluid from seven SLS patients and 30 control patients were also confirmed to
show normal values for erythrocytes, leukocytes, glucose and protein, before being stored at -
80°C until they could be analyzed. Directly before analysis, the samples were brought to room
temperature and the appropriate internal standards (see below) were added. The samples were
acidified to pH 4.5 by addition of 0.1 M HCl, mixed, and pumped slowly through activated
Sep-Pak C18 cartridges (Waters Associates, Milford, MA). The cartridges were washed with
50 ml of distilled H2O and LTs were eluted with 5 ml of 90% aqueous methanol containing 1
mM 4-hydroxy-2,2,6,6-tetramethylpiperidine-N(1)-oxyl (HTMP) and 0.5 mM EDTA. The
eluates were evaporated to dryness under reduced pressure and resuspended in 30% ice-cold
aqueous methanol.
Preparation of 3H-and 18O-labeled analogues as internal standards
3H-labeled LTs were used as internal standards in the extraction/reversed-phase high-
performance liquid chromatography (RP-HPLC)-procedure to correct for recovery losses.
[3H]-LTB4 (7.0 TBq/mmol) and [3H]-LTE4 (4.8 TBq/mmol) were from Du Pont-New England
Nuclear, Boston, MA. 20-OH-[3H]-LTB4 and 20-COOH-[3H]-LTB4 were prepared from [3H]-
LTB4 using rat liver microsomes and cytosol as described [17]. 18O-Labeled 20-OH-LTB4 and
20-COOH-LTB4 were prepared from synthetic 20-OH-LTB4 and 20-COOH-LTB4 (both from
Cascade Biochem. Ltd., University of Reading, UK), respectively, by incubation with H218O
in the presence of butyryl cholinesterase.18
Reversed-phase high-performance liquid chromatography
Fractions containing distinct LTs were obtained by RP-HPLC on a C18 Hypersil column (4.6 x
250 mm, 5-	
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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of 40-80% aqueous methanol within 35 minutes, followed by 30 minutes of 80% aqueous
methanol. All solvents contained 0.1% acetic acid and 1 mmol/l EDTA. The pH was adjusted
to 5.0 with ammonium hydroxide. In addition, 20-OH-LTB4 and 20-COOH-LTB4 were
separated by isocratic elution with 53% aqueous methanol containing 50 mmol/l ammonium
acetate at pH 5.6. Urinary fractions containing LTE4 were prepared by RP-HPLC using as
mobile phase methanol/water (65:35, vol/vol) the aqueous part containing 0.1% acetic acid, 1
mM EDTA, and being adjusted to pH 5.6 by ammonium hydroxide. For all separations, a flow
rate of 1 ml/min was used.
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Quantification of leukotrienes by enzyme immunoassays and gas chromatography-mass
spectrometry
The RP-HPLC eluate was collected in 1-ml fractions of which 300 µl was counted for
calculation of the corresponding 3H-recovery and 700 µl was dried for the subsequent analysis
by enzyme immunoassays and gas chromatography-mass spectrometry. Data were corrected
for the recovery of the 3H-labeled LT added as internal standard. Quantification of the LTB4
and LTE4 was performed by enzyme immunoassays with specific antibodies (Cayman, Ann
Arbor, MI, USA).19 The molar crossreactivities at 50% binding of the LTB4-antibody which
was used for LTB4 quantification were: 100% for LTB4 and <0,01% for LTC4, LTD4 as well
as LTE4. The corresponding specificity for the LTE4-antibody was: LTE4 100%, LTC4 10%,
LTD4 9%, and LTB4 <0.01%. Calibration curves were performed with non-labeled LTB4 and
LTE4 (all Cayman, Ann Arbor, MI, USA) in 8 different concentrations ranging from 15-1500
pg/ml. The interassay coefficients of variation were approximately 10%. Quantification of 20-
OH-LTB4 and 20-COOH-LTB4 in urine as well as in cerebrospinal fluid was performed by
gas chromatography-mass spectrometry using [18O]-labeled leukotrienes as internal standards,
as previously described in detail.18 Levels of the metabolites in urine are expressed as
nmol/mol creatinine, and have a limit of detection of < 15 nmol/mol creatinine. LTB4 and its
metabolites in cerebrospinal fluid are given as pmol/l, with a limit of detection of < 5 pmol/l.
Isolation of PMN
LTB4 degradation was studied in PMN of four SLS patients (two pair of siblings), their
healthy and proven heterozygous parents (n=4), and 10 healthy controls. PMN were isolated
essentially as already described in detail.20 Briefly, after dextran sedimentation PMN were
purified by centrifugation on Ficoll-Paque cushions (Pharmacia, Montreal, Canada). Contami-
nating erythrocytes were removed by hypotonic lysis, and the cells were resuspended in
Tyrode´s solution containing 1 mM calcium, 5 mM magnesium and 0.1% fatty acid-free
bovine serum albumin (Tyrode´s albumin buffer; Miles Laboratories, Elkhart, IN.) at a final
concentration of 1x107 cells/ml. The percentage of neutrophils in the cell preparations used in
this study exceeded 97% and cell viability as determined by Trypan blue exclusion was more
than 98%.
Metabolism of [3H]-LTB4 in isolated PMN
Isolated cells were suspended in Hanks´ balanced salt solution (GIBCO) containing 1.3 mM
CaCl2, and adjusted to pH 7.4 with NaHCO3. 20 x 106 PMN/ml were incubated in
polypropylene test tubes with [3H]-LTB4 in a concentration of 1.0 µM at 37°C for 15 minutes
with constant agitation.15 Incubations were terminated by addition of 1.5 volumes of ice-cold
ethanol. After centrifugation, the supernatants were stored in 80% methanol under argon at –
80°C. 98% of the initial radioactivity was recovered in the aqueous phase. The supernatants
were evaporated to dryness using a SpeedVac rotary evaporator and redissolved in 30%
aqueous methanol for HPLC separation. RP-HPLC was performed on a C18 Hypersil column
with a C18  precolumn (Waters, Milford, MA) as described above. LTs were separated on a
linear gradient of 40-80% aqueous methanol within 35 minutes, followed by 30 minutes of
80% aqueous methanol. All solvents contained 0.1% acetic acid and 1 mmol/l EDTA. The pH
was adjusted to 5.0 with ammonium hydroxide. The flow rate was 1 ml/min. Furthermore, 20-
OH-LTB4 and 20-COOH-LTB4 were separated by isocratic elution with 53% aqueous
methanol containing 50 mmol/l ammonium acetate at pH 5.6. The HPLC eluate was either
measured continuously for tritium radioactivity using a liquid scintillation device (Raytest,
Straubenhardt, Germany) or sampled in 0.5-minute fractions using a fraction collector (LKB,
Bromma, Sweden). Radioactivity was measured in aliquots of the HPLC fractions in a
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scintillation counter (Beckman Instruments, Fullerton, CA, USA). The identification of
metabolites was verified by gas chromatography-mass spectrometry.18 Results were expressed
as a percentage of the initial concentration of LTB4.
RESULTS
The urinary concentrations of LTB4 and its ω-oxidation products for the patients with SLS and
healthy controls are summarized in Table 1. LTB4 and 20-OH-LTB4 were readily detected in
the urine of all patients with SLS, whereas these compounds were undetectable in the urines
of healthy controls. 20-COOH-LTB4, the oxidation product of 20-OH-LTB4, was not detected
in the urine of the patients with SLS nor in the urine of the control subjects. In addition,
urinary LTE4 was found to be within normal ranges indicating an adequate collection of
samples.
Table 1. Concentration of leukotriene (LT) B4, 20-OH-LTB4, 20-COOH-LTB4, and LTE4 in
urine of patients with Sjögren-Larsson syndrome and healthy controls
Leukotriene Sjögren-Larsson
Syndrome (n=13)
Healthy
Controls (n=30)
LTB4 31.0 (14.2)* <5
20-OH-LTB4 306.5 (143.3)* <5
20-COOH-LTB4 <5 <5
LTE4 31.4 (7.1) 32.2 (8.6)
Values are mean (SD), and expressed as nmol/mol creatinine. Differences between patients
and healthy controls were analyzed statistically by using Wilcoxon-Mann-Whitney test. * P <
0.001.
LTB4 in the cerebrospinal fluid of SLS patients was within the same range as found in
the control group (Table 2). 20-OH-LTB4 and 20-COOH-LTB4 were not detected in the
cerebrospinal fluid of controls nor in that of SLS patients.
Table 2. Leukotriene (LT) B4, 20-OH-LTB4, and 20-COOH-LTB4 in cerebrospinal fluid of
patients with Sjögren-Larsson syndrome and controls
Leukotriene Sjögren-Larsson
Syndrome (n=7)
Controls (n=30)
LTB4 137.0 (22.3)* 114.7 (57.1)
20-OH-LTB4 < 15 < 15
20-COOH-LTB4 < 15 < 15
Values are mean (SD), and expressed as pmol/l. Differences between patients and healthy
controls were analyzed statistically by using Wilcoxon-Mann-Whitney test. * P >0.05.
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Investigation of LTB4 degradation in fresh PMN after incubation with [3H]-LTB4
revealed elevated levels of [3H]-LTB4 (ranging from 24.9% to 29.1%) and 20-OH-[3H]-LTB4
(ranging from 63.2% to 70.4%), and no detectable 20-COOH-[3H]-LTB4 (<1%) in the super-
natant of suspended SLS cells (Figure 2). This contrasted with the results for control cells,
where mean (SD) levels of [3H]-LTB4 and 20-OH-[3H]-LTB4 were found to be much lower:
10.6 (2.9)% and 28.2 (3.6)% respectively. Furthermore, roughly half of the of [3H]-LTB4 (51.4
(SD 5.4)%) could be retrieved as 20-COOH-[3H]-LTB4 in control cells. The leukocytes of the
heterozygous parents revealed intermediate values for LTB4 degradation capacity.
Figure 2. The degradation capacity of polymorphonuclear leukocytes for radiolabeled
leukotriene B4 (LTB4) in four patients with Sjögren-Larsson syndrome (•), their four healthy
and proven heterozygous parents (o), and 10 controls (±SD) (♦). Radioactivity of [3H]-LTB4,
20-OH-[3H]-LTB4, and 20-COOH-[3H]-LTB4 is measured after an incubation period of 15
minutes, and expressed as a percentage of the initial concentration of [3H]-LTB4.
DISCUSSION
In monkeys and rabbits, following intravenous administration of LTB4, neither LTB4 nor its
metabolites are detectable in the urine due to rapid and extensive degradation.21 As previously
demonstrated,18 endogenous LTB4 and its metabolites are not detectable in human urine under
physiological conditions (Table 1). The first results of urinary analyses of LTB4 and its
metabolites in a small number of patients with SLS have recently been reported by our
group.16 These data suggested an impairment in the degradation of LTB4 in this syndrome.
The study presented here, confirms the previous findings on SLS urines in a larger series of
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patients and essentially extends the data with the results of investigations of cerebrospinal
fluid and freshly isolated PMN.
The investigations of LTB4 degradation in isolated PMN of SLS patients provide
definite proof for the defect in LTB4 metabolism on the cellular level. The parents are proven
carriers, i.e. heterozygotes, for FALDH deficiency. The fact that they exhibit a subnormal to
intermediate LTB4 degradation capacity underlines the consequence of FALDH deficiency for
LTB4 metabolism.
Interestingly, in contrast to the findings in urine, LTB4 and 20-OH-LTB4 were not
found to be elevated in the cerebrospinal fluid of SLS patients. In general, there is much
uncertainty about the function and metabolism of leukotrienes in the human central nervous
system in physiological as well as pathological circumstances.22-24 The production of the
cysteinyl LTs is well documented in the brain.25 There is minimal metabolism of LTC4 to
LTD4 and LTE4 in the central nervous system, and LTC4 has been shown to be transferred
rapidly from the cerebrospinal fluid into blood by an efficient transport system in the choroid
plexus.26 To the best of our knowledge – surprisingly, granted the available evidence on LTC4
biology – there are no reports in the literature describing either the biosynthesis and
metabolism of LTB4 in the human brain, or the possible presence of a transport system for
LTB4 across the blood-brain barrier. Indirect evidence for the presence of LTB4 synthesis
capacity in the human central nervous system compartment can be found. LTB4
concentrations in the cerebrospinal fluid of control subjects are known to be in the same range
as LTC4 concentrations.23,27 Concentrations of LTB4 (and LTC4) are elevated in patients with
meningitis.27 In patients with HIV infection and toxoplasmic encephalitis, LTB4 (and LTC4)
concentrations in cerebrospinal fluid were significantly decreased, pointing to an inhibiting
effect of Toxoplasma gondii on cerebral LT synthesis.28 Our findings of normal LTB4 levels in
SLS could point to the existence of a transport system across the blood-brain barrier as the
control mechanism for brain LTB4 concentrations, and to the absence of a capacity for LTB4
breakdown in the CNS. This is also supported by the fact that neither ω-oxidation nor β-
oxidation products of LTB4 have ever been detected in the cerebrospinal fluid. Another -
hypothetical - explanation for the normal cerebrospinal fluid values of LTB4 in SLS could be
that the brain has a different enzyme for catalyzing the conversion of 20-OH-LTB4 to 20-
COOH-LTB4. In analogy, it is well known that liver LTB4 degradation and neutrophil LTB4
degradation involve different enzyme systems29 and that cytochrome P-450LTB4 only catalyzes
the first step in degradation.
Defective metabolism of LTB4 is the first biochemical pathway demonstrated to be
abnormal in vivo in patients with SLS. Although many fatty alcohols and fatty aldehydes are
known to be converted by FALDH in vitro, their plasma concentrations are generally not
elevated in SLS patients, or are not elevated in all patients.8,10,12 Moreover, other laboratory
investigations of plasma, urine, and cerebrospinal fluid have failed to detect any diagnostic
abnormality. As a consequence, analyses of urinary LTB4 metabolites offers a new and non-
invasive diagnostic tool for this syndrome.
Experience in our laboratories as well as reports in the literature show a relatively high
residual activity when measuring FALDH activity in homogenates of SLS fibroblasts or
leukocytes.8,10,12 This is still the case even in those patients who have genotypes that predict
the absence of any functional FALDH. It has been postulated that other isozymes, especially
cytosolic or mitochondrial aldehyde dehydrogenases, could in part compensate for FALDH
deficiency. In contrast to these findings, we found no residual FALDH activity at all, when
using radiolabeled LTB4 as the substrate for fresh PMN. This finding might be of importance
for future studies aimed to resolve the correlation between genotype, phenotype and
biochemical defect.
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Defective LTB4 inactivation might play an important pathophysiological role in SLS.
LTB4 and 20-OH-LTB4 have been reported to mediate processes that lead to pruritus and
pain.30,31 The severe pruritus in patients with SLS could thus have its origin in defective LTB4
inactivation. Since available experimental evidence suggests that LTB4 might play a role
during labor,32,33 one could also speculate that a fetus with SLS induces its own (preterm)
birth by excreting large amounts of LTB4 and 20-OH-LTB4 into the amniotic fluid.34 In
addition, LTB4 also upregulates neurotrophins. Their involvement in SLS, however, must
remain speculative. As yet, the literature does neither suggest any role for LTB4 in the other
clinical features of SLS, nor for its involvement in the disturbances of cerebral white matter
on MR imaging and MR spectroscopy. Patients with SLS do not suffer from exuberant
inflammatory responses, or from a disproportional amount of (chronic) inflammatory diseases
including asthma. Their life span seems to be similar to the life span of other, equally
handicapped patients.
Although the pathophysiological role of defective LTB4 metabolism in SLS is
uncertain, our observation provides a powerful rationale for therapeutic trials aimed at
inhibiting LTB4 synthesis. Preliminary results of treatment with zileuton, a 5-lipoxygenase
inhibitor, look very promising and encourage further trials.35
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CHAPTER 4
Defective LTB4 degradation in Sjögren-Larsson syndrome: the
entry for a new therapeutic approach
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CHAPTER 4.1
5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-
Larsson syndrome
M.A.A.P. Willemsen, J.J. Rotteveel, P.M. Steijlen, A. Heerschap, E. Mayatepek
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ARTICLE ABSTRACT
The Sjögren-Larsson syndrome (SLS) is a severe neurocutaneous disorder due to fatty
aldehyde dehydrogenase (FALDH) deficiency. The recent discovery of the role of FALDH in
the degradation of leukotriene B4 (LTB4) opened the way to the development of a new
therapeutic strategy for SLS, i.e. 5-lipoxygenase inhibition. We treated one SLS patient with
zileuton during five weeks. During the treatment period we found decreased values of LTB4
and ω-OH-LTB4. The severity of the pruritus diminished, and favourable changes in the
child’s behavior were observed. The height of the prominent ‘lipid peak’ of cerebral white
matter (that is characteristically found on proton magnetic resonance spectroscopy in SLS
patients) lowered during treatment, and increased again when treatment was stopped. In
conclusion, the beneficial effects of 5-lipoxygenase inhibition in SLS are very promising and
encourage further research.
INTRODUCTION
Sjögren-Larsson syndrome (SLS) is a genetic neurocutaneous disorder, characterized by
ichthyosis, mental retardation and spasticity.1,2 Its neuroradiological features include variable
degrees of disturbed myelination of the central nervous system, with the presence of a highly
characteristic ‘lipid peak’ on proton magnetic resonance spectroscopy (1H-MRS).2 Although
the neurological handicaps present the most salient problems, the everyday life of SLS
patients is hampered by an irritating pruritus. The syndrome is caused by deficient activity of
microsomal fatty aldehyde dehydrogenase (FALDH).1,2 This enzyme catalyzes the oxidation
of different long- and medium-chain fatty aldehydes, whether or not synthesized from fatty
alcohols, to their corresponding fatty acids. It is speculated that accumulation of fatty alcohols
or aldehyde-modified lipids is involved in the pathophysiology of SLS, as might be reflected
by the ‘lipid peak’ on 1H-MRS of the brain. Curative treatment strategies are not available.
Recently, we demonstrated that FALDH has a crucial role in the ω-oxidation, i.e. the
inactivation, of leukotriene B4 (LTB4).3 This finding implicates that the presence of elevated
concentrations of the highly active metabolites LTB4 and ω-OH-LTB4 could contribute to the
pathogenesis of SLS. LTB4 is a pro-inflammatory mediator that is synthesized from
arachidonic acid via the 5-lipoxygenase pathway (Figure 1).4 It is known to be involved in
different disease processes, but its (patho)physiological significance in the central nervous
system and the skin is largely unknown. Animal experiments showed that LTB4 might be
involved in the mechanisms that lead to pain and pruritus.5-7 LTB4 exerts potent mitogenic
effects on human epidermal keratinocytes in vitro, but its role in the proliferation and
differentiation of the human skin in vivo still has to be established.4,8 Zileuton is a commercial
available medicine, used in the treatment of asthma, that blocks the synthesis of LTB4 by
inhibiting 5-lipoxygenase.9
METHODS
We treated a 9-year-old girl with zileuton, after having obtained informed parental consent.
Zileuton was administered in 600 mg doses three times daily, over 5 weeks (Table 1).
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Figure 1. Metabolic pathways of biosynthesis of leukotrienes (LT), prostaglandins, and
thromboxanes, and microsomal degradation of LTB4 to ω-carboxy-LTB4. Zileuton inhibits the
enzyme 5-lipoxygenase.
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Patient
The patient has the characteristic clinical features of SLS, as has been described previously
(Patient B in reference 2). She is confined to a wheelchair due to spasticity of her legs, and
able to speak in short sentences. Pruritus is a constant, impairing symptom. Diagnosis of SLS
had been proven biochemically by demonstrating FALDH deficiency in cultured skin
fibroblasts.
Observational clinical score
The child’s young age and mental retardation hampered the individualized measurement of
the severity of pruritus. Available questionnaires for the assessment of the impact of skin
disease on the quality of life in children were not applicable.10 For that reason we have
constructed a simple scoring system that was used by the parents. They scored four times each
day the severity of the child’s pruritus on a four point scale: 0-none; 1-mild (pruritus without
visible scratches); 2-moderate (pruritus with visible scratches); 3-severe (pruritus with
bleeding or scarring of the skin). The first score each day represented the parental impression
of the child’s sleep disturbance during the preceding night. This score depended mainly on the
aspect of the bedclothes and the skin.
                             ZILEUTON
 (-)
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Laboratory investigations and 1H-MRS
Urinary samples were collected from the first and last micturation of a day in week 0, 3, 5, and
7, and were stored at -80°C until analysis. On the same days, blood samples were taken to
control serum aminotransferases. Urinary LTB4 and ω-OH-LTB4 were separated by reversed-
phase HPLC and subsequently quantified by immunoassays and/or gas chromatography-mass
spectrometry using (18O)-labeled leukotrienes as internal standards, as previously described by
our laboratories.4 Values are expressed as nmol/mol creatinine.
Cerebral 1H-MRS was performed before treatment was started, and was repeated in
week 5, and 2 months after withdrawal of treatment, using the MR system and the techniques
as previously described.2
RESULTS
The treatment with zileuton was tolerated well, and no adverse effects were recorded. During
the treatment period, pruritus was less severe and the girl’s behavior was qualified as ‘striking
more lively and alert’. The mean pruritus score per day without treatment was 6.1 (SD: 2.3).
During the treatment with zileuton the mean score decreased to 2.2 (SD: 1.6) (Table 1). The
aspect of the skin did not change during the treatment period, except for the disappearance of
scratches.
The urinary concentrations of ω-OH-LTB4 and LTB4 showed no diurnal fluctuations.
Therefore, an average value was calculated for each day. The concentrations of LTB4 and ω-
OH-LTB4 decreased approximately 70% during the treatment. After withdrawal of zileuton
they increased again.
1H-MRS of cerebral white matter showed a characteristic peak in the ‘lipid region’
(between 0.8 and 1.6 ppm), reflecting an accumulation of lipids (Figure 2). The height of the
peak decreased during treatment, with lipid/N-acetylaspartate ratios of 1.38 (100%), 0.80
(58%) and 1.12 (81%) before, during, and after treatment respectively.
Table 1. Decreasing severity of pruritus and urinary concentrations of LTB4 and ω-OH-LTB4
during treatment with zileuton.
Week 0 1 2 3 4 5 6 7
Severity of pruritusa 6.7 4.4 2.6 1.0 1.4 1.9 5.3 6.4
LTB4b 35 21 12 26
ω-OH-LTB4b 337 187 93 233
Zileuton
a
 Mean pruritus score per day; minimum score: 0, maximum score: 12. b Urinary
concentrations of LTB4 and ω-OH-LTB4 in nmol/mol creatinine; normal values for both
metabolites: <5 nmol/mol creatinine; mean (SD) urinary concentrations of LTB4 and ω-OH-
LTB4 in 10 SLS patients: 30 (17) and 336 (142) nmol/mol creatinine respectively.
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Figure 2. Sagittal, coronal, and transverse MR images, with 1H-MR spectra. The box
indicates the location of the voxel (2x2x2 cm) from which the 1H-MR spectrum was obtained
before (panel A), during (panel B) and after (panel C) treatment. The spectra show the
common peaks of choline (Cho), creatine (Cr), and N-acetylaspartate (NAA), and a prominent
pathologic lipid peak (arrow) with decreased height during treatment with zileuton.
DISCUSSION
The demonstration of defective LTB4 inactivation offered the rationale for a new treatment
strategy for SLS patients, consisting of 5-lipoxygenase inhibition. In the case presented here,
administering zileuton decreased LTB4 and ω-OH-LTB4 levels and considerably reduced the
severity of pruritus. The extent and characteristics of the ichthyotic skin did not change during
the treatment period, which might be explained by its relative short duration. The
improvement in behavior and the results of cerebral 1H-MRS suggest a possible beneficial
effect in the central nervous system. It has to be established whether the change in
neurological performance results from direct or indirect effects of zileuton on the leukotriene
metabolism in the brain.
In conclusion, the results of this preliminary study should encourage further research
on the benefits of 5-lipoxygenase inhibition in SLS.
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ARTICLE ABSTRACT
The Sjögren-Larsson syndrome (SLS) is an inborn error of lipid metabolism, clinically
characterised by congenital ichthyosis, mental retardation and spasticity. Patients also suffer
from severe pruritus. The degradation of leukotriene (LT) B4 is one of the defective metabolic
routes in SLS. Zileuton inhibits the synthesis of LTB4 and the cysteinyl LTs. Five SLS
patients were treated with zileuton during a period of three months. Favourable effects were
found on pruritus score (P=0.006), general wellbeing, and background activity of electro-
encephalographic studies. Neuropsychological test results did not change statistically
significant. There was, however, a clinically important trend towards improvement of the
speed of information processing. Results of cerebral magnetic resonance imaging and proton
magnetic resonance spectroscopy did not change during therapy. Urinary concentrations of
LTB4 and ω-OH-LTB4 decreased significantly (P=0.02 and P=0.003 respectively), while their
concentrations in cerebrospinal fluid were normal at baseline and remained so after therapy.
Conclusions Patients with SLS might benefit from treatment with zileuton, especially with
respect to the agonising pruritus. The findings reported here, point to a crucial role for LTB4
in the pathogenesis of pruritus.
INTRODUCTION
The Sjögren-Larsson syndrome (SLS; McKusick no. 270200) is a rare genetic neurocutaneous
disorder, originally described as the clinical triad of congenital generalised ichthyosis, mental
retardation and spasticity.1 Most patients exhibit additional signs and symptoms, including
severe pruritus, preterm birth, and ocular abnormalities.2-6 Magnetic resonance imaging (MRI)
of the brain reveals variable degrees of disturbed myelination of the central nervous system,
and proton magnetic resonance spectroscopy (1H-MRS) shows the presence of a highly
characteristic 'lipid' peak in the cerebral white matter.5,7,8 Effective causal therapy strategies
(including dietary regimes) are not available for SLS.4 Although the neurological handicaps
present the most salient problems, the everyday life of SLS patients is hampered by the
severity of the pruritus.
SLS is caused by deficient activity of the microsomal enzyme fatty aldehyde
dehydrogenase (FALDH), due to mutations in the FALDH gene.4 FALDH catalyses the
oxidation of different long- and medium-chain fatty aldehydes derived from fatty alcohol
metabolism and ether glycerolipid catabolism, the α-oxidation of branched-chain phytanic
acid, and the ω-oxidation of leukotriene (LT) B4 (Figure 1).3,4,9-12
It is assumed that the accumulation of fatty alcohols and aldehyde-modified lipids is
involved in the pathophysiology of SLS, as might be reflected by the 'lipid' peak on 1H-MRS
of the brain, and by the presence of crystalline deposits in the ocular fundus. The crucial role
for FALDH in the ω-oxidation, i.e. the inactivation, of LTB4 leads to elevated concentrations
of LTB4 and ω-OH-LTB4 in SLS. These metabolites are biologically highly active and could
as such contribute to the pathogenesis of SLS. LTB4 is a pro-inflammatory mediator
synthesised from arachidonic acid via the 5-lipoxygenase pathway (Figure 1).13-15 It is known
to be involved in different disease processes, but its (patho)physiological significance in the
central nervous system and skin in general is largely unknown.13,14,16,17 Moreover, SLS has no
clinical and histological features that could point to an underlying inflammatory process.
Zileuton is a commercial available medicine, used in the treatment of asthma, which
blocks the synthesis of LTB4 and the cysteinyl LTs by inhibiting 5-lipoxygenase (Figure 1).18
Following our first promising experiences with zileuton in the treatment of one patient with
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SLS,19 we studied its effects in five additional SLS patients. This paper describes the effects
of zileuton in these patients and discusses future treatment protocols.
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Figure 1. Metabolic pathways of biosynthesis of leukotrienes (LTs), prostaglandins (PGs),
and thromboxanes (TXs), and microsomal degradation of LTB4 to ω-COOH-LTB4. 5-HPETE:
5S-hydroxyperoxy-6,8,11,14-eicosatetraenoate. The enzymes denoted are: (1) 5-lipoxygenase,
which is inhibited by zileuton, and (2) the 'SLS-enzyme' fatty aldehyde dehydrogenase
(FALDH).
MATERIALS AND METHODS
Patients and treatment schedule
Five patients (Patients 1-5) with SLS, one boy and four girls, aged 14 to 21 years, were treated
with zileuton after having obtained informed parental consent and with permission of the
hospital's medical ethical committee. The patients had the characteristic clinical features of
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SLS including pruritus and juvenile macular dystrophy with crystalline deposits in the retina.
They did not suffer from any other disorder besides SLS. Pruritus was a constant and
impairing symptom in all patients. Diagnosis of SLS had been proven biochemically by
demonstrating FALDH deficiency in cultured skin fibroblasts, and by molecular studies of the
FALDH gene. Zileuton was administered in 600 mg doses three times daily during the first
1½ months and 600 mg four times daily during the second part of the study. Extensive
clinical, neuroradiological, and laboratory parameters were evaluated at start (t=0) and after 3
months of treatment (t=3). Laboratory controls of serum transaminases and urinary (ω-OH-
)LTB4 were also performed at t=1½ months.
Clinical observations
Since pruritus scoring systems are lacking for young, mentally handicapped patients, we
developed a simple scoring system for the parents based on our experiences in the previous
case study.19,20 The parents scored the severity of the child’s pruritus two times daily. The first
score represented the parental impression of the child’s sleep disturbance during the preceding
night. This score depended mainly on the aspect of the bedclothes and skin, and was given on
a three-point scale: 0-none; 1-mild; 2-moderate to severe. At the end of each day they scored
the severity of pruritus during that day on a four-point scale: 0-none; 1-mild (pruritus without
visible scratches); 2-moderate (pruritus with visible scratches); 3-severe (pruritus with
bleeding or scarring of the skin). Addition of the first and second score resulted in the total
score for that day. To obtain the baseline values, parents started scoring two weeks before
zileuton was given.
Repeated clinical neurological, ophthalmological, and dermatological examinations
were performed by the same clinicians. The retina and the skin were photographed at t=0 and
t=3 months. Motor performance was evaluated by two physical therapists at the same time,
using the Gross Motor Function Measure (GMFM), a criterion-referenced test to measure
gross motor function in children with spasticity.21 This test contains 88 items, divided over
five different dimensions: laying and rolling (17 items), crippling and kneeling (14 items),
sitting (20 items), standing (13 items) and walking, running en jumping (24 items). All items
are scored in a 4 points scale. All measurements were recorded on videotape.
Neuropsychological evaluation
All patients were assessed by the same neuropsychologist at t=0 and t=3 months. External
variables (room, time scheme, order of used materials) were kept identical as much as
possible. The aim of the first investigation (t=0) was to obtain insight in the level of
intellectual functioning and to measure the baseline speed of information processing. At t=3
months, only the speed of information processing was evaluated. Overall intellectual
functioning was assessed by the Wechsler Intelligence Scale for Children Revised.22
Neuropsychological assessment at t=0 and t=3 months further consisted of the following tests:
Bourdon-Vos test for children,23 Stroop color word test,24 and Amsterdam
Neuropsychological Tasks (ANT).25 The ANT consists of tasks that assess baseline speed,
impulse control, visual memory, and visual attention. The results of the Bourdon-Vos test as
well as the subtests of the ANT are given as mean (SD), because these tests score reaction
times that are measured repeatedly. The Dutch version of all tests was used. All reaction time
tasks were measured with a chronometer.
Electro-encephalographic (EEG) studies
All EEGs were recorded in the morning, using a 32-channel Oxford Instruments Profile digital
EEG-system. Nineteen electrodes were placed according to the international 10-20 system.
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The EEG was recorded while the subject was resting (with eyes closed) on a couch in a semi-
darkened room. The sample frequency was 256 Hz. Before computer-analysis of the EEG was
performed the raw data were post-processed. First, a remontage was performed. The resulting
montage was based on a source derivation. Subsequently, the data were digitally filtered using
a bandpass filter of 1.6-50 Hz (in Patient 5 a bandpassfilter of 3.0-50 Hz was used because of
slow activity interfering with the occipital background activity). Next, five segments of 6
seconds in duration without artefacts or signs of drowsiness were selected. These segments
were used for frequency analyses (fast Fourier transformation). The results with respect to the
background activity (i.e. peak frequency of background activity in the posterior regions) are
given in Table 1. Changes in peak frequency of more than 0.25 Hz were considered to be
clinically relevant.
Cerebral MRI and 1H-MRS
Cerebral MRI and 1H-MRS were performed before treatment was started, and repeated at t=3
months.
All MR investigations were performed on a Siemens Magnetom Vision spectrometer
(1.5 T) using a standard circular polarised head coil. For MRI a routine protocol was used
resulting in T1-weighted coronal and sagittal images and proton density and T2-weighted
transversal images.
Single voxel 1H-MR spectra were acquired using stimulated-echo acquisition mode
(STEAM)26 localisation (echo time/mixing time/repetition time=20/30/3000 msec) with and
without water suppression. Cubic voxels of 8 ml were positioned at two locations, mainly
containing either white matter (occipital trigone) or gray matter (central occipital). Nine
healthy control subjects, mean age 18.7 (range 10-25) years, underwent MRI and 1H-MRS
using the same protocols as in the SLS patients. The spectral region between 4.0 and 1.1 ppm
of each water-suppressed spectrum was analysed by LCModel27 to obtain metabolite tissue
contents. To enable fitting of the 'lipid' peak present in the 1H-MR spectra of white matter, the
basis set of spectra was extended with a single resonance at 1.3 ppm representing lipid
methylene proton spins. The spectra of lactate, ethanol, and β-hydroxybutyrate, which all have
some intensity around 1.3 ppm, were excluded from the basis set during the LCModel fit. In
some spectra the signal intensity present at 3.6 ppm was partly fitted to myo-inositol and
partly to glycine. Because a separate study on these patients and control subjects showed
virtually no signal intensity at this position in spectra obtained with a longer echo time of 135
ms (as expected for glycine), the part of this resonance fitted to glycine was recalculated and
also assigned to myo-inositol (Ins). N-acetylaspartate and N-acetylaspartylglutamate are
indicated as 't-NAA' (total NAA); free choline, and the choline-containing compounds
phosphocholine and glycerophosphorylcholine as 'Cho'; glutamine and glutamate as 'Glx'; and
creatine and creatine phosphate as 'Cr'.
Laboratory investigations
Urinary samples were collected at t=0, t=1½, and t=3 months. They were stored at -80°C until
analysis. At the same moments, blood samples were taken to control serum aminotransferases.
Samples of cerebrospinal fluid were taken by lumbar puncture at t=0 and t=3 months and also
stored at -80°C until they could be analysed. Analyses of all samples was performed at the
moment that all patients had completed the full length (three months) of the treatment
protocol. Urinary LTB4, ω-OH-LTB4, and ω-COOH-LTB4, as well as LTB4 and ω-OH-LTB4
in cerebrospinal fluid, were separated by reverse-phase HPLC and subsequently quantified by
immunoassays and/or gas chromatography-mass spectrometry using [18O]-labelled
leukotrienes as internal standards, as previously described in detail.11,12 Levels of the
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metabolites in urine are expressed as nmol/mol creatinine. LTB4 and ω-OH-LTB4
concentrations in cerebrospinal fluid are given as pmol/l.
Statistical analyses
A paired two-tailed t-test was used for statistical analyses of the data.
RESULTS
The results of the clinical observations, neuropsychological assessments, EEGs, 1H-MRS
studies, and concentrations of LTB4 and ω-OH-LTB4 in urine and CSF are summarised in
Table 1.
Clinical observations
None of the parents felt any difficulty in deciding whether or not there were effects of
zileuton. The parents of Patients 3 and 5 found no beneficial or unfavourable changes.
However, to the opinion of the parents of the other three patients, there was a clear and
favourable effect on the child's behaviour, which was considered more lively and more alert.
Pruritus scores improved significantly: the mean score during the treatment period was 33%
below the baseline score (P=0.006). These effects occurred already in the first week of the
therapy and did not improve further after increasing the dose zileuton at t=1½ months.
Repeated neurological, ophthalmological, and dermatological examinations did not
show any differences in motor signs, the number of glistening dots of the retina, and
ichthyosis. Motor performance, as assessed by the GMFM, was judged to be equal at t=0 and
t=3 months. The total GMFM scores are given in Table 1. Notably, the general impression of
the different investigators with regard to a child's alertness and wellbeing was always in good
agreement with the parents' reports.
Neuropsychological evaluation
All patients had a remarkable good mood, were friendly and co-operative. The IQ scores of
Patients 1 to 5, were 48, 48, 56, 54, and 50 respectively, reflecting moderate mental
retardation. No discrepancies were measured between verbal and non-verbal intellectual
performances. Along with their level of intellectual functioning a low pace of information
processing was measured. None of the patients was able to perform the ANT-subtest for
visual memory. For that reason, it was excluded from the study. The Bourdon-Vos was not
performed successfully by Patient 2 due to spasticity, while Patient 5 was unable to perform
the Stroop due to illiteracy. There was a trend towards better performance during therapy. At
t=3 months all patients gave a more alert and adequate impression. Responding and
spontaneous speech seemed improved in a way that the latency period took less time. Less
distraction due to itching was also observed. Group means of most tasks showed a decrease in
reaction time but no statistically significant improvement during treatment (all P-values >
0.05).
Electro-encephalographic studies
All patients showed a slow background activity at the initial examination. In two patients
(Patients 1 and 4) we found a remarkable variant activity with half the frequency of the
occipital background rhythm. At the second recording we found improvement of the
frequency of the occipital background activity in two patients, while the others showed no
changes compared to the first EEG.
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Cerebral MRI and 1H-MRS
The characteristic abnormalities of cerebral imaging in SLS were found in these patients and
consisted of an arrest of myelination, hyperintense signal disturbances of the periventricular
white matter on T2-weighted images, and mild signs of atrophy. Comparison of the MRI
studies at t=0 and t=3 months showed unchanged images for all five patients.
1H-MRS showed a high and sharp peak at position 1.3 ppm in the lipid region of the
spectrum obtained from white matter. The intensity of this peak, that is thought to reflect the
accumulation of lipid molecules due to the underlying inborn error of metabolism, showed no
consistent changes after the treatment period. In patients 1, 2, and 4 the intensity of the peak
increased with 28%, 9%, and 4% respectively, while in patients 3 and 5 it decreased with 12%
and 29%. The mean peak intensity before treatment was 14.7 (SD 6.5) arbitrary units (a.u.),
while it was 15.1 (SD 8.0) a.u. thereafter (P=0.75). In a separate study, we found that the
tissue levels of N-acetylaspartate are normal in cerebral white matter of SLS patients (n=14),
while those of creatine, choline, and especially myo-inositol are elevated. These findings are
thought to reflect cerebral gliosis without obvious neuronal loss. In the present study, the
baseline tissue levels of the metabolites were in the same (abnormal) range, but significant
changes were not found after treatment with zileuton.
Laboratory investigations
Baseline urinary concentrations of LTB4 and ω-OH-LTB4 were highly elevated, while ω-
COOH-LTB4 was not detectable (as expected in SLS11,12). The concentrations decreased
during the treatment period in all patients. The mean concentration of LTB4 fell 41%: from
24.0 (SD 7.6) nmol/mol creatinine before treatment to 14.2 (SD 3.8) nmol/mol creatinine
thereafter (P=0.02). The proportional change for ω-OH-LTB4 showed the same pattern (mean
decrease: 42%; P=0.003). At t=1½ months the concentrations of LTB4 and ω-OH-LTB4 were
in between those at t=0 and t=3 months. The concentrations of LTB4 and ω-OH-LTB4 in
cerebrospinal fluid were - unexpectedly - normal at t=0 and at t=3 months (P=0.24). Serum
aminotransferases were normal at the beginning of the study, and did not change during the
treatment.
DISCUSSION
It is known that the degradation of LTB4, but not of the cysteinyl LTs, is impaired in SLS.11,12
This defect leads to elevated concentrations of LTB4 and ω-OH-LTB4. Since zileuton inhibits
the synthesis of the LTs, it was expected that treatment with zileuton would lead to a decrease
in the abnormal elevated levels of LTB4 and ω-OH-LTB4. This theoretical consideration and
the promising observations in one case,19 motivated us to study the effects of zileuton in a
larger series of SLS patients. However, to predict the clinical effects of zileuton in SLS
remained speculative since the precise pathophysiological role of the defective LTB4
inactivation in SLS is unknown.
As did the parents, we also noticed improvement in the alertness and liveliness of three
children. However, this was not the case in the other two patients. The pruritus score
decreased in all four patients whose parents used the scoring system. Whether the decrease of
the pruritus and the improvement in alertness are independent effects remains to be
determined. Motor performance did not change during the three months of treatment. This
was expected, taking into account that the treatment period was short and that the baseline
condition is characterised by severe motor handicaps (spasticity with contractures) and mental
retardation. Analyses of the results of the neuropsychological tests showed no statistically
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Table 1 Effects of three months treatment with zileuton in five patients with SLS
GroupItem Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Mean Change
Clinical scores
General impression
Pruritus score 1
GMFM 2
Favourable
1.6 (0.5) / 1.2 (0.5)
196 / 203
Favourable
1.8 (0.7) / 1.1 (0.6)
59 / 59
None
2.9 (0.4) / 2.1 (0.5)
159 / 160
Favourable
1.9 (0.3) / 1.1 (0.5)
110 / 107
None
n.a. / n.a
118 / n.a.
2.1 / 1.4
128.4 / 132.3
- 33% **
+ 1%
Neuropsychology
Bourdon-Vos
Stroop I
Stroop II
Stroop III
ANT baseline speed
ANT impulse control
ANT visual attention
21.7 (6.1) / 18.3 (3.1)
115 / 109
132 / 105
179 / 152
752 (547) / 480 (305)
513 (233) / 413 (179)
725 (289) / 586 (209)
n.a. / n.a.
384 / 397
267 / 237
616 / 499
576 (110) / 635 (186)
783 (230) / 737 (162)
943 (209) / 586 (378)
 17.0 (2.6) / 18.6 (3.0)
94 / 81
 109 / 106
213 / 213
522 (391) / 445 (230)
467 (67) / 428 (81)
669 (345) / 686 (339)
30.2 (9.3) / 24.4 (3.5)
84 / 94
154 / 113
247 / 191
685 (217) / 591 (183)
748 (216) / 645 (108)
733 (180) / 696 (217)
24.9 (4.3) / 20.0 (3.0)
n.a. / n.a
n.a. / n.a
n.a. / n.a
539 (235) / 558 (232)
402 (65) / 415 (83)
 692 (150) / 801 (214)
23.5 / 20.3
169.3 / 170.3
165.5 / 140.3
313.8 / 263.8
615 / 542
583 / 528
752 / 671
- 14%
+ 1%
- 15%
- 16%
- 12%
- 9%
- 11%
EEG
O1
O2
4.00 / 3.75 5
4.00 / 3.75 5
7.25 / 8.00
7.50 / 7.75
8.00 / 8.75
8.00 / 8.75
4.75 / 4.75 5
4.75 / 4.75 5
8.25 / 8.25
8.50 / 8.25
1H-MRS 3
Lipid peak
t-NAA
Cho
Cr
Ins
Glx
10.6 / 13.6
13.4 / 9.9
2.4 / 2.1
6.2 / 6.3
4.5 / 6.0
11.6 / 13.0
23.8 / 25.9
11.0 / 7.8
2.6 / 2.0
6.4 / 5.2
7.6 / 6.4
10.2 / 6.1
9.8 / 8.6
11.7 / 12.7
1.9 / 1.9
7.1 / 6.8
5.5 / 5.4
13.9 / 15.3
19.5 / 20.3
10.5 / 10.5
1.7 / 1.8
5.6 / 6.6
6.8 / 6.7
11.2 / 16.0
9.7 / 6.9
9.2 / 11.0
2.3 / 2.4
5.8 / 7.6
4.6 / 5.5
12.8 / 14.5
14.7 / 15.1
11.2 / 10.4
2.2 / 2.0
6.2 / 6.5
5.8 / 6.0
11.9 / 13.0
+ 3%
- 7%
- 9%
+ 5%
+ 3%
+ 9%
Urine 4
LTB4
ω-OH-LTB4
21 / 12
179 / 97
34 / 15
246 / 123
 16 / 10
124 / 79
32 / 21
225 / 154
17 / 13
219 / 124
24.0 / 14.2
198.6 / 115.4
- 41% *
- 42% **
CSF 4
LTB4
ω-OH-LTB4
143 / 128
< 15 / < 15
175 / 152
< 15 / < 15
 110 / n.a.
< 15 / n.a.
146 / 155
< 15 / < 15
116 / 36
< 15 / < 15
138 / 118
< 15 / < 15
- 14%
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Legend of Table 1
The baseline data and the results after three months zileuton are given, separated by a slant
line (t=0 / t=3). A paired two-tailed t-test was used to compare the group results before and
after treatment, * 0.01 < P < 0.05, ** P < 0.01. Units used: results from neuropsychological
tests in seconds (Bourdon-Vos, Stroop) and milliseconds (ANT); 1H-MRS lipid peak in
arbitrary units, other metabolites in mmol/l tissue content; EEG frequency in Hz; urinary
concentrations of LTB4 and ω-OH-LTB4 in nmol/mol creatinine; LTB4 and ω-OH-LTB4
concentrations in CSF in pmol/l. N.a. = not available.
1 Pruritus score: mean baseline score per day / mean score per day during the treatment
period (minimum score: 0, maximum score: 5).
2
 GMFM = Gross Motor Function Measure (maximum score: 352).
3 The tissue levels (SD) for the metabolites in cerebral white matter of healthy controls are:
lipid peak 0.6 (0.6) arbitrary units; t-NAA 9.6 (0.9), Cr 5.1 (0.3), Cho 1.7 (0.3), Ins 4.5 (0.9),
and Glx 12.4 (0.9) mmol/l.
4
 The urinary concentrations of LTB4 and ω-OH-LTB4 are < 5 nmol/mol creatinine in healthy
controls; CSF concentrations (SD) in control subjects are: LTB4 114.7 (57.1) pmol/l, and ω-
OH-LTB4 < 15 pmol/l (reference 12).
5
 Variant activity of the occipital background rhythm.
significant improvement of the group performance after treatment. However, the mean
percentage of improvement of the neuropsychological test scores was 10.9% when the results
of all patients on the speed of information processing tasks were taken together. We consider
this, in view of the other results and the small number of patients, a clinically relevant and
hopeful trend towards a beneficial change.
The EEG improved remarkably in Patient 3, and showed a slight improvement in
Patient 2. The increase of the frequency of the occipital background activity was not
associated with the clinical observations in the patients. However, this finding might plead in
favour of the supposition that treatment with zileuton also may affect the patients central
nervous system functioning.
In contrast to the preliminary findings in the first patient treated with zileuton,19 we
could not demonstrate an effect on the metabolic composition of the brain by 1H-MRS for the
patients as a group in the present study. Decline of the intensity of the 'lipid' peak at 1.3 ppm
in the 1H-MR spectra of cerebral white matter during the treatment with zileuton was only
found in two patients. There might be some explanations for this discrepancy. In a larger study
on 1H-MRS of the cerebral white matter of SLS multiple investigations showed that the
intensity of the 'lipid' peak might fluctuate. Moreover, we have found that zileuton does not
have any effect on the concentration of LTB4 in CSF and that CSF baseline concentrations of
(ω-OH-)LTB4 are even normal. Therefore, it seems that the pathological 'lipid' peak has no
relation with the (systemic) defect in LTB4 degradation. The fact that we observed changes in
the 1H-MR spectrum in the very first patient might theoretically also be caused by her younger
age and by the fact that the spectrum was obtained from another brain region (parietal). The
small number of patients in the present series hampers a definite conclusion, but encourages to
include younger patients in future treatment protocols.
Analyses of LTB4 and ω-OH-LTB4 in urine and CSF were, for logistic and technical
reasons, only performed when the study was completed in all patients. Zileuton was successful
in lowering the concentrations of LTB4 and ω-OH-LTB4 in urine, but they were still much
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higher than the concentrations in healthy controls (Table 1). Increasing the dosage of zileuton
at t=1½ months led to further decrease of the urinary concentrations of LTB4 and ω-OH-LTB4,
but did not result in further clinical improvement of the patients. For these reasons, we
consider it not useful to aim at the lowest possible concentrations of (ω-OH-)LTB4 when
treating SLS patients with zileuton.
In contrast to the systemic effect of zileuton, no biochemical effect could be shown in
the central nervous system compartment. Even more surprising was that the baseline levels of
LTB4 and ω-OH-LTB4 were normal in CSF of SLS patients. The metabolic route for LTB4 in
the central nervous system is unknown, and SLS can obviously not provide clues to its
elucidation. We conclude that the beneficial effects of zileuton on the brain, as suggested by
the clinical observations and the EEG changes during treatment, may be secondary due to
systemic effects.
As with its metabolism, little is known about the (patho)physiological functions of
LTB4 in the skin, and the data on the role of LTB4 in the brain are even scarcer.13,14,16,17 The
initial step of LTB4 inactivation in keratinocytes is, in contrast to the situation in leukocytes
and hepatocytes, catalysed by the enzyme 12-hydroxyeicosanoid dehydrogenase.28 It is not
known if FALDH is involved in the further oxidation of the formed metabolite (12-oxo-
LTB4). LTB4 exerts potent mitogenic effects on human epidermal keratinocytes in vitro, but
its role in the proliferation and differentiation of the human skin in vivo still has to be
established.29 Epicutaneous application of LTB4 results in a cutaneous inflammatory
response,30 and animal experiments showed that LTB4 might be involved in the mechanisms
leading to pain and pruritus.31-33 Both zileuton (which inhibits the synthesis of LTB4 and the
cysteinyl LTs), as well as different cysteinyl LT receptor antagonists (which block the receptor
binding of the cysteinyl LTs but not LTB4) are reported to have beneficial effects on the
pruritus in patients with atopic dermatitis, which is an inflammatory skin disorder
accompanied by extreme pruritus.34-36 The latter findings and the favourable effects of
zileuton in SLS indicate that LTB4 may play an important role in the pathogenesis of pruritus.
In conclusion, our study shows that zileuton has clear biochemical and some
favourable clinical effects in SLS especially with respect to the agonising pruritus. It warrants
future research on dose finding, and the evaluation of the effects in younger children and
longer lasting treatment periods.
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CHAPTER 5
General discussion and future perspectives
The search for a pathophysiological explanation
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Unraveling the pathophysiological processes that lead to the signs and symptoms of SLS is
crucial for our understanding of the syndrome. At best, solving the puzzle offers the rationale
for therapeutic strategies in favor of the patients. Moreover, like all inherited metabolic
diseases in man, studying SLS learns us about human physiology and pathology in general.
Clinical features
In 1957, Torsten Sjögren and Tage Larsson reported on a group of 28 patients with an
identical clinical picture that was dominated by the presence of ichthyosis, mental retardation,
and spastic di- or quadriplegia.1 Nowadays this description of the phenotype is still applicable
to almost all patients with Sjögren-Larsson syndrome (SLS). The phenotype varies slightly
with regard to its severity, but essentially the same features with the age at onset and the same
course co-occur in each patient. Over the years, additional clinical characteristics have been
recognized that occur in the vast majority of SLS patients, namely pruritus, preterm birth
(chapter 2.2), and ocular abnormalities (chapter 2.3). On a superficial view these features
might seem trivial, and the classical clinical triad of neurocutaneous signs easily overshadows
them. However, these additional findings might considerably affect the quality of life.
Additionally, they are of diagnostic value and they might offer clues in the elucidation of the
pathophysiology of SLS.
The course of the disease is generally considered non-progressive.1,2 This seems
especially true for higher cortical functions as well as the ichthyosis. However, we found that
motor performance gradually worsened with increasing age in all patients (chapters 2.1 and
3.1), which is in conformity with the original observations of Sjögren and Larsson themselves.
Most patients are able to walk on their own for some years (eventually with the use of aids),
but loose this capability and get dependent of a wheelchair in the first or second decade of life.
It is unclear what the mechanisms are that underlie this course. Loss of motor functions is not
paralleled by deterioration of cognitive skills, and the results of MRI and MRS studies of the
brain also show no progression during the follow-up periods (chapter 2.4). In a very recent
study we also found arguments for skeletal muscle involvement in SLS, which does not seem
to be caused by upper (or lower) motor neuron disease (chapter 2.5). This finding might mean
that SLS, instead of a neurocutaneous syndrome, is a multi-system disorder. The question is
whether all patients with SLS suffer from a skeletal muscle myopathy and - if so - what its
relative contribution is to the loss of motor capabilities in the first decades of life?
Biochemical characteristics
It took 31 years between the first description of SLS and the discovery of the biochemical
defect that causes the clinical picture. Rizzo et al. demonstrated that fibroblasts of patients
with SLS were unable to metabolize the aliphatic long-chain fatty alcohols hexadecanol (16
carbons) and octadecanol (18 carbons), due to a defect in the fatty alcohol: NAD+
oxidoreductase complex.3 The enzyme that is involved has finally been proven to be the fatty
aldehyde dehydrogenase (FALDH) component of this complex.4 FALDH is located in the
microsomes, and is a member of a large group of aldehyde dehydrogenases that are widely
present in all different tissues and cell compartments. Under in vitro conditions, FALDH has
shown to have the capability of catalyzing the oxidation of many different medium- and long-
chain fatty aldehydes.5 In contrast to this large number of metabolites, the true number of
substrates involved in the pathophysiology of SLS seems to be limited. For many substrates
other aldehyde dehydrogenase or other metabolic pathways seem to compensate for FALDH
deficiency. Nevertheless, the number of substrates and metabolic pathways involved in SLS
might still be large, especially when compared with other inborn errors of metabolism in
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which generally one metabolic route is involved. The pathophysiology of SLS is therefor very
complex, and up to now largely unknown.
The aliphatic fatty alcohols with a chain length of 16 carbons (hexadecanol) and 18
carbons (octadecanol) were the first metabolites proven to be involved in SLS.3,4 FALDH has
also been thought to be involved in the α-oxidation of branched-chain phytanic acid although
metabolites of the involved pathway could not be detected in the sera of  SLS patients.6
However, it was recently demonstrated that the complete phytanic acid α-oxidation is
localized in peroxisomes, and that the oxidation of pristanal to pristanic acid is normal in
fibroblasts with deficient FALDH activity.7 We were able to demonstrate that SLS patients are
deficient in the ω-oxidation of LTB4 (chapters 3.3 and 3.4). This finding further added to the
complexity of SLS' pathophysiology. On the other hand, it offered the basis for a new and
rational treatment strategy of SLS patients.
The discussion on the metabolic basis of SLS is futher complicated, even for the
'established metabolites' hexadecanol, octadecanol, and ω-hydroxy-LTB4. Hexadecanal and
octadecanal, and their precursor fatty alcohols, are traditionally used to prove FALDH
deficiency in the patients’ cells in vitro (leukocytes, cultured fiboblasts or amniocytes). It is,
however, hard to study the different tissues and organ compartments in SLS and to understand
the results that have been found up to now. The concentrations of octadecanol and
hexadecanol could be demonstrated to be elevated in plasma and cultured fibroblasts, but not
in cerebrospinal fluid (CSF).8 The excretion pattern of LTB4 and ω-OH-LTB4 in urine is
highly abnormal and characteristic for SLS, and defective oxidation of LTB4 has been shown
in leukocytes from SLS patients. The levels of LTB4 and ω-OH-LTB4 in CSF, however, are
completely normal. A biochemical marker for SLS in CSF has in fact never been reported.
Aliphatic fatty alcohols with 14 or 20 carbons are examples of substrates that can properly be
used to demonstrate FALDH deficiency in SLS in vitro, but that are not elevated in body
fluids of SLS patients.
The fact that affected (central nervous system and cutaneous) tissues are hardly
available has hampered pathophysiological studies in SLS. Most investigations have so far
been performed using blood leukocytes and cultured skin fibroblasts. The finding of skeletal
muscle involvement in SLS could importantly increase the availability of affected tissue and
thus the possibilities for future research on the biochemical and pathophysiological processes
in SLS.
The genetic basis of FALDH deficiency
In 1994 the SLS gene has been mapped to chromosome 17p11.2, and its genomic organization
and tissue-dependent expression have subsequently been elucidated.9,10 Mutation analyses of
the FALDH gene have identified a rich diversity of mutations.11,12 Most mutations are
missense mutations, but deletions, insertions, splice side mutations, and complex mutations
also occur. A founder effect in Sweden has been postulated, based on the high prevalence of
SLS in Vasterbotton, and the high prevalence of one certain mutation (943C>T) in the
population of Northern Europe. However, with the growing number of patients in whom
genetic analyses has been performed, it has become clear that there is a wide spectrum of
mutations in most populations. Our own report is the only one available at this moment in
which detailed clinical data are given together with the genotype of the patients (chapter 3.1).
It seems to be that almost all mutations in the FALDH gene severely compromise FALDH
activity, and subsequently lead to the severe clinical phenotype of SLS with early onset.
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Pathophysiological considerations and possible treatment strategies
Fatty alcohols are predominantly synthesized from fatty acids, and their main function is to
serve as precursors for the biosynthesis of wax esters and ether glycerolipids. There are
convincing arguments that a fatty alcohol cycle might exist in man.2-4 In this cycle, aliphatic
fatty acids are oxidized to fatty alcohols via fatty acyl-CoA intermediates, and subsequently
further oxidized to fatty aldehydes. These fatty aldehydes are then 'recycled' to their original
fatty acids. The role of the fatty alcohol cylce in man has not been elucidated. Fatty alcohols
have been demonstrated to exert inhibitory effects on the lipolysis of triglycerides by
pancreatic lipase. Moreover, they are  thought to be involved in neuronal growth and
differentation. Abundancy of fatty alcohols, due to FALDH deficiency, does not lead to
increased synthesis of wax esters and ether lipids. Since fatty alcohols are highly lipophylic
molecules, they are expected to intercalate into (intra)cellular membranes or to appear as lipid
droplets. The latter possibility is supported by the presence of a sharp 'lipid' signal in cerebral
white matter on 1H-MR spectroscopy. It is highly probable that the altered lipid compositions
of tissues (skin, central nervous system, retina, and skeletal muscle) impair their functions, but
the underlying pathophysiological mechanisms remain unclear. The effects of fatty alcohols
on pancreatic lipase activity and neuronal growth have not been studied in SLS.
Fatty aldehydes are intermediates of the fatty alcohol metabolism. Moreover, they are
generated by the catabolism of ether glycerolipids and under influence of oxidative stress i.e.
lipid peroxidation.2,13 Fatty aldehydes are highly reactive molecules and as such they are
thought to form adducts with other molecules instead of accumulate like fatty alcohols. In SLS
fibroblasts, phosphatidylethanolamine (PE) has been demonstrated to be a major 'sink' for
fatty aldehydes, that form a Schiff base with the amino group of the ethanolamine.14 The
formation of N-alkyl-PE from PE could seriously interfer with the physiologic role of PE, that
is a prominent lipid in myelin and other membranes. The potential Schiff base reactions of
fatty aldehydes with amino groups in other molecules (proteins, carbohydrates, or lipids),
raises the possibility of many different disturbances of the intra- and extracellular metabolism.
The accumulation of lipids and the subsequent deleterious consequences for cell
functioning are thought to be important mechanisms in the pathophysiology of SLS as just
discussed. Our finding of defective LTB4 metabolism in SLS, revealed another disease
causing mechanism in SLS. FALDH deficiency leads to a metabolic block in the degradation
pathway of metabolites which are biologically highly active. Thus, not only the storage of
lipids (eventually by reaction with other molecules), but also the strong intrinsic biological
functions of some lipids might contribute to SLS. It has been demonstrated that LTB4
potentiates the proliferation of keratinocytes and might be involved in the pathogenesis of
pruritus. Zileuton blocks the synthesis of the leukotrienes. The treatment of SLS patients with
zileuton leads to decrease in pruritus and increase in general wellbeing (chapters 4.1 and 4.2),
further indicating the potential role of disturbed LTB4 in the pathophysiology of SLS.
Both fatty alcohols and fatty aldehydes may also be derived from dietary lipids. It is
assumed that dietary interventions are not effective in SLS. Nevertheless, the dietary
contribution of lipids to the fatty alcohol and fatty aldehyde pool in SLS has never been
studied. Thus, at least from a theoretical point of view, dietary habbits might influence the
phenotype of patients with FALDH deficiency. Furthermore, dietary interventions might still
be of importance in future treatment strategies.
There are arguments to postulate that the metabolism of carotenoids and retinoids is
involved in Sjögren-Larsson syndrome. An excess of carotenoids gives the skin a yellowish-
brown color. The skin of patients with SLS has also a yellowish-brown, sometimes grey
appearance. High doses of the carotenoid canthaxanthine can give rise to a crystalline
retinopathy that shares important features with the macular dystrophy in Sjögren-Larsson
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syndrome.16,17 The human retinal pigment is a mixture of two naturally occuring carotenoids,
namely zeaxanthin and lutein, and several of their oxidation products.18,19 Zeaxanthin is
concentrated in the macular region, whereas lutein is dispersed throughout the entire retina.
The extent and pathways of the postabsorptive metabolism of carotenoids and retinoids is
largely unknown. Yet, it has been established that central and excentric oxidative cleavage of
carotenoids leads to the production of many different aldehydes, including -of course-
retinaldehyde.20,21 Some of these aldehydes might be a substrate for FALDH. Retinaldehyde
itself, however, is thought to be a poor substrate for FALDH and has its own cytosolic
aldehyde dehydrogenase (ALDH1).5,22 We found normal serum concentrations of α-carotene,
β-carotene, lutein, and zeaxanthin in seven SLS patients (unpublished data). It is uncertain
whether this 'negative' finding in serum also means that carotenoids and retinoids are not
involved at the tissue level of the retina and the skin.
Discussing the pathophysiology of SLS we should realize again the clinical features of
the syndrome, especially the course of the disease during the patient’s life. After disclosure of
the complete clinical picture during the first two or three years, the clinical and
neuroradiological abnormalities of the brain turn out to be non-progressive (as discussed
above). The question intrudes whether there is a temporary toxic effect on the central nervous
system during the first years of life, that leaves behind a permanent damage?
Future perspectives
Clinical studies
Now it is possible to identify SLS patients with certainty by demonstrating FALDH deficiency
and by molecular genetic analyses, the next step is to clarify the clinical spectrum of SLS. Is it
really relatively narrow? If so: it will be easier to predict the course in newly diagnozed and
young patients with more certainty. If not: the identification and subsequent biochemical and
genetic studies of more patients with a mild phenotype should offer clues for the elucidation
of mechanisms that might compensate for FALDH deficiency.
Our series of patients includes all Dutch patients with SLS in whom the diagnosis has
been confirmed by proving FALDH deficiency or by mutation analysis. The high number of
young patients suggests that there are adult SLS patients in whom the diagnosis has never
been proven. The identification of these adult SLS patients and study of their phenotypes
could contribute to the knowlegde on the course of the disease. Furthermore, early recognition
of SLS should lead to a diagnosis in the first year of life and could provide an opportunity to
study the changes of the clinical features as well as changes of the 'lipid' peak on the MR
spectra of cerebral white matter early in life.
Identification of a substrate and biochemical assay that reflects the true FALDH
activity in the cells tested, is necessary for the elucidation of a correlation between FALDH
(rest)activity and the phenotype. The first results in our studies on LTB4 degradation in mildly
affected patients, classically affected patients and proven heterozygotes, suggest that LTB4
might be the 'ideal substrate' for this purpose (chapters 3.1 and 3.4).
Pathophysiological studies and therapy
We have to concentrate on those studies that help to unravel the pathophysiological
mechanisms that underlie SLS. Further understanding of these mechanisms leads to rational
treatment strategies. Potential tools could be found in (new) MR spectroscopic techniques: is
it possible to identify the substrate that gives rise to the 'lipid peak' with more certainty?
Histological and biochemical studies of tissues (muscle!?) and body fluids (CSF!?) could
further be helpful. The development of a knock-out animal model for SLS could greatly
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improve the research possibilities, although it has to be established whether an animal model
with FALDH deficiency would reflect the human disorder SLS.
New therapeutic strategies should follow from these studies. Substrate depletion of
fatty alcohols and fatty aldehydes could theoretically be realized by dietary interventions or by
drugs that interfer with the biosynthesis of the involved fatty alcohols and fatty aldehydes (e.g.
5-lipoxygenase inhibition for depleting LTB4). LTB4 receptor antagonists could block the
effects of the increased amounts of LTB4 at the receptor level. Antioxidantia like α-tocopherol
and β-carotene might be of value if it could be demonstrated that lipid peroxidation
substantially contributes to the fatty aldehyde pool in SLS.
In conclusion, the first thing is to understand what happens, the second thing is to try to
intervene.
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This thesis describes clinical, neuroradiological, biochemical and genetic aspects of the
Sjögren-Larsson syndrome (SLS). It also deals with a new treatment strategy for this disorder.
In chapter 2.1 the clinical characteristics and neuroradiological features of a series of patients
are described. This study gives an overview of the knowledge on SLS up to 1998. It mainly
focuses on the neurological consequences of fatty aldehyde dehydrogenase (FALDH)
deficiency: spastic di- or quadriplegia, and mental retardation. Moreover, it deals with the
findings on magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy
(MRS) of the brain, which show white matter abnormalities and the accumulation of lipid
substrates.
Chapter 2.2 deals with preterm birth in SLS. We have found that most patients with SLS were
born preterm, and assume that preterm birth is a so far unrecognized part of the syndrome.
The medical histories of the patients and their mothers make clear that prematurity and
spasticity are intrinsic and concurrent parts of SLS, without causal relation. Preterm birth
might be an early clue to the diagnosis SLS in a neonate with congenital ichthyosis. A
possible explanation for preterm birth in SLS could be the defective inactivation of
leukotriene B4 (see below). If this is the case, than we encounter - in SLS - the extremely rare
situation that the metabolic defect of the fetus influences the timing of the child's birth.
Chapter 2.3 deals with the ocular abnormalities in SLS. All patients with SLS studied by us
have bilateral, glistening yellow-white crystalline deposits that were located in the innermost
retinal layers. Most patients also suffer from photophobia, subnormal visual acuity, myopia,
and astigmatism.
In chapter 2.4 the data on cerebral MRI and MRS are given. The study includes follow-up
measurements in many patients, and all results are systematically calculated (MRS) or scored
(MRI). The pattern of MRI and MRS abnormalities of the brain are found strikingly similar
among SLS patients, but with varying severity. They consist of the accumulation of lipid
substrates, delayed myelination, periventricular gliosis, and a permanent myelin deficit. The
findings presented here concern the first large series of patients with SLS, and are discussed in
view of previous neuroradiological and neuropathological (case) studies.
Chapter 2.5 deals with the abnormal histopathology of quadriceps and gastrocnemic muscles
as found in three patients with SLS. All three specimens show small muscle fibres and a slight
increase in interstitial connective tissue and fat. Additionally, the individual patients have
prominent but different abnormalities on muscle biopsy, namely marked type 1 fibre atrophy,
lobulated fibres, and ring fibres. The overall picture points to skeletal muscle involvement in
SLS. The possible causes of muscle involvement in SLS are discussed. Myopathic changes
may explain why many SLS patients gradually become wheelchair dependent despite stable
central nervous system involvement (i.e. cognitive functions and brain MRI and MRS
abnormalities). Finally, it can be hypothesised that SLS is a multi-system disorder instead of a
neurocutaneous syndrome.
In chapters 3.1 and 3.2 the findings of the molecular genetic studies are described together
with the clinical, neuroradiological, and biochemical abnormalities in SLS. Mutation analyses
of the FALDH gene is performed in 13 families and reveals eight different mutations,
including three that had not been reported previously. The vast majority of SLS patients seem
to be severely affected independent of their genotype.
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Chapters 3.3 and 3.4 describe that FALDH is involved in the metabolism of leukotriene B4
(LTB4). The findings provide unambiguous evidence for defective LTB4 degradation in SLS
patients, and offer new and non-invasive diagnostic tools. SLS can now be diagnosed at the
metabolite level in a urine sample. Moreover, the demonstration of defective LTB4
degradation opens new pathophysiological considerations with the prospect of rational
treatment strategies.
In chapter 4 is reported that the recognition of defective LTB4 degradation in SLS, as
described in the previous chapter, give the opportunity for a therapeutic intervention on a
rational base. The preliminary results of substrate depletion therapy, using the 5-lipoxygenase
inhibitor zileuton, are given in chapter 4.1. In chapter 4.2 the effects of zileuton in a series of
five patients are described. Patients with SLS might benefit from zileuton, especially with
regard to the severe pruritus. It follows that LTB4 plays a role in the pathophysiological
mechanisms that lead to pruritus, at least in SLS.
The current knowledge on the many different aspects of SLS is largely based on the
tremendous work done by Dr WB Rizzo and his collaborators. The results of his studies are
reported, discussed, and used at many places throughout this thesis. We were able to add new
insights into SLS, as described above. Many questions, however, are still unsolved. It remains
a challenge to continue SLS-research.
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SAMENVATTING EN OVERZICHT IN HET NEDERLANDS
Het Sjögren-Larsson syndroom
M.A.A.P. Willemsen, J.J. Rotteveel
(Adapted from / bewerkt naar) Nederlands Tijdschrift voor Neurologie 2001;3:179-185
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INLEIDING
Dit artikel biedt de lezer een overzicht over de klinische, biochemische en genetische aspecten
van het Sjögren-Larsson syndroom (SLS). Volgend uit deze 'basisgegevens' zullen richtlijnen
voor de diagnostiek en behandeling van deze ziekte besproken worden.
SLS werd in de jaren 50 in een Zweedse populatie als aparte entiteit herkend op grond
van het samen voorkomen van drie opvallende symptomen: congenitale ichthyosis, spastische
di- of quadriplegie en mentale retardatie.1 Consanguïniteit binnen deze bevolkingsgroep gaf
aanleiding tot een relatief hoge prevalentie van 8,3 per 100.000. Inmiddels is duidelijk
geworden dat SLS een autosomaal recessief overervende ziekte is, die wereldwijd voorkomt.
In Nederland kenden we eind 2000 19 patiënten, uit 13 families, bij wie de diagnose klinisch
en moleculair biologisch werd gesteld [zie hoofdstuk 3.1 van dit proefschrift]. Gezien het
hoge aantal jonge patiënten in deze groep mag men aannemen dat er nog oudere SLS
patiënten zullen zijn bij wie de diagnose niet werd bewezen. Wellicht dat dit artikel kan
bijdragen tot het alsnog stellen van de diagnose bij die volwassen patiënten.
HET KLINISCHE BEELD1,2
De ichthyosis van SLS is meestal vanaf de geboorte aanwezig. In het begin is de huid
erythemateus veranderd en licht schilferend. Het meest opvallende kenmerk ontwikkelt zich in
de loop van het eerste levensjaar en bestaat uit een sterke rimpeling van de huid met een
oranjebruine, soms grijze verkleuring (Figuur 1). De schilfering staat dan niet meer op de
voorgrond, hoewel de naamgeving ('ichthyosis') dat wel doet vermoeden. De gehele huid is
aangedaan met uitzondering van het gelaat. Haren, nagels en zweetproductie zijn normaal.
Jeuk is een opvallend symptoom bij SLS, in tegenstelling tot de meeste andere vormen van
ichthyosis.
De spasticiteit is symmetrisch en betreft vooral de benen, maar bij veel patiënten in
meer of mindere mate ook de armen. De spraak is soms gekenmerkt door een pseudobulbaire
dysarthrie. Spastische kenmerken worden in de loop van de eerste twee levensjaren duidelijk
en leiden bij veel patiënten in de eerste decade tot contracturen en afhankelijkheid van
hulpmiddelen. De patiënten worden veelal rolstoelafhankelijk. Het intelligentieprofiel is
harmonisch verlaagd, met een totaal IQ tussen 40 en 60. Veel patiënten maken een vertraagde
taalspraak-ontwikkeling door, die ernstiger is dan op grond van het cognitieve defekt vermoed
zou kunnen worden. De stemming is bij bijna elke patiënt opvallend goed, hetgeen - samen
met het vriendelijke karakter - een gunstig effekt heeft op de sociaal functioneren. Epilepsie
komt bij SLS nauwelijks voor. Het klinische neurologische beeld is niet progressief. De ernst
ervan is niet gecorreleerd met de ernst van de huidafwijking. In hoofdstukken 2.1 en 3.1 van
dit proefschrift wordt uitgebreid ingegaan op de klinische neurologische afwijkingen bij SLS.
Bij bestudering van onze patiënten is het duidelijk geworden dat SLS bestaat uit een
uitgebreider symptomencomplex dan de hierboven beschreven trias (Tabel 1). Juist de
additionele symptomen, die bij veel patiënten voorkomen, kunnen belangrijk zijn bij het
stellen van de klinische diagnose. De jeuk is al genoemd als een opvallende bevinding.
Oogheelkundige afwijkingen worden gevonden bij alle SLS patiënten. Deze bestaan met name
uit fotofobie, een suboptimale visus, en een retinopathie die zich kenmerkt door de
aanwezigheid van tientallen kleine retinale kristallen (Figuur 2). Het beeld van de fundus is
zeer karakteristiek voor SLS. Het kan echter gemakkelijk gemist worden bij een fotofoob
kind, dat zich moeilijk laat onderzoeken met fundoscopie. Voor een uitgebreid overzicht van
de oogheelkundige afwijkingen bij SLS wordt verwezen naar hoofdstuk 2.3 van dit
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proefschrift. Premature geboorte zien wij bij de meeste patiënten [zie hoofdstuk 2.2 van dit
proefschrift]. Het voorkomen van prematuriteit kan misleidend zijn bij het duiden van de
neurologische problematiek, en kan op die manier leiden tot vertraagde herkenning of tot
missen van de diagnose SLS.
Items bij klinisch en aanvullend onderzoek Aantal patiënten*
Huid Ichthyosis 100 % (19)
Jeuk 100 % (19)
CZS Mentale retardatie (IQ<70) 89 % (19) **
Spasticiteit 95 % (19) **
Epileptische aanval(len) 21 % (19) ***
Ogen Fotofobie 95 % (19)
Retinale kristallen 100 % (15)
Verminderde visus 93 % (15) **
Geboorte Premature geboorte (< 37 weken) 71 % (17)
Neuroradiologie Cerebrale MRI: witte stof afwijkingen 100 % (16)
Cerebrale 1H-MRS: vet-piek 93 % (14) **
EEG Traag achtergrondsritme 92 % (13) **
Urine Abnormale uitscheiding van (ω-OH-)LTB4 100 % (16)
Tabel 1 Klinische kenmerken en resultaten van aanvullende onderzoeken bij 19 SLS patiënten
uit 13 families (9 , 10 ; gemiddelde leeftijd 18 (range 2 - 46) jaar). Bij alle patiënten werd
de diagnose SLS bewezen door het aantonen van FALDH-deficiëntie in gekweekte
fibroblasten en mutaties in het FALDH-gen. * Gegeven worden: percentage patiënten bij wie
de genoemde afwijking werd gevonden, en tussen haakjes het aantal patiënten dat werd
onderzocht. ** De afwijking werd gevonden bij alle (100%) onderzochte patiënten die lijden
aan het klassieke fenotype van SLS, echter niet bij één of beiden patiënten met het milde
fenotype. *** Geen van de patiënten heeft anti-epileptica nodig.
   
Figuur 1A en B. De huid van de nek (links) en de buik (rechts) van een 14-jarig meisje met
SLS. Let op de sterke rimpeling, de (minimale) schilfering, en de vele krabeffecten.
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Magnetic resonance imaging (MRI) van het brein bij SLS laat (op de T2-gewogen beelden)
drie typen afwijkingen zien. Op de eerste plaats is dat een periventriculaire zone met
hyperintense signaalveranderingen van de witte stof (Figuur 3). Deze signaalveranderingen
strekken zich uit van frontaal naar occipitaal, zijn confluerend, en meestal weinig prominent.
In een minderheid van de gevallen zijn ze zeer uitgesproken, of bestaat er een meer vlekkerig
verdelingspatroon. De afwijkingen worden in de eerste levensjaren zichtbaar en zijn daarna
niet progressief. Ze representeren zeer waarschijnlijk gliose van de witte stof (zie verderop).
De tweede MRI-afwijking die wordt gezien is een vertraagde en onvolledige myelinisatie.
Nagenoeg alle patiënten (leeftijd 0 - 45 jaar) hebben kleine gebieden met ongemyeliniseerde
(frontale, parietale, occipitale en temporale) subcorticale witte stof. De pathofysiologische
mechanismen die bij SLS het proces van de myelinisatie verstoren zijn onduidelijk.
Vertraagde myelinisatie is een aspecifiek fenomeen dat wordt aangetroffen bij een scala aan
aandoeningen zoals primaire witte stof ziekten, chromosomale aandoeningen, congenitale
hydrocephalus, stofwisselingsziekten, en na perinatale asfyxie. De mate van myelinisatie
wordt vaak beschouwd als een maat voor de functionele rijpheid van het brein, maar het is
moeilijk om de functionele consequenties van de afwijkende myelinisatie bij SLS in te
schatten. In sommige gevallen wordt, als derde afwijking, een lichte verwijding van het
ventrikelsysteem en/of de subarachnoïdale ruimten gevonden zonder andere tekenen van
atrofie. Er zijn geen morfogenetische afwijkingen van het brein. SLS patiënten hebben een
normale schedelomtrek.
Proton magnetische resonantie spectroscopie (1H-MRS) van de hersenen laat een zeer
opvallende en karakteristieke afwijking zien, op grond waarvan de klinische diagnose SLS zo
goed als zeker kan worden geacht. Deze afwijking bestaat uit een hoge piek in het MR-
spectrum op de plaats waar vetten resoneren. De piek is in de cerebrale hemisferen
aantoonbaar in de witte stof, maar niet in de grijze stof (Figuur 4). Men gaat er vanuit dat de
piek een weerspiegeling is van de onderliggende stofwisselingsziekte (zie verderop). Het
spectrum van de fysiologisch voorkomende metabolieten laat een patroon zien dat zou kunnen
passen bij gliose zonder duidelijke schade aan of verlies van neuronen (N-acetyl-aspartaat en
gutamine/glutamaat normaal; creatine, choline en myo-inositol verhoogd). Neuropathologisch
onderzoek bij SLS is zeer sporadisch verricht. Het betrof daarbij nooit een patiënt met een
Figuur 2. Fundoscopisch beeld van
het rechter oog van een 17-jarige
patiënte met SLS. Let op de
tientallen kleine, soms confluerende
kristalletjes in het maculaire deel
van de retina.
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(moleculair biologisch) bewezen diagnose. De beschrijvingen zijn echter uniform. De
belangrijkste afwijkingen bestaan uit de aanwezigheid van intra- en extracellulaire
vetdruppeltjes, mild tot ernstig verlies van myeline, enig verlies van neuronen en een
overmaat aan astrocyten. Deze beschrijvingen passen bij de bevindingen bij MRI- en 1H-
MRS-onderzoek van de hersenen. De neuroradiologische afwijkingen bij SLS worden
uitgebreid beschreven en bediscussieerd in hoofdstukken 2.1 en 2.4 van dit proefschrift.
            
            
Figuur 3. MRI beeld (T2-gewogen) van de hersenen van een 14-jarig meisje (A en B) en een
16-jarige jongen met SLS (C en D). Let op de periventriculaire zone van hyperintense
signaalafwijkingen. Bij de meeste patiënten worden lichte afwijkingen gezien (zoals in figuren
A en B); de uitgebreidheid en intensiteit van de MRI-afwijkingen korreleert niet met de ernst
van het klinisch neurologisch beeld.
A
C D
B
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Het elektro-encefalogram laat een traag achtergrondritme zien, zonder andere afwijkingen.
Visual evoked potentials zijn meestal vertraagd. Het perifere zenuwstelsel is klinisch noch
neurofysiologisch betrokken in het ziekteproces.
Milde vormen van SLS zijn beschreven bij vijf patiënten in de literatuur. In onze groep
kennen we twee patiënten met een mild fenotype. Het betreft een broer (42 jaar) en zus (46
jaar) met de kenmerkende huidafwijkingen, hoewel minder uitgebreid dan de andere
patiënten. De man heeft slechts een licht pyramidaal syndroom van de benen (loopt zonder
hulpmiddelen), terwijl de vrouw helemaal geen neurologische afwijkingen heeft. Beiden
hebben een normale intelligentie. Opvallend is dat beiden wel de kristallijne retinopathie
hebben, en lichte MRI-afwijkingen. De klinische en moleculair biologische bevindingen bij
deze beide patiënten worden beschreven in hoofstukken 2.1, 2.3, 2.4, en 3.1 van dit
proefschrift.
01234
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Figuur 4. 1H-MR spectrum van de
witte (A) en de grijze (B) stof van
de hersenen van een 16-jarige
jongen met SLS (zie ook figuur 3C
en D). Let op de hoge 'vetpiek'
(blokpijl) bij 1.3 ppm, die wel in de
witte stof maar niet in de grijze stof
aantoonbaar is. In de hersenen van
gezonden wordt deze piek niet
gezien. Het spectrum van de grijze
stof is normaal. Cho = choline; Cr
= creatine; NAA = n-acetyl-
aspartaat.
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BIOCHEMISCHE ASPECTEN
Dertig jaar nadat de ziekte werd beschreven door Sjögren en Larsson, was het Rizzo die
bewees dat een defekt in de vetstofwisseling ten grondslag ligt aan SLS.3,4 Patiënten met SLS
hebben een deficiëntie van het microsomaal gelokaliseerde enzym vetaldehyde dehydrogenase
(fatty aldehyde dehydrogenase, FALDH). Dit enzym katalyseert [a] de omzetting van
meerdere midden- en lange keten vetaldehyden, afkomstig van vetalcoholen, naar hun
corresponderende vetzuren, [b] de alfa-oxidatie van fytaanzuur en [c] de omega-oxidatie van
leukotrieen B4.3-7 Figuren 5 en 6 illustreren de structuurformules van een aantal van de
betrokken vetten, en de plek van FALDH in de stofwisseling.
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Figuur 5. Vetten die - als alcohol - omgezet kunnen worden door FALDH
CH3-(CH2)16-COOH
octadecaanzuur
CH3-(CH2)16-CO-S-CoA
octadecanoyl-CoA
CH3-(CH2)16-CH2OH
octadecanol
CH3-(CH2)16-CHO
octadecanal
CH3-(CH2)16-COOH
octadecaanzuur
FALDH
/(8.275,((1 %
)<7$$1=885
2&7$'(&$$1=885
Figuur 6. FALDH katalyseert de
omzetting van octadecanal naar
octadecaanzuur.
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Een deficiëntie van FALDH leidt tot een overmaat aan vetalcoholen of vetaldehyden. Men
heeft kunnen bewijzen dat deze moleculen zich intracellulair stapelen, reacties aangaan met
andere molekulen van de cel, of biologisch actief zijn. De vetpiek die wordt gezien bij
cerebrale 1H-MRS weerspiegelt waarschijnlijk de stapeling van een of meerdere vetten. De
overmaat van het biologisch zeer actieve leukotrieen B4 zou een rol kunnen spelen bij
verschillende van de klinische afwijkingen. Over de exacte pathofysiologische mechanismen
die een rol spelen bij SLS is nog veel onduidelijk. Dat FALDH een cruciale rol speelt bij de
LTB4 afbraak werd door ons gevonden. De bevindingen worden beschreven en bediscussieerd
in hoofdstukken 3.3 en 3.4 van dit proefschrift.
GENETISCHE ASPECTEN
SLS is een autosomaal recessief overervende aandoening. Het gen dat codeert voor FALDH
werd de afgelopen jaren gelokaliseerd en gekarakteriseerd. Bij SLS patiënten werden
inmiddels veel verschillende mutaties in het FALDH-gen aangetoond.8,9 Het kan gaan om
verschillende type mutaties zoals onder andere 'missense' mutaties, deleties en inserties. De
mutaties kunnen homozygoot voorkomen, maar vele patiënten hebben twee verschillende
mutaties ('compound heterozygoot'). In de Nederlandse populatie, beschreven in hoofdstuk 3.1
van dit proefschrift, en voor zover bekend ook op mondiaal niveau, komen twee mutaties voor
in ongeveer 50% van de allelen. De eerste is de 'missense' mutatie 943C>T. Door deze mutatie
wordt een evolutionair sterk geconserveerd aminozuur van FALDH, namelijk proline op
positie 315, vervangen door serine. Deze ene verandering van het eiwit (FALDH bestaat uit
485 aminozuren) leidt tot een dramatisch verlies van het katalytisch vermogen van het enzym.
De tweede veel voorkomende mutatie betreft een deletie van twee baseparen, namelijk 1297-
1298delGA, hetgeen leidt tot een verkort ('getrunceerd') eiwit dat zijn functie niet langer kan
uitoefenen.
Genotype-fenotype correlaties zijn niet bekend voor SLS. Vooralsnog lijkt verreweg
het grootste deel van de SLS patiënten te lijden aan het klassieke, ernstige beeld.
In het kader van dit proefschrift werd mutatie-analyse verricht bij de Nederlandse
patiënten met SLS, met daaraan gekoppeld biochemische karakterisering en klinische
beschrijving van de patiënten. Op die manier kon het eerste "genotype-fenotype artikel" over
SLS geschreven worden [zie hoofdstukken 3.1 en 3.2 van dit proefschrift].
DIAGNOSTIEK
Het klinische beeld van SLS is karakteristiek en bevat vele elementen die door een (kinder-)
neuroloog herkend moeten worden, zeker in samenwerking met een dermatoloog en oogarts.
Aanvullend onderzoek in de vorm van MRI en EEG laat wel afwijkingen zien, maar deze zijn
niet specifiek. 1H-MRS kan de klinische diagnose sterk steunen (zie boven).
Routinematig laboratoriumonderzoek van bloed, liquor en urine levert geen enkele
diagnostische afwijking op. Het 'screenende' metabole onderzoek zoals dat in diverse
laboratoria voor stofwisselingsziekten wordt verricht (bijvoorbeeld bestaande uit analyse van
aminozuren, organische zuren, suikers, purines, pyrimidines en zeer lang keten vetzuren),
levert bij een patiënt met SLS evenmin afwijkingen op. De analyse van vetalcoholen of
vetaldehyden in bloed of in weefsels is zeer complex, en de daartoe benodigde technieken zijn
momenteel slechts operationeel in het laboratorium van Dr WB Rizzo (Richmond, USA). Uit
wetenschappelijke interesse, of indien er van een patiënt alleen (ingevroren) urine ter
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beschikking is, kan men leukotrieen B4 laten meten in het Academisch Kinderziekenhuis in
Heidelberg (Dr E Mayatepek). Enzymdiagnostiek en mutatieanalyse leveren het definitieve
bewijs voor de diagnose SLS, en kunnen worden gedaan in witte bloedcellen of in gekweekte
fibroblasten van de huid. Beide onderzoeken worden verricht in het Laboratorium voor
Genetische Metabole Ziekten in het Academisch Medisch Centrum te Amsterdam, onder
leiding van Prof Dr RJA Wanders. Prenatale diagnostiek behoort tot de mogelijkheden, en kan
in datzelfde laboratorium worden gedaan.
BEHANDELING
SLS zou bij voorkeur causaal behandeld moeten worden, ingrijpend op het onderliggende
defekt in de vetstofwisseling. Ondanks de gevorderde inzichten van de laatste jaren, is dat
momenteel slechts beperkt mogelijk. Men heeft geprobeerd met een aangepast (MCT-) dieet
het betrokken deel van de vetstofwisseling te 'bypassen', maar dat leidde niet tot klinische
verbetering. De enige op het biochemische defekt gerichte therapie die momenteel
voorhanden is, bestaat uit remming van de leukotrieensynthese met behulp van zileuton
(dosering vanaf 12 jaar: 4 dd 1 tablet à 600 mg). Deze behandeling, die uitgebreid besproken
wordt in hoofdstukken 4.1 en 4.2 van dit proefschrift, heeft een gunstig effekt op de jeuk en
het algemeen welbevinden bij een deel van de patiënten. Gen- en enzymvervangingstherapie
zijn niet beschikbaar voor SLS. Stamcel- of beenmergtransplantatie zijn nooit geprobeerd.
In het algemeen kan men veel goed doen door SLS symptomatisch te behandelen. Te
denken valt aan ondersteuning van de motore functies (fysiotherapie, ergotherapie, orthesen,
rolstoel, orthopedische correcties van contracturen), de communicatie (logopedie, gebruik van
computer), en speciaal onderwijs. De huidafwijking is moeilijk te behandelen. Men kan
proberen met lokale keratolytische therapie (bijvoorbeeld: ureum bevattende cremes), of met
systemische retinoïden (acitretine) bij oudere kinderen, de hyperkeratose en de jeuk te
verminderen.
CONCLUSIES
SLS is een autosomaal recessieve neurocutane aandoening die op klinische gronden kan
worden vermoed, met 1H-MRS kan worden bevestigd, en op enzym- en DNA-niveau kan
worden bewezen. De ziekte wordt veroorzaakt door een defekt in de vetstofwisseling. De
behandeling is vooralsnog symptomatisch, maar toenemende pathofysiologische inzichten
zullen hopelijk leiden tot meer gerichte therapie.
DANKWOORD
Het is door de inspanningen van een grote groep mensen, dat het hier gepresenteerde overzicht
tot stand heeft kunnen komen. Wij danken allen die de laatste jaren aan 'het SLS onderzoek'
hun bijdrage hebben geleverd.
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Vele mede-auteurs hebben een bijdrage geleverd aan de totstandkoming van de artikelen die
de bouwstenen zijn van dit proefschrift. Het onderzoek is steeds sterk multi-disciplinair van
karakter geweest, en het grote aantal mede-auteurs illustreert dat. Er zijn ook veel mensen
geweest die op de achtergrond een helpende hand boden, toestemming gaven 'hun' patiënt te
zien, een waardevol advies gaven of zorgden voor een broodnodig duwtje in de rug. Een
poging om op deze plaats iedereen te bedanken is gedoemd om te mislukken. Laat ik me
daarom beperken tot een aantal mensen die ik beschouw als 'sleutelfiguren' voor het SLS-
onderzoek en de totstandkoming van dit proefschrift. In de hoop dat alle anderen me zullen
vergeven dat zij hieronder hun naam niet aantreffen. Mijn dank aan hen is er niet minder om!
De drijvende krachten achter het onderzoek waren prof. dr R.C.A. Sengers, prof. dr F.J.M.
Gabreëls en prof. dr J.J. Rotteveel. Beste Rob, dank voor jouw bijdrage aan de totstandkoming
van dit boek, vooral ook voor de gesprekken die we voerden met als onderwerpen 'planning en
strategie'. Alhoewel je amper bereikbaar lijkt (agenda), ben je altijd bereid ('even
binnenlopen'). Beste Fons, je hebt me tijdens de opleiding tot kinderarts de kinderneurologie
in weten te lokken. Hartelijk dank daarvoor! Natuurlijk ook mijn dank voor alle gastvrijheid
tijdens de avonden bij jou thuis, en voor je niet aflatende en stimulerende enthousiasme
gedurende vele momenten. Beste Jan, jij was vanaf het eerste moment betrokken bij de zorg
voor en het onderzoek bij patiënten met SLS. Jij was de grote initiator achter dit proefschrift.
Ik denk dat je je wel eens afgevraagd hebt of je toentertijd overzag wat er nu allemaal van
terechtgekomen is. Je hebt me altijd gesteund, en daarvoor wil ik je hier hartelijk bedanken.
Drie anderen hebben veel werk gehad aan de zaken die in dit boek door mij opgeschreven kon
worden. Zij hebben het SLS-onderzoek essentieel gesteund met hun creatieve en
fundamentele bijdragen en met de (coaching van de) uitvoering van veel laboratoriumwerk.
Natuurlijk doel ik op prof. dr R.J.A. Wanders en drs L. IJlst (Laboratorium voor Genetische
Metabole Ziekten, Academisch Medisch Centrum, Amsterdam) en dr E. Mayatepek
(Universitair Kinderziekenhuis, Heidelberg). Beste Ronald, je bent zo sportief geweest om
jouw SLS-kennis en 'lijstje' met mij te delen. Ik verbaas me blijvend over jouw kennis en
'drive'. SLS was een fantastische kans om samen te werken. Ik hoop dat dat nog lang op een
vruchtbare manier door kan gaan. Beste Lodewijk, je maakte me meer vertrouwd met
biochemisch en genetisch onderzoek, en was voor mij een betrouwbare steun in de hectische
wereld van de moleculaire biologie. Dear Ertan, I am very happy that we could work together
during the past years. You have offered me the opportunity to get in the world of leukotrienes
and to come to the first rational therapeutic intervention for SLS. It was amazing how quick
(and accurate!) you always looked at the manuscripts. Undoubtedly, many other people in
Amsterdam and Heidelberg are also involved in the SLS-research, and I am sure that they
were very busy with it. Therefore, I would like to say "Hartelijk bedankt!" to the whole
Amsterdam group, and "Vielen Dank!" to the Heidelberg group.
Dr P.H.M.F. van Domburg, prof. dr P.M. Steijlen en dr J.C.A. Cruysberg zijn vanaf het begin
betrokken geweest bij de klinische zorg voor SLS. Hun vakmanschap en bijpassende
enthousiasme waren absoluut broodnodig voor dit onderzoek. Beste Peter, je was al aan de
SLS-kar aan het trekken toen ik het stokje van je kon overnemen. Ik wil je graag bedanken
voor de zeer plezierige samenwerking en jouw steun (op een of andere manier vaak net in
tijden dat het wat minder wilde vlotten). Beste Peter, op jouw spreekuur hoorden veel ouders
voor het eerste het woord "Sjögren-Larsson syndroom". Jouw kennis, enorme enthousiasme
en gedrevenheid, waren van grote waarde voor het onderzoek. Dat je met jouw chaotische
manier van spreken, werken (en leven?) in staat bent mensen fantastisch te steunen mag voor
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de één een verassing zijn, voor mij een ervaringsfeit. Beste Hans, jij hoort natuurlijk ook bij
de SLS-pioniers. Jouw nauwgezetheid en minitieuze kijk op patiënten (die veel verder gaat
dan hun ogen) waren voor dit onderzoek van groot belang. Samen met dr A.L. Aandekerk, die
hier zeker niet ongenoemd mag blijven, heb je SLS voor altijd kristalhelder op de
oogheelkundige kaart gezet. Albert, jouw fotografische kennis en vaardigheden zijn hierbij
van onschatbare waarde geweest.
Het SLS-onderzoek kende weinig dalen, maar veel (vette) pieken. Dr M. van der Graaf, beste
Marinette, en prof. dr A. Heerschap, beste Arend, jullie kennis en ervaring op het gebied van
de MR spectroscopie hebben geleid tot een fantastische bijdrage aan het inzicht in SLS. Jullie
manieren van werken zijn zeer verschillend maar volgens mij complementair (1+1=1). Ik liep
altijd met veel plezier bij jullie binnen.
Sommige mensen treden niet gauw op de voorgrond omdat dat niet in hun aard zit. Ze zijn
zeldzaam, en daarom wil ik alleen dr J.G.N. de Jong hier noemen. Beste Jan, hartelijk dank
voor al jouw hulp bij het SLS-werk. Je was een makkelijk toegankelijke vraagbaak voor me,
die me veel van de biochemie heeft bijgebracht. Ik denk met plezier terug aan onze reisjes
Amsterdam-Nijmegen. Jouw rustige en bescheiden karakter is een zegen in deze tijd en van
onschatbare waarde als voorbeeld in de academische wereld.
De leden van de manuscriptcommissie, te weten prof. dr P.C.M. van de Kerkhof, prof. dr M.S.
van der Knaap, dr E. Mayatepek, prof. dr G.W. Padberg en prof. dr R.J.A. Wanders mogen
hier niet ongenoemd blijven. Beste Peter, beste Marjo, beste Ertan, beste George, en beste
Ronald, ik wil jullie hartelijk danken voor het "ja" op Sengers' vraag om het oordeel te vellen
over dit proefschrift, en vooral ook voor de manier waarop jullie dit hebben gedaan.
Adilia Warris en Petr Jira hebben me als vrienden en paranimfen gesteund in de afgelopen
jaren en zullen dat ongetwijfeld ook doen op 19 december 2001. Ik hoop voor hen beiden dat
hun 'boekje' snel af mag komen. Adilia, het was leuk om jullie in Oslo op te zoeken toen je
daar voor jouw eigen onderzoek zat, maar het zou fantastisch zijn als je voorlopig wat dichter
bij ons in de buurt blijft wonen. Petr, wat valt er in een of twee regels te zeggen, na alles wat
we de afgelopen jaren hebben meegemaakt? Laat ik je wat vragen: wanneer gaan we nou
eindelijk weer eens een dag lopen!?
Bijna op het eind wil ik twee mensen bedanken die van onmeetbare invloed zijn geweest op
dit proefschrift. Zij zijn tientallen jaren bezig geweest om de voorwaarden te scheppen voor
de onderzoeker, opdat hij liefdevol opgroeide, zich vrij kon ontwikkelen, en naar eigen keuze
en inzicht zijn leven verder in kon richten. Zij hebben vele uren doorgebracht met hun
kleinkinderen, de kinderen van de onderzoeker, opdat hij zijn werk kon doen. Zij verdienen de
grootste lof. Pa en ma, al mijn dank!
De laatsten zullen de eersten zijn. Lieve Anneloes, lieve Lieve en lieve Flore, wat zijn jullie
fantastische meiden! Wat zou er zonder jullie van mij terecht komen? Anneloes, we zijn de
helft van ons leven al samen. Jij hebt me altijd een bewonderenswaardige hoeveelheid tijd
gegeven, jezelf weggecijferd, en mij ontzien in de dagelijkse rompslomp van een jong gezin.
Het 'papa ziekenuis?' zal vanaf nu minder gehoord worden, dat beloof ik je. We gaan weer
samen fietsen …….
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Michèl Willemsen werd op 10 maart 1968 geboren te Westervoort. In augustus 1980 begon
hij zijn middelbare school op het Thomas à Kempis College te Arnhem, waar hij pas na vele -
uiterst verdrietige - maanden zijn draai kon vinden. Hij genoot het voorrecht om de klassieke
talen ‘in zijn pakket te hebben’. In 1986 slaagde hij het voor het eindexamen VWO. Dat jaar
begon hij met de studie Geneeskunde aan de Katholieke Universiteit Nijmegen. Vier jaar
later, te weten op 5 juli 1990, sloot hij het doctoraalexamen Geneeskunde cum laude af. Het
artsexamen werd vervolgens met succes afgelegd op 19 februari 1993. Als ‘AGNIO’
kindergeneeskunde was hij vanaf dat moment werkzaam op de afdeling Kindergeneeskunde
van het Universitair Medisch Centrum St Radboud te Nijmegen (hoofd, en voor hem later ook
opleider: prof dr RCA Sengers). Op 1 maart 1994 begon hij op die afdeling aan de opleiding
tot kinderarts. In het kader van de opleiding werd de ‘perifere stage’ gelopen in het Nijmeegse
Canisius Wilhelmina Ziekenhuis (opleider: dr PMV van Wieringen) van 1 april 1996 tot 1
april 1997. In de loop van de tijd werd duidelijk dat niet de kindergeneeskunde in z’n volle
breedte, maar de kinderneurologie het vak zou moeten worden waarvoor hij zich in zou gaan
zetten. De tweede helft van de opleiding zag er van opbouw dan ook wat ingewikkelder uit.
Het hele kalenderjaar 1998 werkte hij in het kader van zijn opleiding tot kinderneuroloog op
de afdeling Neurologie van het Universitair Medisch Centrum St Radboud (opleider: prof dr
GWAM Padberg). In het laatste jaar van het vorige millenium werden vervolgens de opleiding
tot kinderarts en die tot kinderneuroloog voortgezet op het Interdisciplinair
Kinderneurologisch Centrum (opleider: prof dr FJM Gabreëls). De eindstreep van beide
opleidingen viel exact samen met het vuurwerk van de Nieuwjaarsnacht waarmee het nieuwe
millenium en ook het leven als kinderneuroloog werd verwelkomd. Vanaf 1 januari 2000 is hij
als kinderneuroloog werkzaam binnen het Interdisciplinair Kinderneurologisch Centrum, met
als aandachtgebied neurometabole en neurodegeneratieve aandoeningen.
Michèl is sinds 1985 stapelgek op Anneloes Bosz, met wie hij sinds 1996 gelukkig is
getrouwd. Samen hebben zij twee prachtige dochters, Lieve en Flore.
